0001213900-23-040152 | 20-F | XBRL Viewer | Altamira Therapeutics LTD

Other comprehensive income / (loss)

(636,858)

Conversion of loan

7,370

3,056,877

3,064,247

Share based payments

368,793

Balance at Dec. 31, 2020

114,172

177,230,300

61,297

(160,635,879)

16,769,890

Total comprehensive loss

Net loss

(17,058,443)

^[1]

772

264,984

265,756

^[1]

Total comprehensive loss

772

(16,793,459)

(16,792,687)

Transactions with owners of the

Capital increase

20,822

7,083,869

7,104,691

Share based/Asset purchase

7,735

2,447,081

1,078,800

3,533,616

Other comprehensive income / (loss)

(156,817)

Conversion of loan

5,168

1,366,087

1,371,255

Share based payments

1,746

540,956

663,601

1,206,303

Balance at Dec. 31, 2021

149,643

188,511,476

62,069

(175,686,937)

13,036,251

Total comprehensive loss

Net loss

(26,528,411)

61,046

441,277

502,323

Total comprehensive loss

61,046

(26,087,134)

(26,026,088)

Transactions with owners of the

Capital increase

86,368

4,146,425

4,232,793

Recognition of equity component of loans with warrants

(35,495)

134,929

Share based payments

342,799

Balance at Dec. 31, 2022

SFr 236,011

SFr 192,622,406

SFr 134,929

SFr 123,115

SFr (201,431,272)

SFr (8,314,811)

[1]	Revised, see note 33.

Deferred income (Details) - Schedule of deferred income - CHF (SFr)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of Deferred Income [Abstract]
Upfront payment	SFr 932,200
Total deferred income	SFr 932,200

Segment information (Tables)

12 Months Ended

Dec. 31, 2022

Segment information [Abstract]

Schedule of group’s non-current assets by the Company’s country

	December 31,		December 31,
	2022		2021
Switzerland		4,339,509		14,734,738
Australia		—		144,854
Total		4,339,509		14,879,592

Trade and Other Payables

12 Months Ended

Dec. 31, 2022

Trade and other payables [Abstract]

Trade and other payables

16. Trade and other payables

	December 31,		December 31,
	2022		2021
Trade accounts payable - third parties		4,767,940		3,544,384
Other		146,464		153,339
Total trade and other payables		4,914,404		3,697,723

Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities - CHF (SFr)	Dec. 31, 2022	Dec. 31, 2021
At amortized cost
Financial assets	SFr 486,359	SFr 1,460,229
At amortized cost
Financial liabilities	13,223,300	5,323,267
Trade And Other Payables [member]
At amortized cost
Financial liabilities	4,914,404	3,697,723
Accrued Expenses [Member]
At amortized cost
Financial liabilities	1,977,614	1,048,575
Loan [Member]
At amortized cost
Financial liabilities	5,869,797
Non-current lease liabilities [Member]
At amortized cost
Financial liabilities	343,629	461,485
Current lease liabilities [Member]
At amortized cost
Financial liabilities	117,856	114,251
Derivative Financial Instruments Liabilities [Member]
At amortized cost
Financial liabilities		1,233
Cash And Cash Equivalents [member]
At amortized cost
Financial assets	15,395	984,191
Other non-current financial assets [Member]
At amortized cost
Financial assets	194,263	199,105
Trade receivables [member]
At amortized cost
Financial assets	6,525	21,746
Other receivables [member]
At amortized cost
Financial assets		255,187
Derivative Financial Instruments Asset [Member]
At amortized cost
Financial assets	SFr 270,176

Accrued Expenses

12 Months Ended

Dec. 31, 2022

Accrued expenses [Abstract]

Accrued expenses

17. Accrued expenses

	December 31,		December 31,
	2022		2021
Accrued research and development costs including milestone payments		741,291		557,391
Professional fees		326,365		179,461
Accrued vacation & overtime		46,868		51,218
Employee benefits incl. share based payments		362,497		196,917
Accrued interest		457,812		—
Other		42,781		63,588
Total accrued expenses		1,977,614		1,048,575

Taxation (Details) - Schedule of income tax expense - CHF (SFr)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Income Tax Expense Abstract
Deferred income tax expense	SFr (52,004)	SFr (570,730)	SFr (389,384)
Deferred income tax gain	62,332	549,110	410,668
Income tax gain/(loss)	SFr 10,329	SFr (21,620)	SFr 21,284

Employee Benefits

12 Months Ended

Dec. 31, 2022

Employee Benefits [Abstract]

Employee benefits

25. Employee benefits

	December 31,		December 31,		December 31,
	2022		2021		2020
Salaries		2,815,411		1,865,633		1,260,359
Pension costs		266,256		165,801		156,843
Other social benefits		294,017		275,258		116,290
Share based payments costs		342,799		1,223,696		351,401
Other personnel expenditures		2,024		214,940		47,295
Total employee benefits		3,720,507		3,745,328		1,932,188

In 2021 share based compensation expense included CHF 902,817 for one regular and one extraordinary share bonus grant related to the strategic repositioning of the Company. The latter, which amounts to CHF 810,252, including CHF 360,112 for a future share grant contingent on achieving the Positive Results related to the Trasir transaction. Share based compensation included expense related to employee stock options of CHF 342,799 in the year 2022 compared to CHF 320,879 in 2021.

Benefit plans

The Company participates in a retirement plan (the “Plan”) organized as an independent collective foundation, that covers all of its employees in Switzerland, including management. The collective foundation is governed by a foundation board. The board is made up of an equal number of employee and employer representatives of the affiliated companies. The Company has no direct influence on the investment strategy of the collective foundation. Moreover, certain elements of the employee benefits are defined in the same way for all affiliated companies. This is mainly related to the annuity factors at retirement and to interest allocated on retirement savings. The employer itself cannot determine the benefits or how they are financed directly. The foundation board of the collective foundation is responsible for the determination of the investment strategy, for making changes to the pension fund regulations and in particular also for defining the financing of the pension benefits.

The old age benefits are based on retirement savings for each employee, coupled with annual retirement credits and interest (there is no possibility to credit negative interest). At retirement age, the insured members can choose whether to take a pension for life, which includes a spouse’s pension, or a lump sum. In addition to retirement benefits, the plan benefits also include disability and death benefits. Insured members may also buy into the scheme to improve their pension provision up to the maximum amount permitted under the rules of the plan and may withdraw funds early for the purchase of a residential property for their own use subject to limitations under Swiss law. On leaving the Company, retirement savings are transferred to the pension institution of the new employer or to a vested benefits institution. This type of benefit may result in pension payments varying considerably between individual years. In defining the benefits, the minimum requirements of the Swiss Law on Occupational Retirement, Survivors and Disability Pension Plans (BVG) and its implementing provisions must be observed. The BVG defines the minimum pensionable salary and the minimum retirement credits. In Switzerland, the minimum interest rate applicable to these minimum retirement savings is set by the Swiss Federal Council at least once every two years. The rate was 1.00% in 2020, 1.00% in 2021 and 1.00% in 2022.

The assets are invested by the collective foundation to which many companies contribute, in a diversified portfolio that respects the requirements of the Swiss BVG. Therefore, disaggregation of the pension assets and presentation of plan assets in classes that distinguish the nature and risks of those assets is not possible. Under the Plan, both the Company and the employee share the costs equally. The structure of the plan and the legal provisions of the BVG mean that the employer is exposed to actuarial risks. The main risks are investment risk, interest risk, disability risk and the risk of longevity. Through the affiliation to a collective foundation, the Company has minimized these risks, since they are shared between a much greater number of participants.

For accounting purposes under IFRS, the plan is treated as a defined benefit plan.

The following tables present information about the net defined benefit liability and its components:

Change in defined benefit obligation
	2022			2021
Defined benefit obligation at January 1		4,677,632			3,529,602
Service costs		256,336			162,200
Plan participants’ contribution		154,116			101,066
Interest cost		13,762			10,464
Actuarial losses		(931,636	)		159,845
Plan amendments		—			(3,115	)
Benefits paid through pension assets		(626,049	)		717,570
Defined benefit obligation at December 31		3,544,161			4,677,632

The defined benefit obligation includes only liabilities for active employees. The weighted average modified duration of the defined benefit obligation at December 31, 2022 is 17.1 years (2021: 19.9 years).

Change in fair value of plan assets
	2022			2021
Fair value of plan assets at January 1		4,009,313			2,662,226
Interest income		12,187			8,586
Return on plan assets excluding interest income		(490,359	)		424,829
Employer contributions		154,116			101,066
Plan participants’ contributions		154,116			101,066
Benefits paid through pension assets		(626,049	)		717,570
Administration expense		(5,369	)		(6,030	)
Fair value of plan assets at December 31		3,207,955			4,009,313

Net defined benefit liability recognized in the statement of financial position

	December 31,		December 31,
	2022		2021
Present value of funded defined benefit obligation	3,544,161		4,677,632
Fair value of plan assets	(3,207,955	)	(4,009,313	)
Net defined benefit liability	336,206		668,319

Defined Benefit Cost

	2022		2021		2020
Service cost		256,336		159,085		151,624
Net interest expense		1,575		1,878		2,053
Administration expense		5,369		6,030		3,166
Total defined costs for the year recognized in profit or loss		263,280		166,993		156,843

Remeasurement of the Defined Benefit Liability

	2022			2021			2020
Actuarial loss (gain) arising from changes in financial assumptions		(876,841	)		(74,284	)		13,031
Actuarial loss (gain) arising from experience adjustments		(54,795	)		463,238			45,881
Actuarial gain arising from demographic assumptions		—			(229,109	)		—
Return on plan assets excluding interest income		490,359			(424,829	)		(32,794	)
Total defined benefit cost for the year recognized in the other comprehensive loss (income)		441,277			(264,984	)		26,118

Assumptions

At December 31	2022			2021			2020
Discount rate		2.20	%		0.30	%		0.20	%
Future salary increase		1.60	%		0.85	%		0.60	%
Pension indexation		0.00	%		0.00	%		0.00	%
Mortality and disability rates		BVG2020			BVG2020			BVG2015G

Sensitivity analysis

Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other assumptions constant, would have affected the defined benefit obligation by the amounts shown below.

December 31,	2022			2021
Change in assumption		0.25% increase			0.25% increase
Discount rate		(117,546	)		(200,601	)
Salary increase		23,058			22,961
Pension indexation		63,916			110,958
Change in assumption		+1 year			+ 1 year
Life expectancy		48,531			98,983

Employee Benefits (Tables)

12 Months Ended

Dec. 31, 2022

Employee Benefits [Abstract]

Schedule of defined benefit plan expense recognized in profit or loss

	December 31,		December 31,		December 31,
	2022		2021		2020
Salaries		2,815,411		1,865,633		1,260,359
Pension costs		266,256		165,801		156,843
Other social benefits		294,017		275,258		116,290
Share based payments costs		342,799		1,223,696		351,401
Other personnel expenditures		2,024		214,940		47,295
Total employee benefits		3,720,507		3,745,328		1,932,188

Schedule of defined benefit obligation

Change in defined benefit obligation
	2022			2021
Defined benefit obligation at January 1		4,677,632			3,529,602
Service costs		256,336			162,200
Plan participants’ contribution		154,116			101,066
Interest cost		13,762			10,464
Actuarial losses		(931,636	)		159,845
Plan amendments		—			(3,115	)
Benefits paid through pension assets		(626,049	)		717,570
Defined benefit obligation at December 31		3,544,161			4,677,632

Change in fair value of plan assets
	2022			2021
Fair value of plan assets at January 1		4,009,313			2,662,226
Interest income		12,187			8,586
Return on plan assets excluding interest income		(490,359	)		424,829
Employer contributions		154,116			101,066
Plan participants’ contributions		154,116			101,066
Benefits paid through pension assets		(626,049	)		717,570
Administration expense		(5,369	)		(6,030	)
Fair value of plan assets at December 31		3,207,955			4,009,313

	December 31,		December 31,
	2022		2021
Present value of funded defined benefit obligation	3,544,161		4,677,632
Fair value of plan assets	(3,207,955	)	(4,009,313	)
Net defined benefit liability	336,206		668,319

Schedule of defined benefit cost and liability assumptions

	2022		2021		2020
Service cost		256,336		159,085		151,624
Net interest expense		1,575		1,878		2,053
Administration expense		5,369		6,030		3,166
Total defined costs for the year recognized in profit or loss		263,280		166,993		156,843

	2022			2021			2020
Actuarial loss (gain) arising from changes in financial assumptions		(876,841	)		(74,284	)		13,031
Actuarial loss (gain) arising from experience adjustments		(54,795	)		463,238			45,881
Actuarial gain arising from demographic assumptions		—			(229,109	)		—
Return on plan assets excluding interest income		490,359			(424,829	)		(32,794	)
Total defined benefit cost for the year recognized in the other comprehensive loss (income)		441,277			(264,984	)		26,118

At December 31	2022			2021			2020
Discount rate		2.20	%		0.30	%		0.20	%
Future salary increase		1.60	%		0.85	%		0.60	%
Pension indexation		0.00	%		0.00	%		0.00	%
Mortality and disability rates		BVG2020			BVG2020			BVG2015G

Schedule of sensitivity analysis for actuarial assumptions

December 31,	2022			2021
Change in assumption		0.25% increase			0.25% increase
Discount rate		(117,546	)		(200,601	)
Salary increase		23,058			22,961
Pension indexation		63,916			110,958
Change in assumption		+1 year			+ 1 year
Life expectancy		48,531			98,983

Taxation (Details) - Schedule of tax loss carry forwards - CHF (SFr)	Dec. 31, 2022	Dec. 31, 2021
Taxation (Details) - Schedule of tax loss carry forwards [Line Items]
Total tax loss carry-forwards	SFr 103,114,677	SFr 109,855,150
Within 1 year [Member]
Taxation (Details) - Schedule of tax loss carry forwards [Line Items]
Total tax loss carry-forwards	27,956,899	28,909,896
Between 1 and 3 years [Member]
Taxation (Details) - Schedule of tax loss carry forwards [Line Items]
Total tax loss carry-forwards	31,668,498	50,673,943
Between 3 and 7 years [Member]
Taxation (Details) - Schedule of tax loss carry forwards [Line Items]
Total tax loss carry-forwards	41,797,708	29,007,049
More than 7 years [Member]
Taxation (Details) - Schedule of tax loss carry forwards [Line Items]
Total tax loss carry-forwards	SFr 1,691,572	SFr 1,264,262

Significant accounting policies (Details) - Schedule of closing rates for the most significant foreign currencies	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Switzerland [Member]
Significant accounting policies (Details) - Schedule of closing rates for the most significant foreign currencies [Line Items]
Reporting entities	5,000
Closing rate	1,000	1,000	1,000
Average exchange rate	1,000	1,000	1,000
United States [Member]
Significant accounting policies (Details) - Schedule of closing rates for the most significant foreign currencies [Line Items]
Reporting entities	1,000
Closing rate	925.1000	911	884
Average exchange rate	955	914.2000	958.1000
Europe [Member]
Significant accounting policies (Details) - Schedule of closing rates for the most significant foreign currencies [Line Items]
Reporting entities	1,000
Closing rate	990.1000	1,036.1000	1,081.7000
Average exchange rate	1,005.000	1,081.000	1,082.5000
Australia [Member]
Significant accounting policies (Details) - Schedule of closing rates for the most significant foreign currencies [Line Items]
Reporting entities	1,000
Closing rate	630.5000	662	682.2000
Average exchange rate	662.9000	686.6000	654.6000

Financial instruments and risk management (Details) - Schedule of carrying amount of each financial asset in the consolidated statement of financial position - CHF (SFr)	Dec. 31, 2022	Dec. 31, 2021
Financial assets
Maximum exposure to credit risk	SFr 216,183	SFr 1,460,229
Cash And Cash Equivalents [member]
Financial assets
Maximum exposure to credit risk	15,395	984,191
Other non-current financial assets [Member]
Financial assets
Maximum exposure to credit risk	194,263	199,105
Trade receivables [member]
Financial assets
Maximum exposure to credit risk	6,525	21,746
Other receivables [Member]
Financial assets
Maximum exposure to credit risk		SFr 255,187

Revision of Prior Period Financial Statements (Tables)

12 Months Ended

Dec. 31, 2022

Revision of Prior Period Financial Statements [Abstract]

Schedule of revised consolidated balance sheet

	As of December 31, 2021
	As reported			Adjustment			As revised
Other receivables		917,833			(246,493	)		671,340
Prepayments		996,910			578,216			1,575,126
Total current assets		3,759,901			331,723			4,091,624
Total assets		18,838,598			331,723			19,170,321
Accumulated deficit		(176,018,660	)		331,723			(175,686,937	)
Total shareholders’ equity attributable to owners of the company		12,704,528			331,723			13,036,251
Total equity and liabilities		18,838,598			331,723			19,170,321

Schedule of revised consolidated statement of profit or loss and other comprehensive loss

	Year ended December 31, 2021
	As reported			Adjustment			As revised
Other income		460,710			(246,493	)		214,217
Research and development		(8,939,037	)		578,216			(8,360,821	)
Total operating expenses		(15,137,338	)		331,723			(14,805,615	)
Operating loss		(17,099,793	)		331,723			(16,768,070	)
Loss before tax		(17,368,546	)		331,723			(17,036,823	)
Net loss attributable of owners of the Company		(17,390,166	)		331,723			(17,058,443	)
Total comprehensive loss attributable to owners of the Company		(17,124,410	)		331,723			(16,792,687	)
Basic and diluted loss per share		(26.26	)		0.50			(25.76	)

Schedule of consolidated statement of cash flows

	Year ended December 31, 2021
	As reported			Adjustment			As revised
Net loss		(17,390,166	)		331,723			(17,058,443	)
Changes in:
Trade and other receivables		(586,612	)		246,493			(340,119	)
Prepayments		(719,321	)		(578,216	)		(1,297,537	)
Cash used in operating activities		(13,627,738	)		—			(13,672,738	)

Commitments and Contingencies (Details) - Schedule of future minimum lease payments under non-cancellable operating leases - CHF (SFr)	Dec. 31, 2022	Dec. 31, 2021
Commitments and Contingencies (Details) - Schedule of future minimum lease payments under non-cancellable operating leases [Line Items]
Minimum finance lease payments payable	SFr 3,450	SFr 3,450
Within one year [Member]
Commitments and Contingencies (Details) - Schedule of future minimum lease payments under non-cancellable operating leases [Line Items]
Minimum finance lease payments payable	3,450	3,450
Between one and five years [Member]
Commitments and Contingencies (Details) - Schedule of future minimum lease payments under non-cancellable operating leases [Line Items]
Minimum finance lease payments payable

Share-Based Compensation (Details) - Schedule of fair value of the options measured - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Equity Incentive Plan 2022 [Member] \| Equity Incentive Plan 2021 [Member] \| One Year Vesting Period [Member]
Share-Based Compensation (Details) - Schedule of fair value of the options measured [Line Items]
Fair value at grant	USD 4.347 (2 year vesting) 1) USD 5.011 (3 year vesting) 1)
Share price at grant date	USD 7.48
Exercise price	USD 6.353
Expected volatility	100.20%
Expected life	2 and 3 years
Expected dividends
Risk-free interest rate	4.45%
Equity Incentive Plan 2022 [Member] \| Two Year Vesting Period [Member]
Share-Based Compensation (Details) - Schedule of fair value of the options measured [Line Items]
Fair value at grant	USD 6.644 (1 year vesting) 2) USD 8.760 (2 year vesting) 2) USD 10.604 (3 year vesting) 2)
Share price at grant date	USD 17.8
Exercise price	USD 20.78
Expected volatility	99.10%
Expected life	1, 2 and 3 years
Expected dividends
Risk-free interest rate	2.87%
Equity Incentive Plan 2021 [Member] \| Equity Incentive Plan 2021 [Member] \| One Year Vesting Period [Member]
Share-Based Compensation (Details) - Schedule of fair value of the options measured [Line Items]
Fair value at grant		USD 18.64 (2 year vesting) 1) USD 22.14 (3 year vesting) 1)
Share price at grant date		USD 32.80
Exercise price		USD 37.78
Expected volatility		93.40%
Expected life		2 and 3 years
Expected dividends
Risk-free interest rate		0.47%
Equity Incentive Plan 2021 [Member] \| Two Year Vesting Period [Member]
Share-Based Compensation (Details) - Schedule of fair value of the options measured [Line Items]
Fair value at grant		USD 24.82 (1 year vesting) 2) USD 37.00 (2 year vesting) 2) USD 43.66 (3 year vesting) 2)
Share price at grant date		USD 70.80
Exercise price		USD 70.220
Expected volatility		101.30%
Expected life		1, 2 and 3 years
Expected dividends
Risk-free interest rate		0.06%

Commitments and Contingencies

12 Months Ended

Dec. 31, 2022

Commitments and contingencies [Abstract]

Commitments and contingencies

29. Commitments and contingencies

Lease commitments

The future minimum lease payments under non-cancellable lease term that are not accounted for in the statement of financial position were as follows:

	December 31,		December 31,
	2022		2021
Within one year		3,450		3,450
Between one and five years		—		—
Total		3,450		3,450

Office lease expenses of CHF 6,001, CHF 52,280 and CHF 50,260 were recorded in 2022, 2021 and 2020, respectively, in the consolidated statement of profit or loss and other comprehensive loss.

Loss Per Share

12 Months Ended

Dec. 31, 2022

Loss per share [Abstract]

Loss per share

28. Loss per share

	December 31,			December 31,			December 31,
	2022			2021			2020
Loss attributable to owners of the Company		(26,528,411	)		(17,058,443	)		(8,200,165	)
Weighted average number of shares outstanding		910,723			662,314			300,707
Basic and diluted loss per share		(29.13	)		(25.76	)		(27.27	)

For the years ended December 31, 2022 and 2021 basic and diluted loss per share is based on the weighted average number of shares issued and outstanding and excludes shares to be issued under the Stock Option Plans (Note 15) as they would be anti-dilutive. As of December 31, 2022, the Company had 157,320 options outstanding under its stock option plans. The average number of options outstanding between January 1, 2022 and December 31, 2022 was 910,723 (662,314 for the period between January 1, 2021 and December 31, 2021). As of December 31, 2022, the Company had warrants to purchase up to 99,171 of its common shares issued and outstanding (as of December 31, 2021, the Company had warrants to purchase up to 12,305 common shares).

Revenue

12 Months Ended

Dec. 31, 2022

Revenue [Abstract]

Revenue

20. Revenue

Set out below is the disaggregation of the Group’s revenue from contracts with customers:

	December 31,		December 31,		December 31,
	2022		2021		2020
Product sales		305,616		63,882		—

Total revenue		305,616		63,882		—

Inventories (Details) - CHF (SFr) SFr in Millions	Dec. 31, 2022	Dec. 31, 2021
Stock Keeping Units [Member]
Inventories (Details) [Line Items]
Finished good inventories amount	SFr 0.9	SFr 2.0

Segment information (Details) - Schedule of group’s non-current assets by the Company’s country - CHF (SFr)	Dec. 31, 2022	Dec. 31, 2021
Segment information (Details) - Schedule of group’s non-current assets by the Company’s country [Line Items]
Non-current assets	SFr 4,339,509	SFr 14,879,592
Switzerland [Member]
Segment information (Details) - Schedule of group’s non-current assets by the Company’s country [Line Items]
Non-current assets	4,339,509	14,734,738
Australia [Member]
Segment information (Details) - Schedule of group’s non-current assets by the Company’s country [Line Items]
Non-current assets		SFr 144,854

Right-of-use assets and lease liabilities (Tables)

12 Months Ended

Dec. 31, 2022

Right-of-use assets and lease liabilities [Abstract]

Schedule of right-of-use assets and lease liabilities

	Office
Right-of-use assets	building			Total
At cost
As of January 1, 2021		—			—
Additions		594,436			594,436
Disposals		—			—
As of December 31, 2021		594,436			594,436
Additions		—			—
Disposals		—			—
As of December 31, 2022		594,436			594,436

Accumulated depreciation
As of January 1, 2021		—			—
Charge for the year		(29,722	)		(29,722	)
Disposals		—			—
As of December 31, 2021		(29,722	)		(29,722	)
Charge for the year		(118,887	)		(118,887	)
Disposals		—			—
As of December 31, 2022		(148,609	)		(148,609	)

Net book value
As of December 31, 2021		564,714			564,714
As of December 31, 2022		445,827			445,827

Schedule of low value and short-term lease expenses

	December 31,		December 31,
Low value and short-term lease expenses	2022		2021

Expense related to short-term leases		6,001		52,280
Expense related to leases of low value assets		—		—
Total		6,001		52,280

Schedule of lease liabilities

	December 31,			December 31,
Lease liabilities	2022			2021
As of January 1		575,736			—
Additions		—			594,436
Interest expense		15,949			3,000
Repayment of lease liability		(130,200	)		(21,700	)
As of December 31		461,485			575,736

thereof non-current		343,629			461,485
thereof current		117,856			114,251

Schedule of maturities of lease liabilities

	December 31,			December 31,
Maturities of lease liabilities	2022			2021

Year 1		130,200			130,200
Year 2		130,200			130,200
Year 3		130,200			130,200
Year 4		97,650			130,200
Year 5		—			97,650
Undiscounted lease payments		488,250			618,450
Less: unearned interest		(26,765	)		(42,714	)
Total		461,485			575,736

Finance Income and Finance Expense (Details) - Schedule of finance income and finance expense - CHF (SFr)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Finance Income and Finance Expense Abstract
Interest income	SFr 969	SFr 3,219	SFr 258
Net foreign currency exchange gain	745,260	1,458,429	3,207,649
Revaluation gain from derivative financial instruments	451,131	5,085
Total finance income	1,197,360	1,466,733	3,207,907
Interest expense (incl. Bank charges)	911,869	189,695	135,151
Net foreign currency exchange loss	690,615	1,129,788	3,541,202
Revaluation loss from derivative financial instruments		416,003	2,250,222
Transaction costs	1,137		219,615
Total finance expense	1,603,621	1,735,486	6,146,190
Finance expense, net	SFr (406,261)	SFr (268,753)	SFr (2,938,283)

Events after the balance sheet date (Details) - Non-adjusting events after reporting period [member]					1 Months Ended
	May 12, 2023 SFr / shares	May 01, 2023	Apr. 17, 2023 $ / shares shares	Apr. 13, 2023	Mar. 31, 2024 CHF (SFr)	Feb. 17, 2023 CHF (SFr) SFr / shares shares
Events after the balance sheet date (Details) [Line Items]
Share capital (in Francs) \| SFr						SFr 1,400,000
Divided common shares (in Shares) \| shares						5,000,000
Common shares price						SFr 0.2
preference shares (in Shares) \| shares						20,000,000
Preferred share price						SFr 0.02
Effective rate				90.00%
Aggregate common shares (in Shares) \| shares			4,341,012
Average conversion price (in Dollars per share) \| $ / shares			$ 1.4475
Events after the balance sheet date description		the Company entered into a convertible loan agreement (the “2023 FiveT Loan Agreement”) with FiveT IM, pursuant to which FiveT IM has agreed to loan to the Company CHF 2,500,000, which bears interest at the rate of 10% per annum and matures 22 months from May 4, 2023. FiveT IM will have the right to convert all or part of the convertible loan, including accrued and unpaid interest, at its option, into common shares, subject to the limitation that FiveT own no more than 4.99% of the common shares at any time. The conversion price was fixed at CHF 1.42 per common share (subject to adjustment for share splits or other similar events). Further, FiveT IM received warrants to purchase an aggregate of 1,625,487 common shares at an exercise price of CHF 1.538 per common share, which may be exercised up to five years.Commencing 60 days after May 4, 2023, but not before July 1, 2023 and subject to availability of an effective registration statement, the Company must repay at least 1/20th of the outstanding loan plus accrued interest pro rata in monthly tranches which, at the Company’s discretion, may be paid at any time during the month either in: (i) cash plus 3% or (ii) common shares, or a combination of both. Such shares will be priced at the lower of (i) the mean daily trading volume weighted average price for the common shares on the 20 trading days preceding the repayment date or (ii) 90% of the daily trading volume weighted average price for common shares on the repayment date. The Company may prepay all or part of the convertible loan after three months.
Convertible percentage					20.00%
Cash proceeds (in Francs) \| SFr					SFr 1,000,000
September 2022 Loan Amendment [Member]
Events after the balance sheet date (Details) [Line Items]
Common shares price	SFr 1.12
Weighted average price percentage	120.00%
Loan agreement description	(i) the mean daily trading volume weighted average price for the common shares on the 20 trading days preceding the repayment date or (ii) 90% of the daily trading volume weighted average price for common shares on the repayment date, and lowered the strike price for the Warrants attached to the loan to CHF 0.881 per common share, which is the Swiss Franc equivalent of the trading volume weighted average price for common shares on the NASDAQ stock exchange on trading day preceding the date of the September 2022 Loan Amendment.
December 2022 Loan Amendment [Member]
Events after the balance sheet date (Details) [Line Items]
Common shares price	SFr 0.881
Common Shares [member]
Events after the balance sheet date (Details) [Line Items]
Divided common shares (in Shares) \| shares						25,000,000
Common shares price						SFr 0.2
Divided amount (in Francs) \| SFr						SFr 5,400,000
Additional common shares (in Shares) \| shares						20,000,000
Additional common shares price						SFr 0.2
Preference shares [member]
Events after the balance sheet date (Details) [Line Items]
preference shares (in Shares) \| shares						20,000,000
Preferred share price						SFr 0.02

General and Administrative Expense

12 Months Ended

Dec. 31, 2022

General and administrative expense [Abstract]

General and administrative expense

24. General and administrative expense

	December 31,		December 31,		December 31,
	2022		2021		2020
Employee benefits and expenses		735,139		1,554,778		811,373
Business development		15,727		967,046		95,663
Travel expenses		95,503		75,829		28,898
Administration expenses		2,669,460		2,245,862		1,645,530
Lease expenses from short-term lease		6,001		52,280		13,871
Depreciation of Right-of-use assets		118,887		29,722		—
Depreciation of tangible assets		—		—		3,555
Capital tax expenses		3,832		21,059		(4,228	)
Total general and administrative expenses		3,644,549		4,946,576		2,594,662

Significant accounting policies (Tables)

12 Months Ended

Dec. 31, 2022

Significant accounting policies [Abstract]

Schedule of closing rates for the most significant foreign currencies

		Geographical	Reporting	December 31,		December 31,		December 31,
Currency		area	entities	2022		2021		2020
CHF	Swiss Franc	Switzerland	5		1.0000		1.0000		1.0000
USD	Dollar	United States	1		0.9251		0.9110		0.8840
EUR	Euro	Europe	1		0.9901		1.0361		1.0817
AUD	Dollar	Australia	1		0.6305		0.6620		0.6822

		Geographical	Reporting
Currency		area	entities	2022		2021		2020
CHF	Swiss Franc	Switzerland	5		1.0000		1.0000		1.0000
USD	Dollar	United States	1		0.9550		0.9142		0.9581
EUR	Euro	Europe	1		1.0050		1.0810		1.0825
AUD	Dollar	Australia	1		0.6629		0.6866		0.6546

Schedule of estimated useful lives

Production equipment		5 years
Office furniture and electronic data processing equipment (“EDP”)		3 years

Employee Benefits (Details) - Schedule of defined benefit cost and liability assumptions - CHF (SFr)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Defined Benefit Cost And Liability Assumptions Abstract
Service cost	SFr 256,336	SFr 159,085	SFr 151,624
Net interest expense	1,575	1,878	2,053
Administration expense	5,369	6,030	3,166
Total defined costs for the year recognized in profit or loss	263,280	166,993	156,843
Actuarial loss (gain) arising from changes in financial assumptions	(876,841)	(74,284)	13,031
Actuarial loss (gain) arising from experience adjustments	(54,795)	463,238	45,881
Actuarial gain arising from demographic assumptions		(229,109)
Return on plan assets excluding interest income	490,359	(424,829)	(32,794)
Total defined benefit cost for the year recognized in the other comprehensive loss (income)	SFr 441,277	SFr (264,984)	SFr 26,118
Discount rate	2.20%	0.30%	0.20%
Future salary increase	1.60%	0.85%	0.60%
Pension indexation	0.00%	0.00%	0.00%
Mortality and disability rates	BVG2020	BVG2020	BVG2015G

Loss Per Share (Details) - Schedule of loss per share - CHF (SFr)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Loss Per Share Abstract
Loss attributable to owners of the Company	SFr (26,528,411)	SFr (17,058,443)	SFr (8,200,165)
Weighted average number of shares outstanding	910,723	662,314	300,707
Basic loss per share	SFr (29.13)	SFr (25.76)	SFr (27.27)

Warrants from Public Offering

12 Months Ended

Dec. 31, 2022

Warrants from Public Offering [Abstract]

Warrants from Public Offering

32. Warrants from Public Offering

On February 21, 2017, the Company completed a public offering (the “February 2017 Offering”) of 500,000 (pre-merger) common shares with a nominal value of CHF 8.00 each and 500,000 (pre-merger) warrants, each warrant entitling its holder to purchase 0.70 of a common share. The net proceeds to the Company from the February 2017 Offering were approximately CHF 9.1 million ($9.1 million), after deducting underwriting discounts and other estimated offering expenses payable by us. The Company had transaction costs amounting to CHF 903,919. The transactions costs were recorded as CHF 397,685 in equity for the issuance of the common shares and CHF 506,234 to finance expense in the statement of profit or loss and comprehensive loss for the issuance of the warrants.

The underwriter was granted a 30-day option to purchase up to 75,000 (pre-merger) additional common shares and/or 75,000 (pre-merger) additional warrants. On February 15, 2017, the underwriter partially exercised its 30-day option to purchase additional common shares and/or warrants in the amount of 67,500 (pre-merger) warrants.

Consequently, the Company issued warrants to purchase up to 397,250 (pre-merger) of its common shares at an exercise price of $24.00 per share. The warrants are exercisable during a five-year period beginning on date of issuance. The fair value calculation of the warrants is based on the Black-Scholes option price model. Assumptions are made regarding inputs such as volatility and the risk-free rate in order to determine the fair value of the warrant. If a warrant is exercised, the Company will receive variable proceeds because the Company’s functional currency is CHF and the exercise price is in USD, which results in the warrants being considered liability instruments. Therefore, the warrants were assigned fair values using the Black-Scholes model. The residual value was assigned to the common share sold along with each warrant in accordance with IAS 32 Financial instruments. The gross proceeds from the February 2017 offering were CHF 9,998,305 of which CHF 5,091,817 (fair value as of February 21, 2017) was assigned to the warrants and CHF 4,906,488 was assigned to equity.

As of December 31, 2021, the outstanding warrants issued in the 2017 February Offering are exercisable for up to 1,986 common shares at an exercise price of $4,800.00. As of December 31, 2021, the fair value of the warrants amounted to CHF 0.00 (2020: CHF 0.00). As the fair value remained unchanged, no revaluation gain or loss resulted for the year ended December 31, 2021. The warrants issued in the February 2017 public offering expired on February 22, 2022, without any warrants having been exercised.

On January 30, 2018, the Company issued warrants in connection with a direct offering of 3,125 common shares, each warrant entitling its holder to purchase 0.6 common shares at an exercise price of $2,000.00 per common share. As of December 31, 2021, the outstanding warrants issued in such offering were exercisable for up to 1,875 common shares at an exercise price of $2,000.00 per common share. As of December 31, 2022 the fair value of the warrants amounted to CHF 0 (2021: CHF 1,233). The revaluation gain of the derivative for the twelve months ended December 31, 2022 amounted to CHF 1,233 (2021: CHF 5,085). Since its initial recognition on January 30, 2018, the fair value of the warrants has decreased by CHF 2,483,747 resulting in a gain in the corresponding amount (fair value as of January 30, 2018: CHF 2,483,747).

On July 17, 2018, the Company issued Series A warrants each entitling its holder to purchase 0.35 of a common share for an aggregate of 15,705 common shares, and Series B warrants entitling its holder to purchase 0.25 of a common share for an aggregate of 11,218 common shares in connection with the July 2018 Registered Offering of 44,872 common shares, each warrant entitling its holder to purchase one common share at an original exercise price of CHF 156.00 per common share. Revaluation gain/(loss) show the changes in fair value of the outstanding Series B warrant issued in connection with this offering.

As of December 31, 2019, 7,261 Series A warrants were exercised for an aggregate amount of CHF 1,132,762 and 7,161 Series B warrants were exercised for an aggregate amount of CHF 1,117,125.

As of December 31, 2019, 7,161 Series B exercised warrants were subject to revaluation at the time that they were exercised and the fair value amounted to CHF 3,005,348. Since its initial recognition on July 17, 2018 the fair value of the warrants has increased by CHF 2,433,099, resulting in a loss in the corresponding amounts (fair value as of July 17, 2018: CHF 572,249). On June 18, 2020, the Series B warrants expired without further warrants being exercised.

Due to the expiry on June 18, 2020, no Series B warrants were outstanding and subject to revaluation on December 31, 2022 and 2021.

Cash and Cash Equivalents

12 Months Ended

Dec. 31, 2022

Cash and cash equivalents [Abstract]

Cash and cash equivalents

13. Cash and cash equivalents

	December 31,		December 31,
	2022		2021
Cash in bank accounts		15,395		984,191
Cash on hand		—		—
Total cash and cash equivalents		15,395		984,191

Revenue (Tables)

12 Months Ended

Dec. 31, 2022

Revenue [Abstract]

Schedule of disaggregation of the group’s revenue from contracts with customers

	December 31,		December 31,		December 31,
	2022		2021		2020
Product sales		305,616		63,882		—

Total revenue		305,616		63,882		—

Consolidated Statement of Profit or Loss and Other Comprehensive Income/(Loss) - CHF (SFr)

12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

^[1]

Dec. 31, 2020

Consolidated Statement Of Profit Or Loss And Other Comprehensive Income Loss Abstract

Revenue

SFr 305,616

SFr 63,882

Cost of Sales

(1,443,855)

(2,240,554)

Gross profit

(1,138,239)

(2,176,672)

Other operating income

709,449

214,217

174,475

Research and development

(19,677,756)

(8,360,821)

(2,862,979)

Sales and marketing

(2,381,384)

(1,498,218)

General and administrative

(3,644,549)

(4,946,576)

(2,594,662)

Operating loss

(26,132,479)

(16,768,070)

(5,283,166)

Interest income

969

3,219

258

Interest expense

(911,869)

(189,695)

(135,151)

Foreign currency exchange gain/(loss), net

54,645

328,641

(333,553)

Revaluation gain/(loss) from derivative financial instruments

451,131

(410,918)

(2,250,222)

Net loss attributable to owners of the Company

(1,137)

(219,615)

Loss before tax

(26,538,740)

(17,036,823)

(8,221,449)

Income tax gain/(loss)

10,329

(21,620)

21,284

(26,528,411)

(17,058,443)

(8,200,165)

Items that will never be reclassified to profit or loss

Remeasurements of defined benefit liability, net of taxes of CHF 0

441,277

264,984

(26,118)

Items that are or may be reclassified to profit or loss

Foreign currency translation differences, net of taxes of CHF 0

61,046

772

88,862

Other comprehensive income/(loss), net of taxes of CHF 0

502,323

265,756

62,744

Total comprehensive loss attributable to owners of the Company

SFr (26,026,088)

SFr (16,792,687)

SFr (8,137,421)

Basic loss per share (in Francs per share)

SFr (29.13)

SFr (25.76)

SFr (25.27)

[1]	Revised, see note 33.

Research and Development Expense

12 Months Ended

Dec. 31, 2022

Research and development expense [Abstract]

Research and development expense

22. Research and development expense

	December 31,		December 31,		December 31,
	2022		2021		2020
Pre-clinical projects		509,224		587,019		242,617
Clinical projects		3,237,649		2,379,536		476,972
Product and process development		473,246		1,100,453		614,744
Employee benefits and expenses		2,585,242		1,897,155		1,120,814
Lease expenses from short-term lease		—		—		34,147
Patents and trademarks		240,380		465,587		246,592
Regulatory projects		153,863		354,507		110,612
Impairment intangible assets		12,397,148		1,529,929		—
Depreciation tangible assets		81,004		46,635		16,481
Total research and development expense		19,677,756		8,360,821		2,862,979

Research and development expenses were capitalized in the amount of CHF 1,975,784 during 2022 compared to CHF 2,839,369 in 2021. As of December 31, 2022, all capitalized development costs related to the project AM-125 were impaired.

Consolidated Statement of Cash Flows - CHF (SFr)	12 Months Ended
Consolidated Statement of Cash Flows - CHF (SFr)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of cash flows [abstract]
Net loss	SFr (26,528,411)	SFr (17,058,443)	SFr (8,200,165)
Depreciation	118,887	76,357	20,036
Impairment of intangible assets	12,397,148	1,529,929
Deferred income	932,200
Unrealized foreign currency exchange loss/(gain), net	(46,087)	(279,329)	10,818
Net interest expense	891,651	174,593	127,160
Share based payments	342,799	1,206,303	368,793
Transaction costs	1,137		219,615
Employee benefits	109,164	65,927	80,811
Revaluation loss/(gain) derivative financial instruments	(451,131)	410,918	2,250,222
Income tax loss/(gain)	(10,329)	21,620	(21,284)
Total	(12,242,972)	(13,852,125)	(5,143,994)
Inventories	827,577	(839,221)
Trade and other receivables	(103,601)	(340,119)	254,438
Prepayments	856,429	(1,297,537)	156,661
Trade and other payables	1,263,196	2,937,019	(175,878)
Accrued expenses	716,140	(280,755)	65,303
Net cash used in operating activities	(8,683,231)	(13,672,738)	(4,843,470)
Cash flows from investing activities
Purchase of intangibles	(2,142,806)	(3,325,952)	(2,315,232)
Cash paid for other non-current financial assets		(179,104)
Interest received	969		258
Net cash used in investing activities	(2,141,837)	(3,505,056)	(2,314,974)
Cash flows from financing activities
Proceeds from offerings and warrant exercises	3,962,618	6,842,940	16,074,996
Transaction costs	(35,496)	(156,817)	(636,858)
Proceeds from loans	6,038,627		1,522,931
Repayment of loan		(50,000)
Repayment of lease liabilities	(114,251)	(18,700)
Interest paid	(19,503)	(3,699)
Net cash from financing activities	9,831,995	6,613,724	16,961,069
Net increase / (decrease) in cash and cash equivalents	(993,073)	(10,564,070)	9,802,625
Cash and cash equivalents at beginning of the period	984,191	11,258,870	1,384,720
Net effect of currency translation on cash	24,277	289,391	71,525
Cash and cash equivalents at end of the period	SFr 15,395	SFr 984,191	SFr 11,258,870

General and Administrative Expense (Details) - Schedule of general and administrative expense - CHF (SFr)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of General and Administrative Expense Abstract
Employee benefits and expenses	SFr 735,139	SFr 1,554,778	SFr 811,373
Business development	15,727	967,046	95,663
Travel expenses	95,503	75,829	28,898
Administration expenses	2,669,460	2,245,862	1,645,530
Lease expenses from short-term lease	6,001	52,280	13,871
Depreciation of Right-of-use assets	118,887	29,722
Depreciation of tangible assets			3,555
Capital tax expenses	3,832	21,059	(4,228)
Total general and administrative expenses	SFr 3,644,549	SFr 4,946,576	SFr 2,594,662

Sales and Marketing Expense (Tables)

12 Months Ended

Dec. 31, 2022

Sales and Marketing Expense [Abstract]

Schedule of Sales and marketing expense

	December 31,		December 31,		December 31,
	2022		2021		2020
Marketing and sales expenses		2,131,696		1,132,864		—
Employee benefits and expenses		249,688		204,157		—
Product samples		—		161,167		—
Total sales and marketing		2,381,384		1,498,218		—

Inventories (Details) - Schedule of inventories - CHF (SFr)	Dec. 31, 2022	Dec. 31, 2021
Schedule of Inventories Abstract
Finished goods	SFr 11,644	SFr 839,221
Total	SFr 11,644	SFr 839,221

Related Party Transactions (Details) - CHF (SFr)		3 Months Ended	12 Months Ended
Related Party Transactions (Details) - CHF (SFr)	Sep. 09, 2022	Mar. 08, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Related Party Transactions (Details) [Line Items]
Fees paid				SFr 231,770
Fees payment for other services				3,025
Agreement amount	SFr 600,000
Short term loan		SFr 100,000	SFr 305,616	63,882
Bearing interest rate		5.00%
Payroll charge			1,038,810	810,671	434,017
Fees amount			183,058	165,245	163,476
Share based payments			223,286	240,408	261,988
Pension amount			49,050	29,467	26,870
Stock option amount			107,110	49,480	SFr 38,455
Gremaud GmbH [Member]
Related Party Transactions (Details) [Line Items]
Fees paid			195,988	14,720
Fees payment for other services			SFr 0	SFr 161,596
Loan agreement [Member]
Related Party Transactions (Details) [Line Items]
Agreement amount	SFr 200,000

Accrued Expenses (Details) - Schedule of accrued expenses - CHF (SFr)	Dec. 31, 2022	Dec. 31, 2021
Schedule of Accrued Expenses Abstract
Accrued research and development costs including milestone payments	SFr 741,291	SFr 557,391
Professional fees	326,365	179,461
Accrued vacation & overtime	46,868	51,218
Employee benefits incl. share based payments	362,497	196,917
Accrued interest	457,812
Other	42,781	63,588
Total accrued expenses	SFr 1,977,614	SFr 1,048,575

Other receivables (Details) - Schedule of other receivables - CHF (SFr)	Dec. 31, 2022	Dec. 31, 2021
Schedule of Other Receivables Abstract
R&D tax credit receivable	SFr 672,600	SFr 224,465
Receivable from share issuance		255,187
Value added tax receivable	78,650	168,851
Withholding tax receivable		7,336
Receivable from suppliers and other	4,737	15,501
Total other receivables	SFr 755,987	SFr 671,340

New standards, amendments and interpretations adopted by the Group

12 Months Ended

Dec. 31, 2022

New standards, amendments and interpretations adopted by the Group [Abstract]

New standards, amendments and interpretations adopted by the Group

4. New standards, amendments and interpretations adopted by the Group

In 2022, the following revised standards have been adopted:

IAS 16		Amendments to IAS 16, Proceeds before Intended Use

IAS 37		Amendments to IAS 37, Onerous contracts – Costs of Fulfilling a Contract

IFRS 3		Amendments to IFRS 3, References to the Conceptual Framework

IFRS 1, IFRS 9, IFRS		Annual improvements to IFRS Standards 2018-2020 Cycle
16, IAS 41

Adoption has not had a material impact on the amounts reported in these financial statements but may impact the accounting for future transactions and arrangements.

A number of new standards, amendments to standards and interpretations are effective for annual periods beginning after January 1, 2023, and have not been applied in preparing these consolidated financial statements.

				Planned
				application
			Effective	by the
Standard/Interpretation		Impact	date	Group
New standards, interpretations or amendments
IFRS 17	Insurance contracts	1)	January 1, 2023	FY 2023

IAS 1	Amendments to IAS 1, Classification of Liabilities as Current or Non-current	1)	January 1, 2023	FY 2023

IAS 1	Amendments to IAS 1 and IFRS practice Statement 2, Disclosure of Accounting Policies	1)	January 1, 2023	FY 2023

IAS 8	Amendments to IAS 8, Definition of Accounting Estimates	1)	January 1, 2023	FY 2023

IAS 12	Amendments to IAS 12, Deferred tax related to Assets and Liabilities arising from a Single Transaction	1)	January 1, 2023	FY 2023

IFRS 10, IAS 28	Amendments to IFRS 10 and IAS 28, Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	1)	To be set	To be set

1)	No material impact on the Group is expected from these standards and amendments issued but not effective.

Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated statement of profit or loss and other comprehensive loss	12 Months Ended
	Dec. 31, 2021 USD ($) $ / shares
As reported [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated statement of profit or loss and other comprehensive loss [Line Items]
Other income	$ 460,710
Research and development	(8,939,037)
Total operating expenses	(15,137,338)
Operating loss	(17,099,793)
Loss before tax	(17,368,546)
Net loss attributable of owners of the Company	(17,390,166)
Total comprehensive loss attributable to owners of the Company	$ (17,124,410)
Basic and diluted loss per share (in Dollars per share) \| $ / shares	$ (26.26)
Adjustment [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated statement of profit or loss and other comprehensive loss [Line Items]
Other income	$ (246,493)
Research and development	578,216
Total operating expenses	331,723
Operating loss	331,723
Loss before tax	331,723
Net loss attributable of owners of the Company	331,723
Total comprehensive loss attributable to owners of the Company	$ 331,723
Basic and diluted loss per share (in Dollars per share) \| $ / shares	$ 0.5
As revised [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated statement of profit or loss and other comprehensive loss [Line Items]
Other income	$ 214,217
Research and development	(8,360,821)
Total operating expenses	(14,805,615)
Operating loss	(16,768,070)
Loss before tax	(17,036,823)
Net loss attributable of owners of the Company	(17,058,443)
Total comprehensive loss attributable to owners of the Company	$ (16,792,687)
Basic and diluted loss per share (in Dollars per share) \| $ / shares	$ (25.76)

Research and Development Expense (Details) - CHF (SFr)	12 Months Ended
Research and Development Expense (Details) - CHF (SFr)	Dec. 31, 2022	Dec. 31, 2021
Research and development expense [Abstract]
Research and development expense capitalized	SFr 1,975,784	SFr 2,839,369

Property and Equipment (Details) - Schedule of property and equipment - CHF (SFr)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
At cost [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment	SFr 587,194	SFr 587,194
Property, plant and equipment	587,194	587,194
Additions
Disposals
Accumulated depreciation [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment	(587,193)	(540,558)
Property, plant and equipment	(587,193)	(587,193)
Charge for the year		(46,635)
Disposals
Net book value [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment	1
Property, plant and equipment	1	1
Production equipment [Member] \| At cost [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment	353,488	353,488
Property, plant and equipment	353,488	353,488
Additions
Disposals
Production equipment [Member] \| Accumulated depreciation [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment	(353,488)	(306,972)
Property, plant and equipment	(353,488)	(353,488)
Charge for the year		(46,516)
Disposals
Production equipment [Member] \| Net book value [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment
Property, plant and equipment
Office furniture and EDP [Member] \| At cost [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment	233,706	233,706
Property, plant and equipment	233,706	233,706
Additions
Disposals
Office furniture and EDP [Member] \| Accumulated depreciation [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment	(233,705)	(233,586)
Property, plant and equipment	(233,705)	(233,705)
Charge for the year		(119)
Disposals
Office furniture and EDP [Member] \| Net book value [Member]
Property and Equipment (Details) - Schedule of property and equipment [Line Items]
Property, plant and equipment	1
Property, plant and equipment	SFr 1	SFr 1

Right-of-use assets and lease liabilities (Details) - Schedule of right-of-use assets and lease liabilities - CHF (SFr)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Right-of-use assets and lease liabilities (Details) - Schedule of right-of-use assets and lease liabilities [Line Items]
Cost Beginning	SFr 594,436
Accumulated depreciation Beginning	(29,722)
Net Book Value Beginning	445,827	564,714
Net Book Value Ending		445,827
Additions		594,436
Disposals
Cost Ending	594,436	594,436
Charge for the year	(118,887)	(29,722)
Accumulated depreciation Ending	(148,609)	(29,722)
Office Building [Member]
Right-of-use assets and lease liabilities (Details) - Schedule of right-of-use assets and lease liabilities [Line Items]
Cost Beginning	594,436
Accumulated depreciation Beginning	(29,722)
Net Book Value Beginning	445,827	564,714
Net Book Value Ending		445,827
Additions		594,436
Disposals
Cost Ending	594,436	594,436
Charge for the year	(118,887)	(29,722)
Accumulated depreciation Ending	SFr (148,609)	SFr (29,722)

Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2022

Loss per share [Abstract]

Schedule of loss per share

	December 31,			December 31,			December 31,
	2022			2021			2020
Loss attributable to owners of the Company		(26,528,411	)		(17,058,443	)		(8,200,165	)
Weighted average number of shares outstanding		910,723			662,314			300,707
Basic and diluted loss per share		(29.13	)		(25.76	)		(27.27	)

Revision of Prior Period Financial Statements (Details)	1 Months Ended
Revision of Prior Period Financial Statements (Details)	Oct. 25, 2022 CHF (SFr)
Revision of Prior Period Financial Statements [Abstract]
Reverse share split	SFr 1.31
Revised reverse share split	SFr 1.29

Financial instruments and risk management (Details) - Schedule of fair value measurement of derivative financial instrument - CHF (SFr)

12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Derivative financial instrument [Member]

Financial instruments and risk management (Details) - Schedule of fair value measurement of derivative financial instrument [Line Items]

SFr 1,233

SFr 316,757

^[1]

(1,233)

410,918

^[2]

(726,442)

Financial instruments and risk management (Details) - Schedule of fair value measurement of derivative financial instrument [Line Items]

1,233

Loans [Member]

523,920

^[1]

6,038,627

(50,000)

^[2]

(168,830)

(473,920)

Lease liabilities [Member]

5,869,797

Financial instruments and risk management (Details) - Schedule of fair value measurement of derivative financial instrument [Line Items]

575,736

(130,200)

(21,700)

^[1]

15,949

597,436

^[2]

Financial instruments and risk management (Details) - Schedule of fair value measurement of derivative financial instrument [Line Items]

461,485

575,736

Total [Member]

576,969

840,677

^[1]

5,908,427

(71,700)

(1,233)

410,918

^[2]

(152,881)

(602,926)

Schedule of other operating income

SFr 6,331,282

SFr 576,969

[1]	The financing cash flows are from loan borrowings or loan and lease repayments.
[2]	Other non-cash changes include conversion of convertible loan including de-recognition of embedded derivative and initial recognition of lease liability.

Other Operating Income (Tables)

12 Months Ended

Dec. 31, 2022

Other operating income [Abstract]

	December 31,		December 31,		December 31,
	2022		2021		2020
Income from R&D tax incentive (Government grants)		700,122		211,664		—
Refund of share issuance stamp duty		—		—		100,002
Other income		9,327		2,553		74,473
Total other operating income		709,449		214,217		174,475

Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure of Accrued expenses [Abstract]

Schedule of accrued expenses

	December 31,		December 31,
	2022		2021
Accrued research and development costs including milestone payments		741,291		557,391
Professional fees		326,365		179,461
Accrued vacation & overtime		46,868		51,218
Employee benefits incl. share based payments		362,497		196,917
Accrued interest		457,812		—
Other		42,781		63,588
Total accrued expenses		1,977,614		1,048,575

Revision of Prior Period Financial Statements

12 Months Ended

Dec. 31, 2022

Revision of Prior Period Financial Statements [Abstract]

Revision of Prior Period Financial Statements

33.

Revision of Prior Period Financial Statements

In connection with the preparation of our consolidated financial statements, we identified an immaterial error with regard to advance payments for research and development costs and related tax credits for the annual period ended December 31, 2021. The error was mainly related to investigator float payments to a contract research organization. Due to COVID and other reasons, the scheduled services had not been provided by the end of the year and therefore the payments should have been recognized as advance payments and not as R&D expenses. We evaluated the error and determined that the related impact was not material to our financial statements for any prior periods, but that correction of the impact of the error would be significant to our results of operations for the six months ended June 30, 2022. Accordingly, we have revised previously reported financial information for such immaterial error, as previously disclosed in our Annual Report on Form 20-F for the year ended December 31, 2021. A summary of revisions to our previously reported financial statements presented herein for comparative purposes is included below.

Revised consolidated Balance Sheet

	As of December 31, 2021
	As reported			Adjustment			As revised
Other receivables		917,833			(246,493	)		671,340
Prepayments		996,910			578,216			1,575,126
Total current assets		3,759,901			331,723			4,091,624
Total assets		18,838,598			331,723			19,170,321
Accumulated deficit		(176,018,660	)		331,723			(175,686,937	)
Total shareholders’ equity attributable to owners of the company		12,704,528			331,723			13,036,251
Total equity and liabilities		18,838,598			331,723			19,170,321

Revised consolidated Statement of Profit or Loss and Other Comprehensive Loss

	Year ended December 31, 2021
	As reported			Adjustment			As revised
Other income		460,710			(246,493	)		214,217
Research and development		(8,939,037	)		578,216			(8,360,821	)
Total operating expenses		(15,137,338	)		331,723			(14,805,615	)
Operating loss		(17,099,793	)		331,723			(16,768,070	)
Loss before tax		(17,368,546	)		331,723			(17,036,823	)
Net loss attributable of owners of the Company		(17,390,166	)		331,723			(17,058,443	)
Total comprehensive loss attributable to owners of the Company		(17,124,410	)		331,723			(16,792,687	)
Basic and diluted loss per share		(26.26	)		0.50			(25.76	)

Basic and diluted loss per share as presented in the financial statements as of December 31, 2021, prior to the one-for-twenty reverse share split on October 25, 2022 was CHF 1.31, and the revised number would have been CHF 1.29.

Revised consolidated Statement of Cash Flows

We revised our consolidated statement of cash flows for the year ended December 31, 2021. There was no impact on net cash used in operating activities.

	Year ended December 31, 2021
	As reported			Adjustment			As revised
Net loss		(17,390,166	)		331,723			(17,058,443	)
Changes in:
Trade and other receivables		(586,612	)		246,493			(340,119	)
Prepayments		(719,321	)		(578,216	)		(1,297,537	)
Cash used in operating activities		(13,627,738	)		—			(13,672,738	)

Share-Based Compensation (Details) - Schedule of key terms and conditions related to the grants	12 Months Ended
	Dec. 31, 2022
Share-Based Compensation (Details) - Schedule of key terms and conditions related to the grants [Line Items]
Number of options outstanding	22,268
Vesting conditions	1 year service from grant date
Contractual life of options	6 years
Equity Incentive Plan Employees / Board [Member]
Share-Based Compensation (Details) - Schedule of key terms and conditions related to the grants [Line Items]
Number of options outstanding	67,682
Vesting conditions	2 years’ service from grant date (50%)
Contractual life of options	8 years
Equity Incentive Plan Employees / Board One [Member]
Share-Based Compensation (Details) - Schedule of key terms and conditions related to the grants [Line Items]
Number of options outstanding	67,682
Vesting conditions	3 years’ service from grant date (50%)
Contractual life of options	8 years

Cost of Sales (Tables)

12 Months Ended

Dec. 31, 2022

Cost of Sales [Abstract]

Schedule of cost of sales

	December 31,		December 31,		December 31,
	2022		2021		2020
Product purchases, packaging and logistics		362,584		173,758		—
Employee benefit and expenses		150,438		89,238		—
Inventory write-down		930,833		1,977,558		—
Total cost of sales		1,443,855		2,240,554		—

Document And Entity Information	12 Months Ended
Document And Entity Information	Dec. 31, 2022 shares
Document Information Line Items
Entity Registrant Name	Altamira Therapeutics Ltd.
Trading Symbol	CYTO
Document Type	20-F
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding	1,180,053
Amendment Flag	false
Entity Central Index Key	0001601936
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	false
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-36582
Entity Incorporation, State or Country Code	D0
Entity Address, Address Line One	Clarendon House
Entity Address, Address Line Two	2 Church Street
Entity Address, City or Town	Hamilton
Entity Address, Postal Zip Code	HM11
Entity Address, Country	BM
Title of 12(b) Security	Common Shares, par value CHF 0.20 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Accounting Standard	International Financial Reporting Standards
Auditor Firm ID	1235
Auditor Name	Roland Mueller
Auditor Location	Zurich, Switzerland
Business Contact
Document Information Line Items
Entity Address, Address Line One	Clarendon House
Entity Address, Address Line Two	2 Church Street
Entity Address, City or Town	Hamilton HM11
Entity Address, Postal Zip Code	HM11
Entity Address, Country	BM
Contact Personnel Name	Thomas Meyer
City Area Code	+1 (441)
Local Phone Number	295 59 50

Inventories (Tables)

12 Months Ended

Dec. 31, 2022

Inventories [Abstract]

Schedule of inventories

	December 31,		December 31,
	2022		2021

Finished goods		11,644		839,221
Total		11,644		839,221

Share-Based Compensation (Details) - CHF (SFr)	12 Months Ended
Share-Based Compensation (Details) - CHF (SFr)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-Based Compensation (Details) [Line Items]
Options granted (in Shares)	97,742	17,113
Share based payment	SFr 346,035	SFr 1,206,303	SFr 368,793
Total expense recognized for equity-settled share-based payment transactions	SFr 346,035	SFr 1,223,696	SFr 351,401
Bottom of range [member]
Share-Based Compensation (Details) [Line Items]
Stock options exercise price (in Francs per share)	SFr 5.88	SFr 15.03
Top of range [member]
Share-Based Compensation (Details) [Line Items]
Stock options exercise price (in Francs per share)	SFr 584.66	SFr 575.8

Inventories

12 Months Ended

Dec. 31, 2022

Inventories [Abstract]

Inventories

10. Inventories

	December 31,		December 31,
	2022		2021

Finished goods		11,644		839,221
Total		11,644		839,221

The Company's inventory of finished goods consisted of the product Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. Bentrio has a limited shelf life, which may affect the salability of the product, and is packaged in various configurations (stock keeping units, “SKUs”) for different markets and in different languages to address specific requirements under national rules and regulations or by trade channels. During product launch, shelf life is still relatively short since data from supporting stability studies are still limited; this tends to restrict salability through certain trade channels. In addition, there is only limited visibility on product take-up across different markets due to the lack of a sales history, and national rules and regulations may require prior approval of certain marketing materials and messages. Based on a management review of the inventory as at December 31, 2022 for any obsolete or slow-moving items, the Company wrote down finished good inventories in the amount of CHF 0.9 million in 2022 (2021: CHF 2.0 million). The amount of the write down was expensed to the income statement under Cost of Sales.

Capital and Reserves (Details) $ / shares in Units, $ in Millions									12 Months Ended
	Dec. 05, 2022	Jun. 01, 2021	Mar. 04, 2021 CHF (SFr) shares	Mar. 04, 2021 $ / shares	Dec. 03, 2020	Dec. 01, 2020 CHF (SFr) shares	Dec. 01, 2020 $ / shares	May 15, 2019	Dec. 31, 2022 USD ($) shares
Capital and Reserves [Abstract]
Description of purchase agreement	Pursuant to the purchase agreement, LPC agreed to subscribe for up to $10,000,000 of our common shares over the 24-month term of the purchase agreement. As consideration for LPC’s irrevocable commitment to purchase common shares upon the terms of and subject to satisfaction of the conditions set forth in the 2022 Commitment Purchase Agreement, the Company agreed to issue 50,000 common shares immediately to LPC as commitment shares. In 2022, no common shares were issued to LPC under the 2022 Commitment Purchase Agreement. The 2022 Commitment Purchase Agreement replaced the 2020 Commitment Purchase Agreement. Under the 2020 Commitment Purchase Agreement, LPC agreed to subscribe for up to $10,000,000 of our common shares over the 30-month term of the purchase agreement. Prior to its termination we had issued 325,000 common shares for aggregate proceeds of $4.0 million to LPC under the 2020 Commitment Purchase Agreement. The 2020 Commitment Purchase Agreement replaced the 2018 Commitment Purchase Agreement. Under the 2018 Commitment Purchase Agreement agreed to purchase common shares for up to $10,000,000 over the 30-month term of the Purchase Agreement. Prior to its termination we had issued 29,375 common shares for aggregate proceeds of $1.8 million to LPC under the LPC Purchase Agreement.
Securities purchase agreements description		the Company completed the acquisition of Trasir. The upfront acquisition price of $2.5 million was paid with 38,219 non-registered common shares at $65.40 each to the selling shareholders. In addition, 459 non-registered common shares were issued to reimburse $30,000 in expenses incurred by certain selling Trasir shareholders.			the Company entered into securities purchase agreements with several institutional investors for the purchase and sale of 100,000 common shares at an offering price of $80.00 per share, pursuant to a registered direct offering. The net proceeds of the offering were approximately $7.3 million.
Convertible loan amount			SFr 604,545			SFr 895,455			$ 2.5
Common shares			25,841			36,850
Conversion price \| $ / shares				$ 27			$ 27
Interest rate \| SFr			SFr 40,628
Description of public offering								the Company completed a public offering of (i) 22,000 common shares with a par value of CHF 16.00 each, together with warrants to purchase 22,000 common shares, and (ii) 86,064 pre-funded warrants, with each pre-funded warrant exercisable for one common share, together with warrants to purchase 86,064 common shares, including 5,500 common shares and warrants to purchase 5,500 common shares sold pursuant to a partial exercise by the underwriters of the underwriters’ over-allotment option (the “May 2019 Registered Offering”). The exercise price for the pre-funded warrants was CHF 0.20 per common share and for the warrants CHF 86.80. The net proceeds to us from the May 2019 Registered Offering were approximately $7.7 million, after deducting underwriting discounts and other offering expenses payable by us. All pre-funded warrants were exercised in 2019. In December 2020, 63,192 warrants were exercised. The remaining 44,872 warrants were exercised in March 2021.
Offering price \| $									$ 25.0
Sale of common stock									116,843
Common shares for an aggregate									1,505,244
Aggregate offering price \| $									$ 12.1

Basis of preparation (Details)			12 Months Ended
Basis of preparation (Details)	Mar. 04, 2021 CHF (SFr)	Dec. 01, 2020 CHF (SFr)	Dec. 31, 2022 CHF (SFr)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 CHF (SFr)
Basis of preparation (Details) [Line Items]
Total cash \| SFr			SFr 15,395			SFr 984,191
Cash and cash equivalents (in Francs) \| SFr			15,000
Issuance of common shares \| $				$ 5,100,000
Convertible loan	SFr 604,545	SFr 895,455		2,500,000
Milestone payment			700,000	1,000,000
Tax asset (in Francs) \| SFr			SFr 41,430			SFr 31,879
OligoPhore™ [Member]
Basis of preparation (Details) [Line Items]
Financing instruments \| $				12,900,000
SemaPhore™ [Member]
Basis of preparation (Details) [Line Items]
Financing instruments \| $				$ 9,100,000
Switzerland [Member]
Basis of preparation (Details) [Line Items]
Tax term			7 years	7 years
United States [Member]
Basis of preparation (Details) [Line Items]
Tax term			20 years	20 years
Bottom of range [member]
Basis of preparation (Details) [Line Items]
Total cash \| SFr			SFr 15,000,000
Bottom of range [member] \| Board of Directors [Member]
Basis of preparation (Details) [Line Items]
Total cash \| $					$ 15
Top of range [member]
Basis of preparation (Details) [Line Items]
Total cash \| SFr			SFr 17,000,000
Top of range [member] \| Board of Directors [Member]
Basis of preparation (Details) [Line Items]
Total cash \| $					$ 17,000,000

Taxation (Details) - Schedule of effective income tax expense - CHF (SFr)

12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Schedule of Effective Income Tax Expense Abstract

Loss before income tax

SFr (26,538,740)

SFr (17,036,823)

^[1]

SFr (8,221,449)

Income tax at statutory tax rates applicable to results in the respective countries

3,641,775

2,348,057

991,120

Effect of unrecognized temporary differences

(125,260)

(632,031)

(302,557)

Effect of unrecognized taxable losses

(3,015,088)

(1,885,486)

(184,881)

Effect of impairment of assets

(75,375)

Effect of previously unrecognized deferred tax asset

97,458

Effect of expenses not considerable for tax purposes

(47,894)

Effect of impact from application of different tax rates

(491,098)

223,215

(531,962)

Income tax gain/(loss)

SFr 10,329

SFr (21,620)

SFr 21,284

[1]	Revised, see note 33.

Financial instruments and risk management (Details) - Schedule of fair value measurement of assets and liabilities and valuation techniques - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Level 2 [Member] \| Derivative Financial Instruments, Assets [Member]
Financial instruments and risk management (Details) - Schedule of fair value measurement of assets and liabilities and valuation techniques [Line Items]
liabilities – Warrants from public offerings		$ 1,233
Level 3 [Member] \| Derivative Financial Instruments, Assets [Member]
Financial instruments and risk management (Details) - Schedule of fair value measurement of assets and liabilities and valuation techniques [Line Items]
Derivative financial liabilities – Embedded Derivatives FiveT Convertible Loan
Level 3 [Member] \| Derivative financial asset - Option LPC purchase agreement [Member]
Financial instruments and risk management (Details) - Schedule of fair value measurement of assets and liabilities and valuation techniques [Line Items]
Derivative financial asset - Option LPC purchase agreement	Asset 270,176	Asset

- Definition

The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity’s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity’s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity’s own equity instruments. For this purpose the entity’s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity’s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]

+ References + Details

Other receivables

12 Months Ended

Dec. 31, 2022

Other receivables [Abstract]

Other receivables

11. Other receivables

	December 31,		December 31,
	2022		2021
R&D tax credit receivable		672,600		224,465
Receivable from share issuance		—		255,187
Value added tax receivable		78,650		168,851
Withholding tax receivable		—		7,336
Receivable from suppliers and other		4,737		15,501
Total other receivables		755,987		671,340

As described in Note 3, Significant accounting policies, the Company obtains government grants under the Australian R&D Tax Incentive program. The R&D tax credit receivable as of December 31, 2022 relates to the reimbursement application for compensation of R&D expenditures incurred in 2022. Other receivables were not considered impaired in the years presented herein.

Consolidated Statement of Profit or Loss and Other Comprehensive Income/(Loss) (Parentheticals) - CHF (SFr)

12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

^[1]

Dec. 31, 2020

Consolidated Statement Of Profit Or Loss And Other Comprehensive Income Loss Abstract

Remeasurements of defined benefit liability, net of taxes

SFr 0

Foreign currency translation differences, tax

Other comprehensive income/(loss), net

SFr 0

Diluted loss per share (in Francs per share) (in Francs per share)

SFr (29.13)

SFr (25.76)

SFr (25.27)

[1]	Revised, see note 33.

Segment information

12 Months Ended

Dec. 31, 2022

Segment information [Abstract]

Segment information

6. Segment information

Geographical information

The Group’s non-current assets by the Company’s country of domicile were as follows:

	December 31,		December 31,
	2022		2021
Switzerland		4,339,509		14,734,738
Australia		—		144,854
Total		4,339,509		14,879,592

Non-current assets for geographical information exclude financial instruments and deferred tax assets.

Intangible assets

12 Months Ended

Dec. 31, 2022

Intangible assets [Abstract]

Intangible assets

9. Intangible assets

				IP & Data						Internally
	Licenses			rights			Patents			generated			Total
At cost
As of January 1, 2021		1,482,520			193,989			417,216			7,021,685			9,115,410
Exchange differences		—			—			—			(3,654	)		(3,654	)
Additions		3,893,681			—			55,938			2,783,431			6,733,050
As of December 31, 2021		5,376,201			193,989			473,154			9,801,462			15,844,806
Exchange differences		—			—			—			168			168
Additions		—			—			275,281			1,700,503			1,975,784
As of December 31, 2022		5,376,201			193,989			748,435			11,502,133			17,820,758

Accumulated amortization and impairment losses
As of January 1, 2021		—			—			—			—			—
Impairment		(1,482,520	)		(47,409	)		—			—			(1,529,929	)
As of December 31, 2021		(1,482,520	)		(47,409	)		—			—			(1,529,929	)
Impairment		—			(146,580	)		(748,435	)		(11,502,133	)		(12,397,148	)
As of December 31, 2022		(1,482,520	)		(193,989	)		(748,435	)		(11,502,133	)		(13,927,077	)

Net book value
As of December 31, 2021		3,893,681			146,580			473,154			9,801,462			14,314,877
As of December 31, 2022		3,893,681			—			—			—			3,893,681

Intangible assets comprise upfront and milestone payments related to licenses and capitalized development costs.

Commencing with the business year 2018, the Company recorded intangibles related to direct development expenditure of its AM-125 program. In 2019, a US patent on AM-125 was issued and a related EU application was allowed. As a consequence, we started to capitalize patent prosecution and registration costs and in 2022, we capitalized an amount of CHF 275,281 (2021: CHF 55,938). The additions to internally generated intangibles of CHF 1,700,503 includes an adjustment of government grants of CHF 40,653 under the Australian R&D tax incentive program. The amount of CHF 2,783,431 capitalized in 2021 was net of CHF 94,118 government grants obtained.

Based on the impairment testing performed under IFRS as of December 31, 2022, all intangible assets related to the AM-125 project were written off. Accordingly, the Company recorded an impairment of CHF 12,397,148 to its recoverable amount for AM-125 taking in consideration uncertainties regarding the realization of the cash flows in connection with the planned sale or the out-licensing of the AM-125 assets. The recoverable amount was calculated based on an out-license model of AM-125 at current development stage. The recoverable amount of the relevant intangible asset has been determined to be nil on the basis of their value in use, with consideration of fair value less costs of disposal not supporting a higher recoverable amount.

In 2021 the intangible assets related to the projects AM-101, AM-111 and AM-201 were impaired.

The remaining intangible assets are related to the acquisition of Trasir Therapeutics Inc. in 2021, which was treated as an asset acquisition because substantially all the fair value of Trasir was concentrated in a worldwide exclusive license agreement with Washington University (Note 3). Amortization will commence once the intangible assets are available for use, which will be the case after regulatory approvals are obtained and the related products are available for use.

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2022

Property and Equipment [Abstract]

Schedule of property and equipment

				Office
	Production			furniture
	equipment			and EDP			Total
At cost
As of January 1, 2021		353,488			233,706			587,194
Additions		—			—			—
Disposals		—			—			—
As of December 31, 2021		353,488			233,706			587,194
Additions		—			—			—
Disposals		—			—			—
As of December 31, 2022		353,488			233,706			587,194

Accumulated depreciation
As of January 1, 2021		(306,972	)		(233,586	)		(540,558	)
Charge for the year		(46,516	)		(119	)		(46,635	)
Disposals		—			—			—
As of December 31, 2021		(353,488	)		(233,705	)		(587,193	)
Charge for the year		—			—			—
Disposals		—			—			—
As of December 31, 2022		(353,488	)		(233,705	)		(587,193	)

Net book value
As of December 31, 2021		—			1			1
As of December 31, 2022		—			1			1

Capital and Reserves (Details) - Schedule of issued share capital (Parentheticals) - SFr / shares	Dec. 31, 2022	Dec. 31, 2021
Ordinary Shares Nominal Value [member]
Capital and Reserves (Details) - Schedule of issued share capital (Parentheticals) [Line Items]
Nominal value of common shares	SFr 0.2	SFr 0.2

Right-of-use assets and lease liabilities (Details) - Schedule of lease liabilities - CHF (SFr)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of Lease Liabilities [Abstract]
As of January 1	SFr 575,736
thereof non-current	343,629	461,485
thereof current	117,856	114,251
Additions		594,436
Interest expense	15,949	3,000
Repayment of lease liability	(130,200)	(21,700)
As of December 31	SFr 461,485	SFr 575,736

Significant accounting policies (Details)	12 Months Ended
Significant accounting policies (Details)	Dec. 31, 2022 USD ($)	Dec. 31, 2021	Dec. 31, 2022 CHF (SFr)	Jun. 01, 2021
Significant accounting policies (Details) [Line Items]
Number of operating segments	1
Share capital percentage				100.00%
Purchase price description	(i) 38,219 non-registered common shares of the Company, par value CHF 0.20 per share, calculated based on a value of $2,500,000 divided by the average closing price of the Common Shares on the 15 trading days preceding the closing date (the “Reference Price”, which amounted to $65.40 per Common Share); (ii) contingent on the occurrence of positive results from a subsequent post-closing scientific study led by Trasir (“Positive Results”), $1,500,000 of common shares of the Company to be calculated based on the average closing price of the common shares on the 15 trading days preceding the occurrence of Positive Results; and (iii) $210,000 for expenses incurred by certain selling Trasir shareholders paid in $180,000 in cash and 459 non-registered common shares based on the Reference Price.
Minimum royalty term	12 years
Aggregate amount \| $	$ 4,375,000
License agreement description	The acquisition of Trasir was treated as an asset acquisition because substantially all the fair value is concentrated in a single identifiable asset, the License Agreement with WU. The acquisition of the license is settled to a large extent in exchange for a variable number of the Company’s publicly listed shares. IFRS 2 “Share-based payments” was applied. With regards to the contingent part of the purchase price as mentioned under (ii) above, a downward adjustment of CHF 269,700 to the estimated fair value was made to reflect the possibility of not meeting the condition of Positive Results. As of December 31, 2021 and December 31, 2022, the total carrying amount of the license acquired amounted to CHF 3,893,681, including directly attributable transaction costs of CHF 198,246.
Leases amount \| SFr			SFr 5,000
Granted share option percentage	50.00%
Granted term	2 years
Research and development expenditures percentage	48.50%
License [member]
Significant accounting policies (Details) [Line Items]
Estimated useful life		10 years
Board of Directors [Member]
Significant accounting policies (Details) [Line Items]
Granted term	1 year
Equity Incentive Plan [Member]
Significant accounting policies (Details) [Line Items]
Granted term	3 years
Remaining granted percentage	50.00%

Cash and Cash Equivalents (Tables)

12 Months Ended

Dec. 31, 2022

Cash and cash equivalents [Abstract]

Schedule of cash and cash equivalents

	December 31,		December 31,
	2022		2021
Cash in bank accounts		15,395		984,191
Cash on hand		—		—
Total cash and cash equivalents		15,395		984,191

Deferred income (Details) - 12 months ended Dec. 31, 2022 SFr in Millions, $ in Millions	CHF (SFr)	USD ($)
Deferred Income [Abstract]
Upfront payment amount	SFr 0.9	$ 1

Financial instruments and risk management (Details) - Schedule of reasonably alternative assumptions for the valuation of the option component of the convertible loan - CHF (SFr)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Financial instruments and risk management (Details) - Schedule of reasonably alternative assumptions for the valuation of the option component of the convertible loan [Line Items]
Change in volatility	(5.00%)
Effect on result before taxes on CHF
Change in volatility [Member]
Financial instruments and risk management (Details) - Schedule of reasonably alternative assumptions for the valuation of the option component of the convertible loan [Line Items]
Change in volatility	5.00%
Effect on result before taxes on CHF

Loss Per Share (Details) - Schedule of loss per share (Parentheticals) - SFr / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Loss Per Share Abstract
Diluted loss per share	SFr (2,808)	SFr (25.76)	SFr (27.27)

Loans

12 Months Ended

Dec. 31, 2022

Loans [Abstract]

Loans

31. Loans

	December 31,		December 31,
	2022		2021
Convertible loan February 2022		4,898,377		—
Loans with warrants		871,420		—
Short-term loan from related party		100,000		—
Total		5,869,797		—

Convertible Loan Agreements

	December 31,			December 31,
	2022			2021
As of January 1		—			473,920
Gross proceeds at disbursement date		5,000,000			—
Embedded derivative, separated		(449,898	)		—
Transaction costs allocated to host		(10,236	)		—
Carrying amount at initial recognition		4,539,866			—

Converted principal amount		—			(644,813	)
Accrued interest		447,945			8,348
Amortization		358,511			162,545
Total		5,346,322			—
Accrued interest balance of December 31		447,945			—
Convertible loan balance of December 31		4,898,377			—

On December 28, 2022, the Company entered into two separate loan agreements with two private investors (“Private Lenders”), pursuant to which Private Lenders has agreed to loan to the Company an aggregate of CHF 250,000 and CHF 100,000, respectively, which loans bear interest at the rate of 5% per annum and mature as of May 30, 2023. The Company agreed to grant to Private Lenders warrants to purchase an aggregate 33,700 and 13,480 common shares. The warrants will be exercisable at an exercise price of CHF 4.4512 per share for up to five years from the date of issuance.

The loans with warrants are classified as a hybrid contract containing a host that is a financial liability and embedded derivatives (warrants) separated from the host. The embedded derivatives are classified as an equity component as they may be settled by the company exchanging a fixed amount of cash for a fixed number of its own equity instruments. The embedded derivatives are valued at initial recognition applying a Black-Scholes option pricing model. The valuation is based on input parameters, classified as Level 3. The fair value of the embedded derivative at initial recognition amounted to CHF 48,185 and was directly recognized in equity. The initial fair value of the liability component was derived by subtracting the fair value of the equity component from the nominal value of the loan. The host is subsequently carried at amortized cost, as of December 31, 2022, the carrying amount of the host amounted to CHF 305,873 and is included in the balance sheet under current liabilities.

On September 9, 2022, the Company entered into a loan agreement with FiveT Investment Management Ltd. (“FiveT IM”), Dominik Lysek and Thomas Meyer, the Company’s CEO (the “Lenders”), pursuant to which the Lenders have agreed to loan to the Company an aggregate of CHF 600,000.00 (the “September 2022 Loan Agreement”), which loan bears interest at the rate of 5% per annum and matures as of March 31, 2023. The Company agreed to issue to the Lenders warrants to purchase an aggregate 41,666 common shares. Such warrants became exercisable immediately at an exercise price of CHF 7.20 per share, may be exercised up to five years from the date of issuance and may be exercised on a cashless basis in certain circumstances specified therein. Mr. Meyer lent CHF 200,000 of the total principal amount.

The loan with warrants is classified as a hybrid contract containing a host that is a financial liability and embedded derivatives (warrants) separated from the host. The embedded derivatives are classified as an equity component as they may be settled by the company exchanging a fixed amount of cash for a fixed number of its own equity instruments. The embedded derivatives are valued at initial recognition applying a Black-Scholes option pricing model. The valuation is based on input parameters, classified as Level 3. The fair value of the embedded derivative at initial recognition amounted to CHF 86,744 and was directly recognized in equity. The initial fair value of the liability component was derived by subtracting the fair value of the equity component from the nominal value of the loan. The host is subsequently carried at amortized cost, as of December 31, 2022, the carrying amount of the host amounted to CHF 561,062 and is included in the balance sheet under current liabilities.

On February 4, 2022, the Company entered into a convertible loan agreement with FiveT IM. The convertible loan of CHF 5.0 million, as amended (the “FiveT Loan”) carried interest at the rate of 10% per annum and was to mature on May 31, 2023. FiveT IM had the right to convert all or part of the FiveT Loan, including accrued and unpaid interest, at its option, into common shares, subject to the limitation that the Lender own no more than 4.9% of the common shares at any time. On April 13, 2023, the Company and FiveT IM entered into an amendment to the FiveT Loan (the “FiveT Loan Amendment”), which amended the conversion price of the FiveT Loan to a fixed price equal to the lower of (a) the mean daily trading volume weighted average price (“VWAP”) of the Company’s common shares on the Nasdaq Stock Market on the 20 trading days preceding the effective date of the FiveT Loan Amendment or (b) 90% of the VWAP on the effective date of the FiveT Loan Amendment. From April 13, 2023 to April 17, 2023, FiveT IM converted the entire FiveT Loan into an aggregate of 4,341,012 common shares at an average conversion price of $1.4475 per share. As a result, the FiveT Loan is no longer outstanding and has been terminated.

The FiveT Loan was classified as a hybrid contract containing a host that is a financial liability and embedded derivatives separated from the host and measured at fair value with all changes in fair value recognized in profit or loss. The embedded financial derivatives are initially valued by an independent consultant, applying a simulation-based valuation approach. The valuation of the embedded financial derivatives is based on input parameters, classified as Level 3. One of the significant inputs is the historical volatility of the Company’s common shares. The underlying share price development has been simulated based on a Geometric Brownian Motion (GBM). In accordance with the GBM definition, a normalized, sustainable level of volatility was applied. The normalized volatility used at initial recognition was 90.7%, over a lookback period of 12 months. Other significant assumptions relate to the expected exercise date, the expected execution date, the calculation of the repayment amount, as well as assumptions with regards to the early repayment trigger and to the conversion option in Altamira shares. The embedded derivatives of the convertible loan are closely related to each other and are therefore accounted for as a single instrument (i.e., a compound derivative). Due to the conversion based on market share price, the conversion right may result in a variable number of conversion shares and the embedded derivatives are therefore classified as a financial liability.

As of December 31, 2022, the carrying amount of the host for the unconverted outstanding loan amounted to CHF 4,898,377 and is included in the balance sheet under current liabilities. The fair value of the embedded derivatives amounted to CHF 0 (at initial recognition February 8, 2022: CHF 449,898). A revaluation gain related to fair value measurement of embedded derivatives of CHF 449,898 as well as effective interest expenses and transaction costs of CHF 807,593 in total were recorded in profit or loss.

On September 7, 2020, our affiliate Altamira Medica AG (“Altamira Medica”) and Auris Medical Holding Ltd. (“the Company”) entered into a convertible loan agreement with FiveT Capital Holding AG (“FiveT”) to raise CHF 1,500,000 to fund the initial development of AM-301. The loan had a term of 18 months and carried interest at 8% p.a., which would not be paid in cash but added to the loan outstanding amount. At maturity, the unconverted outstanding amount of the loan including accrued interest would become payable in cash. Altamira Medica may choose to repay the total outstanding amount including the accrued interest at 130%, first time after 6 months with a prior written notice of 1 month. Prior to the expiry of the repayment notice period, the lender may convert the repayment amount.

Under the convertible loan agreement FiveT has the right to convert the outstanding principal amount including interest into the Company’s common shares or alternatively into Altamira Medica shares. The pricing of a conversion into our common shares is at the lower of 150% of the share price at close of the disbursement date ($27.00 fixed on September 8, 2020) and 95% of the average price of our common share at close of the 5 trading dates preceding the date of the conversion notice. However, the conversion price shall not be less than the higher of the par value and the backward-looking 3-month floor price of 75% of the average closing price of our common shares. The pricing of a conversion into Altamira Medica shares is at the lower of CHF 3.00 and the issue price of a qualified financing round, meaning that a third-party investor will hold at least 10% of Altamira Medica shares after completion of such financing round. The convertible loan agreement further contains a limitation on the conversion rights in the sense that they may not result in an ownership interest of more than 9.99% in the Company or 49.99% in Altamira Medica. By December 31, 2020, an amount of CHF 895,455 has been converted into 36,850 common shares of the Company (at a conversion price of $27.00).

The convertible loan is classified as a hybrid contract containing a host that is a financial liability and embedded derivatives separated from the host and measured at fair value with all changes in fair value recognized in profit or loss. The embedded financial derivatives are valued by an independent consultant initially and at period end at fair value, applying a simulation-based valuation approach. The valuation of the embedded financial derivatives is based on input parameters, classified as Level 3. One of the significant inputs is the historical volatility of the Company’s common shares. The underlying share price development has been simulated based on a Geometric Brownian Motion (GBM). In accordance with the GBM definition, a normalized, sustainable level of volatility was applied. The normalized volatility used as per December 31, 2020 was 90.9%, over a lookback period of 12 months. Other significant assumptions relate to the expected exercise date, the expected execution date, the calculation of the repayment amount, as well as assumptions with regards to the early repayment trigger and to the conversion option in Altamira Medica shares. The embedded derivatives of the convertible loan are closely related to each other and are therefore accounted for as a single instrument (i.e., a compound derivative). Due to the conversion based on market share price, the conversion right may result in a variable number of conversion shares and the embedded derivatives are therefore classified as a financial liability.

The carrying amount of the host contract at initial recognition is the difference between the carrying amount of the hybrid contract and the fair value of the embedded derivatives. The host is then subsequently measured at amortized cost, using the effective interest rate method. As of December 31, 2020, the carrying amount (including accrued interest) of the host for the unconverted outstanding loan amounted to CHF 473,920 and is included in the balance sheet under current liabilities. On March 4, 2021, the remaining amount of CHF 644,813 including amortization and interest was converted into 25,841 common shares of of the Company at a conversion price of $27.00. As a result, the carrying amount of the convertible loan as of December 31, 2021 is CHF 0.

The fair value of the embedded derivatives of the outstanding loan units amounted to CHF 0 (31.12.2020: CHF 310,439 included in current derivative financial instruments). Expenses related to fair value measurement of embedded derivatives of CHF 416,003 (2020: CHF 2,248,257) as well as effective interest and transaction costs of CHF 170,893 (2020: CHF 127,418) were recorded as financial expenses in profit or loss.

Deferred income (Tables)

12 Months Ended

Dec. 31, 2022

Deferred Income [Abstract]

Schedule of deferred income

	December 31,		December 31,
	2022		2021
Upfront payment		932,200		—
Total deferred income		932,200		—

Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated statement of profit or loss and other comprehensive loss (Parentheticals)	12 Months Ended
	Dec. 31, 2021 $ / shares
As reported [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated statement of profit or loss and other comprehensive loss (Parentheticals) [Line Items]
Diluted loss per share (in Dollars per share)	$ (26.26)
Adjustment [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated statement of profit or loss and other comprehensive loss (Parentheticals) [Line Items]
Diluted loss per share (in Dollars per share)	0.50
As revised [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated statement of profit or loss and other comprehensive loss (Parentheticals) [Line Items]
Diluted loss per share (in Dollars per share)	$ (25.76)

Right-of-use assets and lease liabilities (Details) - Schedule of low value and short-term lease expenses - CHF (SFr)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of Low Value and Short Term Lease Expenses [Abstract]
Expense related to short-term leases	SFr 6,001	SFr 52,280
Expense related to leases of low value assets
Total	SFr 6,001	SFr 52,280

Reporting entity

12 Months Ended

Dec. 31, 2022

Reporting entity [Abstract]

Reporting entity

1. Reporting entity

Altamira Therapeutics Ltd. (the “Company”) is an exempted company incorporated under the laws of Bermuda. The Company began its operations as a corporation organized in accordance with Swiss law and domiciled in Switzerland under the name Auris Medical Holding AG (“Auris Medical (Switzerland)”). Following shareholder approval at an extraordinary general meeting of shareholders held on March 8, 2019 and upon the issuance of a certificate of continuance by the Registrar of Companies in Bermuda on March 18, 2019, the Company discontinued as a Swiss company and, pursuant to Article 163 of the Swiss Federal Act on Private International Law and pursuant to Section 132C of the Companies Act 1981 of Bermuda (the “Companies Act”), continued existence under the Companies Act as a Bermuda company with the name “Auris Medical Holding Ltd.” (the “Redomestication”). On March 18, 2019, the common shares of the Company began trading on the Nasdaq Capital Market under the trading symbol “EARS”. The Company’s registered office is located at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda. On July 21, 2021, the Company changed its name to Altamira Therapeutics Ltd. Since July 26, 2021, the Company’s common shares are traded under the trading symbol “CYTO”. On October 25, 2022, the Company effected a one-for-twenty reverse share split (the “2022 Reverse Share Split”) of the Company’s issued and outstanding common shares. Unless indicated or the context otherwise requires, all per share amounts and numbers of common shares in this report have been retrospectively adjusted for the 2022 Reverse Share Split, as if such 2022 Reverse Share Split occurred on the first day of the periods presented.

These consolidated financial statements comprise the Company and its subsidiaries (together referred to as the “Group” and individually as “Group entities”). The Company is the ultimate parent of the following Group entities:

●

Auris Medical AG, Basel, Switzerland (100%) with a nominal share capital of CHF 2,500,000

●

Otolanum AG, Zug, Switzerland (100%) with a nominal share capital of CHF 100,000

●

Zilentin AG, Zug, Switzerland (100%), with a nominal share capital of CHF 100,000

●

Altamira Medica AG, Zug, Switzerland (100%), with a nominal share capital of CHF 3,000,000

●

Altamira Therapeutics, Inc., Dover, Delaware, United States (100%) with a nominal share capital of $100

●

Auris Medical Ltd., Dublin, Ireland (100%) with a nominal share capital of EUR 100

●

Auris Medical Pty Ltd, Melbourne, Australia (100%), with a nominal share capital of AUD 100

The Company is a clinical-and commercial-stage biopharmaceutical company developing therapeutics that address important unmet medical needs. It is currently active in two areas: the development of RNA delivery technology and therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; AM-401 for the treatment of KRAS driven cancer, AM-411 for the treatment of rheumatoid arthritis; preclinical), and nasal sprays for protection against airborne allergens, and where approved, viruses (Bentrio®; commercial) or the treatment of vertigo (AM-125; Phase 2). The Company is working to reposition the Company around RNA delivery technology while exploring strategic options to either divest or partner its non-RNA traditional businesses.

Intangible assets (Details)	12 Months Ended
Intangible assets (Details)	Dec. 31, 2022 CHF (SFr)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 CHF (SFr)
Disclosure Of Intangible Assets Text Block Abstract
Capitalized amount	SFr 275,281		SFr 55,938
Intangibles amount government grants	1,700,503		SFr 94,118
Intangibles net amount	40,653
Capitalized net	SFr 2,783,431
Impairment amount (in Dollars) \| $		$ 12,397,148

Accounting Policies, by Policy (Policies)

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Basis of consolidation

Basis of consolidation

Subsidiaries

Subsidiaries are entities controlled by the Group. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases.

Transactions eliminated on consolidation

All inter-company balances, transactions and unrealized gains on transactions have been eliminated in consolidation. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.

Segment reporting

Segment reporting

A segment is a distinguishable component of the Group that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Group’s other components.

The Chief Executive Officer is determined to be the Group’s Chief Operating Decision Maker (“CODM”). The CODM assesses the performance and allocates the resources of the Group as a whole, as all of the Group’s activities are focusing on the development of therapeutics for important unmet medical needs. Financial information is only available for the Group as a whole. Therefore, management considers there is only one operating segment under the requirements of IFRS 8, Operating Segments.

Foreign currency

Foreign currency

Foreign currency transactions

Items included in the financial statements of Group entities are measured using the currency of the primary economic environment in which the entity operates. Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss. Non-monetary items that are measured based on historical cost in a foreign currency are not re-translated.

Foreign operations

Assets and liabilities of Group entities whose functional currency is other than CHF are included in the consolidation by translating the assets and liabilities into the reporting currency at the exchange rates applicable at the end of the reporting period. Income and expenses are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transaction).

These foreign currency translation differences are recognized in Other Comprehensive income/(loss) and presented in the foreign currency translation reserve in equity. When a foreign operation is disposed of such that control is lost, the cumulative amount in the translation reserve related to that foreign operation is reclassified to profit or loss as part of the gain or loss on disposal.

Closing rates for the most significant foreign currencies relative to CHF:

		Geographical	Reporting	December 31,		December 31,		December 31,
Currency		area	entities	2022		2021		2020
CHF	Swiss Franc	Switzerland	5		1.0000		1.0000		1.0000
USD	Dollar	United States	1		0.9251		0.9110		0.8840
EUR	Euro	Europe	1		0.9901		1.0361		1.0817
AUD	Dollar	Australia	1		0.6305		0.6620		0.6822

Average exchange rates for the year for the most significant foreign currencies relative to CHF:

		Geographical	Reporting
Currency		area	entities	2022		2021		2020
CHF	Swiss Franc	Switzerland	5		1.0000		1.0000		1.0000
USD	Dollar	United States	1		0.9550		0.9142		0.9581
EUR	Euro	Europe	1		1.0050		1.0810		1.0825
AUD	Dollar	Australia	1		0.6629		0.6866		0.6546

Property and equipment

Property and equipment

Property and equipment is measured at historical costs less accumulated depreciation and any accumulated impairment losses. Historical costs include expenditures that are directly attributable to the acquisition of the items. When parts of an item of tangible assets have different useful lives, they are accounted for as separate tangible asset items (major components). Depreciation is calculated on a straight-line basis over the expected useful life of the individual asset. The applicable estimated useful lives are as follows:

Production equipment		5 years
Office furniture and electronic data processing equipment (“EDP”)		3 years

Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognized. All other repairs and maintenance are charged to profit or loss during the financial period in which they are incurred.

Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate. When an asset is reviewed for impairment, the asset’s carrying amount may be written down immediately to its recoverable amount, provided the asset’s carrying amount is greater than its estimated recoverable amount. Management assesses the recoverable amount by assessing the higher of its fair value less costs to sell or its value in use.

Cost and accumulated depreciation related to assets retired or otherwise disposed are removed from the accounts at the time of retirement or disposal and any resulting gain or loss is included in profit or loss in the period of disposition.

Intangible assets

Intangible assets

Research and development

Expenditures on the Group’s research programs are not capitalized, they are expensed when incurred.

Expenditures on the Group’s development programs are generally not capitalized except if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group intends to and has sufficient resources to complete development and to use or sell the asset. For the development projects of the Group, these criteria are generally only met when regulatory approval for commercialization is obtained. For the AM-125 program for the treatment of vertigo it was the Group’s assessment up to 2022 that the criteria mentioned above were met and therefore direct development expenditures were capitalized for AM-125 in 2020, 2021 and 2022, including intellectual property-related costs for the prosecution and registration of patents . As of December 31, 2022, all capitalized direct development costs related to AM-125 were impaired based on the impairment test performed under IFRS.

Licenses, intellectual property and data rights

Intellectual property rights that are acquired by the Group are capitalized as intangible assets if they are controlled by the Group, are separately identifiable and are expected to generate future economic benefits, even if uncertainty exists as to whether the research and development will ultimately result in a marketable product. Consequently, upfront and milestone payments to third parties for the exclusive use of pharmaceutical compounds in specified areas of treatment are recognized as intangible assets.

Measurement

Intangible assets acquired that have finite useful lives are measured at cost less accumulated amortization and any accumulated impairment losses.

Subsequent expenditure

Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated goodwill and brands, is recognized in profit or loss as incurred.

Amortization

All licenses of the Group have finite lives. Amortization will commence once the Group’s intangible assets are available for use which will be the case after regulatory approvals are obtained and the related products are available for use. Amortization of licenses is calculated on a straight-line basis over the period of the expected benefit or until the license expires, whichever is shorter. The estimated useful life is 10 years or the remaining term of patent protection. The Group assesses at each statement of financial position date whether intangible assets which are not yet ready for use are impaired.

Impairment of non-financial assets

Impairment of non-financial assets

Property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units). An impairment loss is recognized as the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell or value in use. Impairment losses are recognized in profit or loss. Assets that were previously impaired are reviewed for possible reversal of the impairment at each reporting date. Any increase in the carrying amount of an asset will be based on the depreciated historical costs had the initial impairment not been recognized.

Asset purchase

Asset purchase

On June 1, 2021, we acquired 100% of the share capital of privately held Trasir Therapeutics Inc. (“Trasir”) through the merger of our subsidiary Auris Medical Inc. with and into Trasir (the “Merger”), with Trasir surviving the merger as the surviving entity. Trasir was subsequently renamed Altamira Therapeutics, Inc. and redomiciled in Dover, Delaware. Founded in 2014, Trasir has been a pioneer in the development of nanoparticles for extrahepatic oligonucleotide delivery.

The purchase price for Trasir comprised: (i) 38,219 non-registered common shares of the Company, par value CHF 0.20 per share, calculated based on a value of $2,500,000 divided by the average closing price of the Common Shares on the 15 trading days preceding the closing date (the “Reference Price”, which amounted to $65.40 per Common Share); (ii) contingent on the occurrence of positive results from a subsequent post-closing scientific study led by Trasir (“Positive Results”), $1,500,000 of common shares of the Company to be calculated based on the average closing price of the common shares on the 15 trading days preceding the occurrence of Positive Results; and (iii) $210,000 for expenses incurred by certain selling Trasir shareholders paid in $180,000 in cash and 459 non-registered common shares based on the Reference Price.

Trasir’s main asset is an exclusive license agreement (the “License Agreement”) with Washington University located in St. Louis, Missouri (“WU”). Pursuant to the License Agreement, WU granted Trasir an exclusive, worldwide, royalty-bearing license (with the right to sublicense) during the term of the License Agreement under certain patent rights owned or controlled by WU to research, develop, make, have made, sell, offer for sale, use and import pharmaceutical products covered under such patent rights for all fields of use. Such licensed products may include “silencing RNA” (siRNAs) pharmaceutical preparations formulated in combination with Trasir’s proprietary delivery technologies. In consideration for such worldwide, exclusive license, the Company (through its acquisition of Trasir, described above) will be obligated to pay WU: annual license maintenance fees in the low five figures through first commercial sale; pre-clinical and clinical regulatory milestones; sales milestones; and a low single digit royalty based on annual net sales of licensed products worldwide for at least the applicable patent term or period of marketing exclusivity, whichever is longer, but in no case less than a minimum royalty term of 12 years; and a percentage share (in the double digits) of sublicensing revenues received by the Company in connection with licensed products. Such regulatory and sales milestones may total up to an aggregate of $4,375,000. In the event the Company fails to meet certain regulatory diligence milestones, WU will have the right to terminate the license.

The acquisition of Trasir was treated as an asset acquisition because substantially all the fair value is concentrated in a single identifiable asset, the License Agreement with WU. The acquisition of the license is settled to a large extent in exchange for a variable number of the Company’s publicly listed shares. IFRS 2 “Share-based payments” was applied. With regards to the contingent part of the purchase price as mentioned under (ii) above, a downward adjustment of CHF 269,700 to the estimated fair value was made to reflect the possibility of not meeting the condition of Positive Results. As of December 31, 2021 and December 31, 2022, the total carrying amount of the license acquired amounted to CHF 3,893,681, including directly attributable transaction costs of CHF 198,246.

Leases

Leases

The Group assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Group recognizes lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets.

Right-of-use assets

The Group recognizes right-of-use assets at the commencement date of the lease. Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurements of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date. Unless the Group is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life and the lease term. Right-of-use assets are subject to impairment.

Lease liabilities

At the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties for terminating a lease, if the lease term reflects the Group exercising the option to terminate. The variable lease payments that do not depend on an index or a rate are recognized as expense in the period during which the event or condition that triggers the payment occurs. In calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accumulation of interest and reduced by the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset.

Short-term leases and leases of low-value assets

The Group applies the short-term lease recognition exemption to its short-term leases. It also applies the lease of low-value assets recognition exemption to leases that are considered of low value (i.e. below CHF 5,000). Lease payments on short-term leases and leases of low-value assets are recognized as expense over the lease term.

Inventories

Inventories

Inventories are stated at the lower of cost and net realizable value. Cost comprises direct materials and, where applicable, direct labor costs and those overheads that have been incurred in bringing the inventories to their present location and condition. Cost is calculated using the first-in, first-out method. Net realizable value represents the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution.

Financial instruments

Financial instruments

The Group classifies its financial assets in the following categories: loans and receivables based on the expected loss model. The classification depends on the nature and purpose of the financial assets and is determined at the time of initial recognition.

Recognition and derecognition of non-derivative financial assets and liabilities

The Group initially recognizes loans and receivables and debt securities issued on the date when they are originated. All other financial assets and financial liabilities are initially recognized on the trade date.

The Group derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred, or it neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control over the transferred asset. Any interest in such derecognized financial assets that is created or retained by the Group is recognized as a separate asset or liability.

The Group derecognizes a financial liability when its contractual obligations are discharged, cancelled, or expired.

Financial assets and financial liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Group has a legal right to offset the amounts and intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously.

Non-derivative financial assets and liabilities—measurement

Loans and receivable

These are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Loans and receivables are initially recognized at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, they are measured at amortized cost using the effective interest method, less expected losses.

Cash and cash equivalents

The Group considers all short-term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to an insignificant risk of changes in value with original maturities of three months or less at the date of the purchase to be cash equivalents.

Non-derivative financial liabilities—measurement

Non-derivative financial liabilities are initially recognized at fair value less any directly attributable transaction costs. Subsequent to initial recognition, these liabilities are measured at amortized cost using the effective interest method.

Convertible loans

In a convertible loan classified as a hybrid contract containing a host and a separated embedded derivative, both classified as liability, the carrying amount of the host contract at initial recognition is the difference between the carrying amount of the hybrid contract and the fair value of the embedded derivative. Transaction costs that relate to the issue of the convertible loan are allocated to the host and embedded derivative in proportion to the allocation of the gross proceeds. Transaction costs relating to the embedded derivative are immediately recognized in profit and loss. Transaction costs relating to the host contract are included in the carrying amount of the liability. The host contract is then subsequently measured at amortized cost, using the effective interest method.

Share capital

All shares of the Company are registered shares and classified as part of shareholders’ equity. Incremental costs directly attributable to the issue of the Company’s shares, net of any tax effects, are recognized as a deduction from equity. The warrants are classified as a financial liability at fair value through profit or loss and the cost allocated to the liability component will be immediately expensed to the income statement.

The Company has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future.

Repurchase and reissue of ordinary shares (treasury shares)

When shares recognized as equity are repurchased, the amount of the consideration paid, which includes directly attributable costs, net of any tax effects, is recognized as a deduction from equity. Repurchased shares are classified as treasury shares and are presented in the treasury share reserve. When treasury shares are sold or reissued subsequently, the amount received is recognized as an increase in equity and the resulting surplus or deficit (calculated as the difference between initial cost and fair value) on the transaction is presented within share premium.

Impairment of non-derivative financial assets

Impairment of non-derivative financial assets

Financial assets are assessed at each reporting date to determine whether there is objective evidence of impairment.

Objective evidence that financial assets are impaired includes:

●

default or delinquency by a debtor;

●

indications that a debtor or issuer will enter bankruptcy;

●

adverse changes in the payment status of borrowers or issuers;

●

the disappearance of an active market for a security; or

●

observable data indicating that there is measurable decrease in expected cash flows from a group of financial assets.

Financial assets measured at amortized cost

The Group considers evidence of impairment for these assets at an individual asset level. An impairment loss is calculated as the difference between an asset’s carrying amount and the present value of the estimated future cash flows discounted at the asset’s original effective interest rate. Losses are recognized in profit or loss and reflected in an allowance account. When the Group considers that there are no realistic prospects of recovery of the asset, the relevant amounts are written off. If the amount of impairment loss subsequently decreases and the decrease can be related objectively to an event occurring after the impairment was recognized, then the previously recognized impairment loss is reversed through profit or loss.

Derivative Financial Instruments

Derivative Financial Instruments

Derivative financial instruments (assets) are accounted as the cost to obtain the rights from a third party to issue shares under the purchase agreement and changes in fair value are shown as profit or loss. The fair value calculation of the derivative financial instrument (asset) is adjusted on the utilization of the asset based on total dollar amount of the purchase agreement.

Derivative financial instruments (liabilities) are accounted at fair value and changes in fair value are shown as profit or loss. The fair value calculation of the derivative financial instruments is based on the Black-Scholes option pricing model. Assumptions are made for volatility and the risk-free rate in order to estimate the fair value of the instrument. Transaction cost related to derivative financial instruments are recorded through profit and loss.

Embedded Derivatives

Derivatives may be embedded in another contractual arrangement. The Group accounts for an embedded derivative separately from the host contract when:

The host contract is not an asset in the scope of IFRS 9

The host contract is not itself carried at fair value through profit and loss (FVPL)

The terms of the Embedded Derivative would meet the definition of a derivative if they were contained in a separate contract

The economic characteristics and risks of the embedded derivative are not closely related to the economic characteristics and risks of the host

The separated embedded derivative in the 2022 FiveT convertible loan was initially measured at fair value by an independent consultant applying a simulation-based valuation approach. On December 31, 2022, the embedded derivative was measured based on the Black-Scholes option pricing model, resulting in a fair value of zero. Assumptions are made for volatility, risk free rate and other features of the instrument. All changes in the fair value of embedded derivatives were recognized in profit and loss.

Income tax

Income tax

Income tax expense comprises current and deferred tax. It is recognized in profit or loss except to the extent that it relates to a business combination, or items recognized directly in equity or in Other Comprehensive Income.

Current tax

Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to tax payable or receivable in respect of previous years. It is measured using tax rates enacted or substantively enacted at the reporting date.

Deferred tax

Deferred income tax is recognized, using the balance sheet liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred tax is not recognized for:

●

temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss;

●

temporary differences related to investments in subsidiaries to the extent that the Group is able to control the timing of the reversal of the temporary differences and it is probable that they will not reverse in the foreseeable future; and

●

taxable temporary differences arising on the initial recognition of goodwill.

Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.

Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off tax assets against tax liabilities and when they relate to income taxes levied by the same taxation authority and the Group intends to settle its tax assets and liabilities on a net basis.

Employee benefits

Employee benefits

The Group maintains a pension plan for all employees in Switzerland through payments to a legally independent collective foundation. This pension plan qualifies under IFRS as defined benefit pension plan. There are no pension plans for the subsidiaries in Ireland, Australia and the United States.

The recognized asset is limited to the present value of economic benefits available in the form of any future refunds from the plan or reductions in future contributions to the plan. In order to calculate the present value of economic benefits, consideration is given to any minimum funding requirements.

Remeasurements of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognized immediately in Other Comprehensive Income. Past service costs, including curtailment gains or losses, are recognized immediately in general and administrative expenses within the operating results. Settlement gains or losses are recognized in general and administrative expenses within the operating results. The Group determines the net interest expense (income) on the net defined benefit liability (asset) for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period or in case of any significant events between measurement dates to the then-net defined benefit liability (asset), taking into account any changes in the net defined benefit liability (asset) during the period as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognized in profit or loss.

Share-based compensation

Share-based compensation

The Company maintains a share-based payment plan in the form of a stock option plan for its employees, members of the Board of Directors as well as key service providers. Stock options are granted at the Board’s discretion without any contractual or recurring obligations.

The share-based compensation plans qualify as equity settled plans. The grant-date fair value of share-based payment awards granted to employees is recognized as an expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the awards. Under the Company’s Long Term Equity Incentive Plan (the “Equity Incentive Plan” or “EIP”), 50% of granted share options granted to employees vest after a period of service of two years from the grant date and the remaining 50% vest after a period of service of three years from the grant date. Share options granted to members of the Board of Directors granted from 2016 onwards vest after a period of one year after the grant date.

The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that meet the related service and non-market performance conditions at the vesting date. Share-based payments that are not subject to any further conditions are expensed immediately at grant date. In the year the options are exercised the proceeds received net of any directly attributable transaction costs are credited to share capital (par value) and share premium.

Valuation of share options

Option pricing and values are determined based on the Black Scholes option pricing model and assumptions are made for inputs such as volatility of the Company’s stock and the risk-free rate.

Provisions

Provisions

Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, where it is more likely than not that an outflow of resources will be required to settle the obligation, and where a reliable estimate can be made of the amount of the obligation. Provisions are not recognized for future operating losses. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability.

Revenue recognition

Revenue recognition

The Group recognizes revenue from the license of intellectual property and from the sale of products. To assess revenue recognition for arrangements that the Group determines are within the scope of IFRS 15, the Group performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Group satisfies a performance obligation. The Group only applies the five-step model to contracts when it is probable that the Group will collect the consideration it is entitled to in exchange for services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of IFRS 15, the Group assesses the services promised within each contract and determine those that are performance obligations and assess whether each promised service is distinct.

License of intellectual property

The Group recognizes as revenue its non-refundable license fees, milestone payments and royalties when its customer obtains control of promised services, in an amount that reflects the consideration which the Group expects to receive in exchange for those rendered services. If the license to the Group’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Group recognizes revenues when the license conveys a right of use, or there is a right of access to the underlying intellectual property. However, revenue for a license that provides a right to use the Company’s intellectual property before the beginning of the period during which the customer is able to use and benefit from the license is deferred. Revenue from sales-based royalty, in exchange for a license of intellectual property is recognized only when the subsequent sale occurs and the performance obligation to which the sales-based royalty has been allocated has been satisfied (in whole or in part).

Sale of products

The Group currently sells only one product, Bentrio®, a drug-free nasal spray for protection against airborne viruses and allergens. Revenue from sale of products is recognized at the point in time when control of the asset is transferred to the customer, generally on delivery of the product if no other agreement has been made. Revenue is net of value-added tax, rebates, discounts and returns.

Government grants

Government grants

Government grants are not recognized until there is reasonable assurance that the Group will comply with the conditions attaching to them and that the grants will be received. Government grants are recognized in profit or loss on a systematic basis over the periods in which the Company recognizes as expenses the related research and development costs for which the grants are intended to compensate. Government grants that are receivable as compensation for expenses already incurred are recognized in profit or loss in the period in which they become receivable.

The company obtains credits under the Australian R&D Tax Incentive program (R&DITC). The program provides a tax offset of up to 48.5% of eligible R&D expenditures. If the tax offset exceeds the Company’s tax liability, the balance is paid in cash after submission of a valid claim. Based on the specific features of the program, IAS 20 Government Grants is applied for the accounting treatment of the Australian R&DITC. The reimbursement application is made by the Company annually, once the fiscal year is closed, based on the financial statements. The income from grants related to R&D expenditures are presented separately under the heading of ‘other operating income’. Grants that relate to the acquisition of an asset are recognized in profit or loss as the asset is depreciated or amortized. These grants are recognized as a reduction in the cost of the asset.

Earnings/(loss) per share

Earnings/(loss) per share

Basic earnings/(loss) per share are calculated by dividing the net profit/(loss) attributable to owners of the Company by the weighted average number of shares outstanding during the period. Diluted earnings/(loss) per share are calculated by dividing the net profit/(loss) attributable to the owners of the Company by the weighted average number of shares outstanding during the period adjusted for the conversion of all dilutive potential ordinary shares.

Right-of-use assets and lease liabilities

12 Months Ended

Dec. 31, 2022

Right-of-use assets and lease liabilities [Abstract]

Right-of-use assets and lease liabilities

8. Right-of-use assets and lease liabilities

	Office
Right-of-use assets	building			Total
At cost
As of January 1, 2021		—			—
Additions		594,436			594,436
Disposals		—			—
As of December 31, 2021		594,436			594,436
Additions		—			—
Disposals		—			—
As of December 31, 2022		594,436			594,436

Accumulated depreciation
As of January 1, 2021		—			—
Charge for the year		(29,722	)		(29,722	)
Disposals		—			—
As of December 31, 2021		(29,722	)		(29,722	)
Charge for the year		(118,887	)		(118,887	)
Disposals		—			—
As of December 31, 2022		(148,609	)		(148,609	)

Net book value
As of December 31, 2021		564,714			564,714
As of December 31, 2022		445,827			445,827

	December 31,		December 31,
Low value and short-term lease expenses	2022		2021

Expense related to short-term leases		6,001		52,280
Expense related to leases of low value assets		—		—
Total		6,001		52,280

	December 31,			December 31,
Lease liabilities	2022			2021
As of January 1		575,736			—
Additions		—			594,436
Interest expense		15,949			3,000
Repayment of lease liability		(130,200	)		(21,700	)
As of December 31		461,485			575,736

thereof non-current		343,629			461,485
thereof current		117,856			114,251

	December 31,			December 31,
Maturities of lease liabilities	2022			2021

Year 1		130,200			130,200
Year 2		130,200			130,200
Year 3		130,200			130,200
Year 4		97,650			130,200
Year 5		—			97,650
Undiscounted lease payments		488,250			618,450
Less: unearned interest		(26,765	)		(42,714	)
Total		461,485			575,736

Share-Based Compensation (Details) - Schedule of number and weighted average exercise prices - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of Number And Weighted Average Exercise Prices Abstract
Number of options, Outstanding	66,476	51,927
Weighted average exercise price, Outstanding	$ 33	$ 31.6
Weighted average remaining term, Outstanding	6 years 6 months 21 days	7 years 3 days
Number of options, Exercisable	28,796	14,419
Weighted average exercise price, Exercisable
Weighted average remaining term, Exercisable
Number of options, Expired during the year
Weighted average exercise price, Expired during the year
Weighted average remaining term, Expired during the year
Number of options, Forfeited during the year	(6,488)	(2,565)
Weighted average exercise price, Forfeited during the year
Weighted average remaining term, Forfeited during the year
Number of options, Exercised during the year
Weighted average exercise price, Exercised during the year
Weighted average remaining term, Exercised during the year
Number of options, Granted during the year	97,742	17,113
Weighted average exercise price, Granted during the year	$ 9.4	$ 45.4
Weighted average remaining term, Granted during the year
Number of options, Outstanding	157,730	66,476
Weighted average exercise price, Outstanding	$ 19.28	$ 33
Weighted average remaining term, Outstanding	6 years 2 months 19 days	6 years 6 months 21 days

Revision of Prior Period Financial Statements (Details) - Schedule of consolidated statement of cash flows	12 Months Ended
	Dec. 31, 2021 USD ($)
As reported [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of consolidated statement of cash flows [Line Items]
Net loss	$ (17,390,166)
Changes in:
Trade and other receivables	(586,612)
Prepayments	(719,321)
Cash used in operating activities	(13,627,738)
Adjustment [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of consolidated statement of cash flows [Line Items]
Net loss	331,723
Changes in:
Trade and other receivables	246,493
Prepayments	(578,216)
Cash used in operating activities
As revised [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of consolidated statement of cash flows [Line Items]
Net loss	(17,058,443)
Changes in:
Trade and other receivables	(340,119)
Prepayments	(1,297,537)
Cash used in operating activities	$ (13,672,738)

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2022-03-24
-Paragraph 18
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard
-URIDate 2022-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2022-03-24
-Paragraph 32
-Subparagraph a
-Clause ii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_ii&doctype=Standard
-URIDate 2022-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2022-03-24
-Paragraph 24
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_b&doctype=Standard
-URIDate 2022-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2022-03-24
-Paragraph 28
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard
-URIDate 2022-03-24

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Note Effective on first application of IFRS 9
-Name IFRS
-Number 4
-IssueDate 2022-03-24
-Paragraph 39L
-Subparagraph e
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard
-URIDate 2022-03-24

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2022-03-24
-Paragraph 23
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard
-URIDate 2022-03-24

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2022-03-24
-Paragraph B10
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2022-03-24

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Note Effective 2023-01-01
-Name IFRS
-Number 17
-IssueDate 2022-03-24
-Paragraph 113
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard
-URIDate 2022-03-24

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 81A
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_a&doctype=Standard
-URIDate 2022-03-24

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 106
-Subparagraph d
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_i&doctype=Standard
-URIDate 2022-03-24

+ Details

Loans (Details) - Schedule of loans - CHF (SFr)	12 Months Ended
Loans (Details) - Schedule of loans - CHF (SFr)	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Loans Abstract
Convertible loan February 2022	SFr 4,898,377
Loans with warrants	871,420
Short-term loan from related party	100,000
Total	SFr 5,869,797

Employee Benefits (Details) - CHF (SFr)	12 Months Ended
Employee Benefits (Details) - CHF (SFr)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Employee Benefits [Abstract]
Share based compensation expense		SFr 902,817
Grant contingent amount	SFr 810,252
Future share grant contingent	360,112
Employee stock options	SFr 342,799	SFr 320,879
Interest rate term		2 years
Benefit plans interest rate	1.00%	1.00%	1.00%
Weighted average duration defined benefit obligation	19 years 10 months 24 days	17 years 1 month 6 days

Capital and Reserves (Details) - Schedule of common shares - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of Common Shares Abstract
Beginning balance	748,213	570,858
Exercise of warrants		44,872
LPC equity line	315,000
ATM program	116,843	59,235
Share-based payments (bonus)		8,731
Conversion convertible loan		25,841
Shares issued for Trasir acquisition		38,676
Fractional shares	(3)
Ending balance	1,180,053	748,213

Finance Income and Finance Expense (Details)	12 Months Ended
Finance Income and Finance Expense (Details)	Dec. 31, 2022 CHF (SFr)	Dec. 31, 2021 CHF (SFr)	Dec. 31, 2021 USD ($)
Finance Income and Finance Expense (Details) [Line Items]
Gain from derivative financial instruments	SFr 451,131
Revaluation of the financial derivatives	449,898
Revaluation of outstanding warrants	1,233		$ 5,085
Revaluation loss from derivative financial instruments		SFr 416,003
Finance expenses included interest paid	SFr 19,503
Maximum [Member]
Finance Income and Finance Expense (Details) [Line Items]
Finance expenses included interest paid		3,699
Minimum [Member]
Finance Income and Finance Expense (Details) [Line Items]
Finance expenses included interest paid		SFr 0

Capital and Reserves (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure of Capital and reserves [Abstract]

Schedule of issued share capital

	December 31,				December 31,
	2022				2021
	Number		CHF		Number		CHF
Common shares with a par value of CHF 0.20 each		1,180,053		236,011		748,213		149,643
Total		1,180,053		236,011		748,213		149,643

Schedule of common shares

	Common Shares
	(Number)
	2022			2021
As of January 1		748,213			570,858
Exercise of warrants		—			44,872
LPC equity line		315,000			—
ATM program		116,843			59,235
Share-based payments (bonus)		—			8,731
Conversion convertible loan		—			25,841
Shares issued for Trasir acquisition		—			38,676
Fractional shares		(3	)		—
Total, as of December 31		1,180,053			748,213

Cost of Sales

12 Months Ended

Dec. 31, 2022

Cost of Sales [Abstract]

Cost of Sales

21. Cost of Sales

	December 31,		December 31,		December 31,
	2022		2021		2020
Product purchases, packaging and logistics		362,584		173,758		—
Employee benefit and expenses		150,438		89,238		—
Inventory write-down		930,833		1,977,558		—
Total cost of sales		1,443,855		2,240,554		—

Other receivables (Tables)

12 Months Ended

Dec. 31, 2022

Other receivables [Abstract]

Schedule of other receivables

	December 31,		December 31,
	2022		2021
R&D tax credit receivable		672,600		224,465
Receivable from share issuance		—		255,187
Value added tax receivable		78,650		168,851
Withholding tax receivable		—		7,336
Receivable from suppliers and other		4,737		15,501
Total other receivables		755,987		671,340

Taxation (Details)	12 Months Ended
Taxation (Details)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Income Tax Text Block Abstract
Weighted average tax rate	13.70%	13.50%	12.10%
Gross tax loss carry forwards, description	the Group had unrecognized tax loss carryforwards amounting to CHF 103.1 million (2021: CHF 109.9 million), of which CHF 101.4 million related to Auris Medical AG, Otolanum AG, Zilentin AG and Altamira Medica AG in Switzerland, CHF 1.7 million to Altamira Therapeutics Inc. in the United States (2021: CHF 108.6 million for Auris Medical AG, Otolanum AG, Zilentin AG and Altamira Medica AG and CHF 1.3 million for Auris Medical Inc.).

Financial instruments and risk management (Details) - Schedule of analysis the remaining contractual maturities of financial liabilities - CHF (SFr)	Dec. 31, 2022	Dec. 31, 2021
Financial instruments and risk management (Details) - Schedule of analysis the remaining contractual maturities of financial liabilities [Line Items]
Trade and other payables	SFr 4,914,404	SFr 3,697,723
Accrued expenses	1,977,614	1,048,575
Loan and borrowings	6,117,069
Non-current lease liabilities	358,050	488,250
Current lease liabilities	130,200	130,200
Derivative financial instruments		1,233
Total	13,497,337	5,365,981
Less than 3 months [Member]
Financial instruments and risk management (Details) - Schedule of analysis the remaining contractual maturities of financial liabilities [Line Items]
Trade and other payables	4,914,404	3,697,723
Accrued expenses	1,977,614	1,048,575
Loan and borrowings	5,759,877
Non-current lease liabilities
Current lease liabilities	32,550	32,550
Derivative financial instruments
Total	12,684,445	4,778,848
Between 3 months and 2 years [Member]
Financial instruments and risk management (Details) - Schedule of analysis the remaining contractual maturities of financial liabilities [Line Items]
Trade and other payables
Accrued expenses
Loan and borrowings	357,192
Non-current lease liabilities	130,200	130,200
Current lease liabilities	97,650	97,650
Derivative financial instruments
Total	585,042	227,850
2 years and later [Member]
Financial instruments and risk management (Details) - Schedule of analysis the remaining contractual maturities of financial liabilities [Line Items]
Trade and other payables
Accrued expenses
Loan and borrowings
Non-current lease liabilities	227,850	358,050
Current lease liabilities
Derivative financial instruments		1,233
Total	227,850	359,283
Carrying amount [Member]
Financial instruments and risk management (Details) - Schedule of analysis the remaining contractual maturities of financial liabilities [Line Items]
Trade and other payables	4,914,404	3,697,723
Accrued expenses	1,977,614	1,048,575
Loan and borrowings	5,869,797
Non-current lease liabilities	343,629	461,485
Current lease liabilities	117,856	114,251
Derivative financial instruments		1,233
Total	SFr 13,223,300	SFr 5,323,267

Related Party Transactions (Tables)

12 Months Ended

Dec. 31, 2022

Schedule of related party transaction

	Executive Management						Board of Directors						Total
	2022		2021		2020		2022		2021		2020		2022		2021		2020
Short term benefits		989,760		781,204		407,147		183,058		165,245		163,476		1,172,818		946,449		570,623
Post-employee benefits years		49,050		29,467		26,870		—		—		—		49,050		29,467		26,870
Share Bonuses		—		902,817		—		—		—		—		—		902,817		—
Share-based payment charge		172,115		192,362		204,840		51,171		48,046		57,148		223,286		240,408		261,988
Total		1,210,925		1,905,850		638,857		234,229		213,291		220,624		1,445,154		2,119,141		859,481

Intangible assets (Details) - Schedule of intangible assets - CHF (SFr)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Intangible assets (Details) - Schedule of intangible assets [Line Items]
At cost, Beginning Balance		SFr 9,115,410
At cost, Exchange differences	SFr 168	(3,654)
At cost, Additions	1,975,784	6,733,050
At cost, Ending Balance	17,820,758	15,844,806
Accumulated amortization and impairment losses, Beginning Balance	(1,529,929)
Accumulated amortization and impairment losses, Impairment	(12,397,148)	(1,529,929)
Accumulated amortization and impairment losses, Ending Balance	(13,927,077)	(1,529,929)
Net book value	3,893,681	14,314,877
Licenses [Member]
Intangible assets (Details) - Schedule of intangible assets [Line Items]
At cost, Beginning Balance		1,482,520
At cost, Exchange differences
At cost, Additions		3,893,681
At cost, Ending Balance	5,376,201	5,376,201
Accumulated amortization and impairment losses, Beginning Balance	(1,482,520)
Accumulated amortization and impairment losses, Impairment		(1,482,520)
Accumulated amortization and impairment losses, Ending Balance	(1,482,520)	(1,482,520)
Net book value	3,893,681	3,893,681
IP & Data rights [Member]
Intangible assets (Details) - Schedule of intangible assets [Line Items]
At cost, Beginning Balance		193,989
At cost, Exchange differences
At cost, Additions
At cost, Ending Balance	193,989	193,989
Accumulated amortization and impairment losses, Beginning Balance	(47,409)
Accumulated amortization and impairment losses, Impairment	(146,580)	(47,409)
Accumulated amortization and impairment losses, Ending Balance	(193,989)	(47,409)
Net book value		146,580
Patents [Member]
Intangible assets (Details) - Schedule of intangible assets [Line Items]
At cost, Beginning Balance		417,216
At cost, Exchange differences
At cost, Additions	275,281	55,938
At cost, Ending Balance	748,435	473,154
Accumulated amortization and impairment losses, Beginning Balance
Accumulated amortization and impairment losses, Impairment	(748,435)
Accumulated amortization and impairment losses, Ending Balance	(748,435)
Net book value		473,154
Internally generated [Member]
Intangible assets (Details) - Schedule of intangible assets [Line Items]
At cost, Beginning Balance		7,021,685
At cost, Exchange differences	168	(3,654)
At cost, Additions	1,700,503	2,783,431
At cost, Ending Balance	11,502,133	9,801,462
Accumulated amortization and impairment losses, Beginning Balance
Accumulated amortization and impairment losses, Impairment	(11,502,133)
Accumulated amortization and impairment losses, Ending Balance	(11,502,133)
Net book value		SFr 9,801,462

Events after the balance sheet date

12 Months Ended

Dec. 31, 2022

Events after the balance sheet date [Abstract]

Events after the balance sheet date

34. Events after the balance sheet date

On February 17, 2023 a Special General Meeting of the shareholders of the Company approved the increase of its authorized share capital from CHF 1,400,000 divided into 5,000,000 common shares of CHF 0.20 each and 20,000,000 preference shares of CHF 0.02 each to CHF 5,400,000 divided into 25,000,000 common shares of CHF 0.20 each and 20,000,000 preference shares of CHF 0.02 each, by the creation of an additional 20,000,000 common shares of CHF 0.20 each ranking pari-passu with the existing common shares of the Company.

On April 13, 2023, the Company and FiveT IM entered into an amendment to the FiveT Loan (the “FiveT Loan Amendment”), which amended the conversion price of the FiveT Loan to a fixed price equal to the lower of (a) the mean daily trading volume weighted average price (“VWAP”) of the Company’s common shares on the Nasdaq Stock Market on the 20 trading days preceding the effective date of the FiveT Loan Amendment or (b) 90% of the VWAP on the effective date of the FiveT Loan Amendment. From April 13, 2023 to April 17, 2023, FiveT IM converted the entire FiveT Loan into an aggregate of 4,341,012 common shares at an average conversion price of $1.4475 per share. As a result, the FiveT Loan is no longer outstanding and has been terminated.

On May 1, 2023, the Company entered into a convertible loan agreement (the “2023 FiveT Loan Agreement”) with FiveT IM, pursuant to which FiveT IM has agreed to loan to the Company CHF 2,500,000, which bears interest at the rate of 10% per annum and matures 22 months from May 4, 2023. FiveT IM will have the right to convert all or part of the convertible loan, including accrued and unpaid interest, at its option, into common shares, subject to the limitation that FiveT own no more than 4.99% of the common shares at any time. The conversion price was fixed at CHF 1.42 per common share (subject to adjustment for share splits or other similar events). Further, FiveT IM received warrants to purchase an aggregate of 1,625,487 common shares at an exercise price of CHF 1.538 per common share, which may be exercised up to five years.

Commencing 60 days after May 4, 2023, but not before July 1, 2023 and subject to availability of an effective registration statement, the Company must repay at least 1/20th of the outstanding loan plus accrued interest pro rata in monthly tranches which, at the Company’s discretion, may be paid at any time during the month either in: (i) cash plus 3% or (ii) common shares, or a combination of both. Such shares will be priced at the lower of (i) the mean daily trading volume weighted average price for the common shares on the 20 trading days preceding the repayment date or (ii) 90% of the daily trading volume weighted average price for common shares on the repayment date. The Company may prepay all or part of the convertible loan after three months. Until March 31, 2024, FiveT may cause the Company to redeem the convertible loan for cash in an amount of up to 20% of the cash proceeds from an out-licensing or divestiture transaction executed by the Company that results in gross cash proceeds of at least CHF 1,000,000.

On May 12, 2023, the Company and the Lenders entered into an amendment to the loan agreement concluded on September 9, 2022 (the “September 2022 Loan Amendment”), which extended the maturity date of the loan from May 31, 2023 to July 31, 2023, introduced a right for Lenders to convert the loan into common shares of the Company at CHF 1.12 per common share, which is the Swiss Franc equivalent of 120% of the mean daily trading volume weighted average price for common shares on the NASDAQ stock exchange on the 20 trading days preceding the date of the September 2022 Loan Amendment, and a right for the Company to repay the loan in common shares of the Company priced at the lower of (i) the mean daily trading volume weighted average price for the common shares on the 20 trading days preceding the repayment date or (ii) 90% of the daily trading volume weighted average price for common shares on the repayment date, and lowered the strike price for the Warrants attached to the loan to CHF 0.881 per common share, which is the Swiss Franc equivalent of the trading volume weighted average price for common shares on the NASDAQ stock exchange on trading day preceding the date of the September 2022 Loan Amendment.

On May 12, 2023, the Company and the Private Lenders entered into an amendment to the loan agreement concluded on December 28, 2022 (the December 2022 Loan Amendment”), which extended the maturity date of the loan from May 31, 2023 to July 31, 2023 and lowered the strike price for the Warrants attached to the loan to CHF 0.881 per common share, which is the Swiss Franc equivalent of the trading volume weighted average price for common shares on the NASDAQ stock exchange on trading day preceding the date of the December 2022 Loan Amendment.

Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents - CHF (SFr)	Dec. 31, 2022	Dec. 31, 2021
Schedule of Cash And Cash Equivalents Abstract
Cash in bank accounts	SFr 15,395	SFr 984,191
Cash on hand
Total cash and cash equivalents	SFr 15,395	SFr 984,191

Loans (Details)							1 Months Ended		12 Months Ended
Loans (Details)	Sep. 09, 2022 CHF (SFr) SFr / shares shares	Feb. 08, 2022 CHF (SFr)	Feb. 04, 2022	Mar. 04, 2021 CHF (SFr) shares	Mar. 04, 2021 $ / shares	Sep. 07, 2020	Dec. 28, 2022 CHF (SFr) SFr / shares shares	Sep. 07, 2020 CHF (SFr)	Dec. 31, 2022 CHF (SFr)	Dec. 31, 2021 CHF (SFr)	Dec. 31, 2020 CHF (SFr)
Loans (Details) [Line Items]
Convertible loan agreement amount	SFr 600,000							SFr 1,500,000
Interest rate	5.00%					8.00%	5.00%	8.00%
Purchase of warrants (in Shares) \| shares	41,666						33,700
Aggregate of common shares (in Shares) \| shares							13,480
warrants exercise share (in Francs per share) \| SFr / shares	SFr 7.2						SFr 4.4512
Issuance term	5 years						5 years
Equity amount	SFr 86,744						SFr 48,185			SFr 3,533,616
Carrying amount	561,062						305,873		SFr 4,898,377
Convertible loan description			The convertible loan of CHF 5.0 million, as amended (the “FiveT Loan”) carried interest at the rate of 10% per annum and was to mature on May 31, 2023. FiveT IM had the right to convert all or part of the FiveT Loan, including accrued and unpaid interest, at its option, into common shares, subject to the limitation that the Lender own no more than 4.9% of the common shares at any time. On April 13, 2023, the Company and FiveT IM entered into an amendment to the FiveT Loan (the “FiveT Loan Amendment”), which amended the conversion price of the FiveT Loan to a fixed price equal to the lower of (a) the mean daily trading volume weighted average price (“VWAP”) of the Company’s common shares on the Nasdaq Stock Market on the 20 trading days preceding the effective date of the FiveT Loan Amendment or (b) 90% of the VWAP on the effective date of the FiveT Loan Amendment. From April 13, 2023 to April 17, 2023, FiveT IM converted the entire FiveT Loan into an aggregate of 4,341,012 common shares at an average conversion price of $1.4475 per share.
Expected volatility			90.70%
Derivative amount		SFr 449,898							0
Fair value measurement									449,898
Transaction costs									SFr 807,593
Accrued interest						130.00%
Pricing of conversion description									The pricing of a conversion into our common shares is at the lower of 150% of the share price at close of the disbursement date ($27.00 fixed on September 8, 2020) and 95% of the average price of our common share at close of the 5 trading dates preceding the date of the conversion notice. However, the conversion price shall not be less than the higher of the par value and the backward-looking 3-month floor price of 75% of the average closing price of our common shares. The pricing of a conversion into Altamira Medica shares is at the lower of CHF 3.00 and the issue price of a qualified financing round, meaning that a third-party investor will hold at least 10% of Altamira Medica shares after completion of such financing round. The convertible loan agreement further contains a limitation on the conversion rights in the sense that they may not result in an ownership interest of more than 9.99% in the Company or 49.99% in Altamira Medica. By December 31, 2020, an amount of CHF 895,455 has been converted into 36,850 common shares of the Company (at a conversion price of $27.00).
Volatility percentage											90.90%
Outstanding loan amount				SFr 644,813							SFr 473,920
Common shares (in Shares) \| shares				25,841
Conversion price per share (in Dollars per share) \| $ / shares					$ 27
Convertible loan amount										SFr 0
Outstanding loan									SFr 0
Derivative amount									310,439
Embedded derivatives									416,003		2,248,257
Effective interest									SFr 170,893		SFr 127,418
Mr. Meyer lent [Member]
Loans (Details) [Line Items]
Principal amount	SFr 200,000
Top of range [member]
Loans (Details) [Line Items]
Convertible loan agreement amount							250,000
Bottom of range [member]
Loans (Details) [Line Items]
Convertible loan agreement amount							SFr 100,000

Consolidated Statement of Financial Position	Dec. 31, 2022 CHF (SFr)	Dec. 31, 2021 CHF (SFr)
Non-current assets
Property and equipment	SFr 1	SFr 1
Right-of-use assets	445,827	564,714
Intangible assets	3,893,681	14,314,877
Other non-current financial assets	194,263	199,105
Total non-current assets	4,533,772	15,078,697
Current assets
Inventories	11,644	839,221
Trade receivables	6,525	21,746
Other receivables	755,987	671,340
Prepayments	709,266	1,575,126
Derivative financial instruments	270,176
Cash and cash equivalents	15,395	984,191
Total current assets	1,768,993	4,091,624
Total assets	6,302,765	19,170,321
Equity
Share capital	236,011	149,643
Share premium	192,622,406	188,511,476
Other reserves	258,044	62,069
Accumulated deficit	(201,431,272)	(175,686,937)
Total shareholders’ (deficit)/equity attributable to owners of the Company	(8,314,811)	13,036,251
Derivative financial instruments		1,233
Non-current lease liabilities	343,629	461,485
Employee benefit liability	336,206	668,319
Deferred income	932,200
Deferred tax liabilities	125,870	142,484
Total non-current liabilities	1,737,905	1,273,521
Current liabilities
Loan	5,869,797
Current lease liabilities	117,856	114,251
Trade and other payables	4,914,404	3,697,723
Accrued expenses	1,977,614	1,048,575
Total current liabilities	12,879,671	4,860,549
Total liabilities	14,617,576	6,134,070
Total equity and liabilities	SFr 6,302,765	SFr 19,170,321

Trade and Other Payables (Tables)

12 Months Ended

Dec. 31, 2022

Trade and other payables [Abstract]

Schedule of trade and other payables

	December 31,		December 31,
	2022		2021
Trade accounts payable - third parties		4,767,940		3,544,384
Other		146,464		153,339
Total trade and other payables		4,914,404		3,697,723

Capital and Reserves (Details) - Schedule of issued share capital - CHF (SFr)	Dec. 31, 2022	Dec. 31, 2021
Capital and Reserves (Details) - Schedule of issued share capital [Line Items]
Number	1,180,053	748,213
Value (CHF)	SFr 236,011	SFr 149,643
Ordinary Shares Nominal Value [member]
Capital and Reserves (Details) - Schedule of issued share capital [Line Items]
Number	1,180,053	748,213
Value (CHF)	SFr 236,011	SFr 149,643

Right-of-use assets and lease liabilities (Details) - Schedule of maturities of lease liabilities - CHF (SFr)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of Maturities of Lease Liabilities [Abstract]
Year 1	SFr 130,200	SFr 130,200
Year 2	130,200	130,200
Year 3	130,200	130,200
Year 4	97,650	130,200
Year 5		97,650
Undiscounted lease payments	488,250	618,450
Less: unearned interest	(26,765)	(42,714)
Total	SFr 461,485	SFr 575,736

Deferred income

12 Months Ended

Dec. 31, 2022

Deferred Income [Abstract]

Deferred income

18. Deferred income

	December 31,		December 31,
	2022		2021
Upfront payment		932,200		—
Total deferred income		932,200		—

Deferred income includes an upfront payment of $ 1 million (CHF 0.9 million) related to the exclusive licensing and distribution agreement with Nuance for Bentrio® in the defined territory. Revenue recognition for the upfront payment is deferred until transfer of production to Nuance, which will occur 4 years after Nuance obtaining the first national registration of Bentrio® in the territory or upon Nuance’s cumulative orders for Bentrio® reaching a contractually defined minimum quantity of Bentrio® from the Company, whichever comes later. The upfront payment described above was incorrectly recorded as revenue in the Unaudited Condensed Consolidated Interim Financial Statements of the Company as of June 30, 2022 and for the six months ended June 30, 2022, furnished with the Securities and Exchange Commission on November 30, 2022. The foregoing information will be presented in accordance with the treatment used herein in the comparatives included in the June 30, 2023 financial statements, and we will reflect the correct treatment in restated financial statements as of June 30, 2022 and for the six months ended June 30, 2022 to be filed with a Form 6-K/A following the issuance of this Form 20-F.

Prepayments (Tables)

12 Months Ended

Dec. 31, 2022

Prepayments [Abstract]

Schedule of prepayments

	December 31,		December 31,
	2022		2021
Advance payments to suppliers		659,861		1,437,708
Insurance		49,405		137,418
Total prepayments		709,266		1,575,126

Related Party Transactions (Details) - Schedule of related party transaction - CHF (SFr)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Related Party Transactions (Details) - Schedule of related party transaction [Line Items]
Short term benefits	SFr 1,172,818	SFr 946,449	SFr 570,623
Post-employee benefits years	49,050	29,467	26,870
Share Bonuses		902,817
Share-based payment charge	223,286	240,408	261,988
Total	1,445,154	2,119,141	859,481
Executive Management [Member]
Related Party Transactions (Details) - Schedule of related party transaction [Line Items]
Short term benefits	989,760	781,204	407,147
Post-employee benefits years	49,050	29,467	26,870
Share Bonuses		902,817
Share-based payment charge	172,115	192,362	204,840
Total	1,210,925	1,905,850	638,857
Board of Directors [Member]
Related Party Transactions (Details) - Schedule of related party transaction [Line Items]
Short term benefits	183,058	165,245	163,476
Post-employee benefits years
Share Bonuses
Share-based payment charge	51,171	48,046	57,148
Total	SFr 234,229	SFr 213,291	SFr 220,624

Commitments and Contingencies (Details) - CHF (SFr)	12 Months Ended
Commitments and Contingencies (Details) - CHF (SFr)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Commitments And Contingent Liabilities [Abstract]
Office lease expenses	SFr 6,001	SFr 52,280	SFr 50,260

Prepayments (Details) - Schedule of prepayments - CHF (SFr)	Dec. 31, 2022	Dec. 31, 2021
Schedule of Prepayments Abstract
Advance payments to suppliers	SFr 659,861	SFr 1,437,708
Insurance	49,405	137,418
Total prepayments	SFr 709,266	SFr 1,575,126

Financial instruments and risk management (Details) - Schedule of quantitative data about the exposure of financial assets and liabilities to currency risk	Dec. 31, 2022 USD ($)	Dec. 31, 2022 EUR (€)	Dec. 31, 2022 AUD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 EUR (€)	Dec. 31, 2021 AUD ($)
Financial instruments and risk management (Details) - Schedule of quantitative data about the exposure of financial assets and liabilities to currency risk [Line Items]
Net statement of financial position exposure -asset/(liability)	$ 218,261	€ (1,656,992)	$ 879,531	$ 1,556,537	€ (2,344,941)	$ 1,274,271
Cash and cash equivalents [Member]
Financial instruments and risk management (Details) - Schedule of quantitative data about the exposure of financial assets and liabilities to currency risk [Line Items]
Net statement of financial position exposure -asset/(liability)	1,791	3,462		388,950	539,474
Trade and other receivables [Member]
Financial instruments and risk management (Details) - Schedule of quantitative data about the exposure of financial assets and liabilities to currency risk [Line Items]
Net statement of financial position exposure -asset/(liability)	1,523,292	91,864	879,531	1,436,086	26,843	1,274,271
Trade and other payables [Member]
Financial instruments and risk management (Details) - Schedule of quantitative data about the exposure of financial assets and liabilities to currency risk [Line Items]
Net statement of financial position exposure -asset/(liability)	(1,086,206)	(1,452,883)		(104,676)	(2,615,791)
Accrued expenses [Member]
Financial instruments and risk management (Details) - Schedule of quantitative data about the exposure of financial assets and liabilities to currency risk [Line Items]
Net statement of financial position exposure -asset/(liability)	$ (220,616)	€ (299,435)		$ (163,823)	€ (295,467)

Trade and Other Payables (Details) - Schedule of trade and other payables - CHF (SFr)	Dec. 31, 2022	Dec. 31, 2021
Schedule of Trade And Other Payables Abstract
Trade accounts payable - third parties	SFr 4,767,940	SFr 3,544,384
Other	146,464	153,339
Total trade and other payables	SFr 4,914,404	SFr 3,697,723

Financial instruments and risk management

12 Months Ended

Dec. 31, 2022

Financial instruments and risk management [Abstract]

Financial instruments and risk management

5. Financial instruments and risk management

The following table shows the carrying amounts of financial assets and financial liabilities:

	December 31,		December 31,
	2022		2021
Financial assets
At amortized cost
Cash and cash equivalents		15,395		984,191
Other non-current financial assets		194,263		199,105
Trade receivables		6,525		21,746
Other receivables		—		255,187
At fair value through profit and loss
Derivative financial instruments		270,176		—
Total financial assets		486,359		1,460,229

Financial liabilities
At amortized cost
Trade and other payables		4,914,404		3,697,723
Accrued expenses		1,977,614		1,048,575
Loan		5,869,797		—
Non-current lease liabilities		343,629		461,485
Current lease liabilities		117,856		114,251
At fair value through profit and loss
Derivative financial instruments		—		1,233
Total financial liabilities		13,223,300		5,323,267

Fair values

The carrying amount of cash and cash equivalents, financial assets, trade and other receivables, trade and other payables, accrued expenses, loan and lease liabilities is a reasonable approximation of their fair value due to the short-term nature of these instruments.

Financial risk factors

The Group’s activities expose it to a variety of financial risks: market risk, credit risk, interest rate and liquidity risk. The Group’s overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the Group’s financial performance. Management identifies, evaluates and controls financial risks. No financial derivatives have been used in 2022 and 2021 to hedge risk exposures. The Group invests its available cash in instruments with the main objectives of preserving principal, meeting liquidity needs and minimizing foreign exchange risks. The Group allocates its liquid assets to first tier Swiss or international banks.

Liquidity risk

The Group’s principal source of liquidity is its cash reserves which are mainly obtained through the issuance of new shares. The Group has succeeded in raising capital to fund its development activities to date and has raised funds that will allow it to meet short-term development expenditures. The Company will require regular capital injections to continue its development work, which may be dependent on meeting development milestones, technical results and/or commercial success. Management monitors rolling forecasts of the Group’s liquidity requirements to ensure it has sufficient cash to meet operational needs. The ability of the Group to maintain adequate cash reserves to sustain its activities in the medium term is highly dependent on the Group’s ability to raise further funds. Consequently, the Group is exposed to continued liquidity risk.

The table below analysis the remaining contractual maturities of financial liabilities, including estimated interest payments as of December 31, 2022 and 2021. The amounts disclosed in the table are the undiscounted cash flows:

	Carrying amount		Less than 3 months		Between 3 months and 2 years		2 years and later		Total
December 31, 2022
Trade and other payables		4,914,404		4,914,404		—		—		4,914,404
Accrued expenses		1,977,614		1,977,614		—		—		1,977,614
Loan and borrowings		5,869,797		5,759,877		357,192		—		6,117,069
Non-current lease liabilities		343,629		—		130,200		227,850		358,050
Current lease liabilities		117,856		32,550		97,650		—		130,200
Derivative financial instruments		—		—		—		—		—
Total		13,223,300		12,684,445		585,042		227,850		13,497,337

	Carrying amount		Less than 3 months		Between 3 months and 2 years		2 years and later		Total
December 31, 2021
Trade and other payables		3,697,723		3,697,723		—		—		3,697,723
Accrued expenses		1,048,575		1,048,575		—		—		1,048,575
Loan and borrowings		—		—		—		—		—
Non-current lease liabilities		461,485		—		130,200		358,050		488,250
Current lease liabilities		114,251		32,550		97,650		—		130,200
Derivative financial instruments		1,233		—		—		1,233		1,233
Total		5,323,267		4,778,848		227,850		359,283		5,365,981

Fair values as at

Financial assets / liabilities

December 31,
2022

December 31,
2021

Fair value
hierarchy

Valuation technique(s) and key input(s)

Derivative fiinancial

Liability

Level 2

Black-Scholes option pricing model

liabilities – Warrants from public offerings

—

1,233

The share price is determined by Company’s NASDAQ quoted price.

The strike price and maturity are defined by the contract. The volatility assumption is driven by Company’s historic quoted share price and the risk free rate is estimated based on observable yield curves at the end of each reporting period.

Derivative financial liabilities – Embedded Derivatives FiveT Convertible Loan

—

Level 3

Black-Scholes option pricing model

The valuation is based on input parameters classified as level 3. Input parameters include the historical volatility of AMHL shares, risk-free rate, expected remaining life, expected exercise date and share prices of AMHL at valuation dates.

Derivative financial asset - Option LPC purchase agreement

Asset

270,176

Asset

—

Level 3

The fair value is equal to the price paid to the counterparty for obtaining the right under the purchase agreement. The price paid corresponds to the fair value of 50,000 commitment shares issued to LPC as consideration for its commitment to purchase our common shares under the purchase agreement.

Subsequent, the fair value is adjusted proportionally for the part of the right consumed.

For level 3 financial liability, the sensitivity analysis below represents the potential absolute change in fair value. The favorable and unfavorable effects on the result before taxes, resulting from using reasonably alternative assumptions for the valuation of the option component of the Convertible Loan (FiveT) has been calculated by recalibrating the modes using unobservable inputs based on an average change in volatility of 5%.

	Dec 31, 2022					Dec 31, 2021
	Increase/Decrease in volatility assumption			Effect on result before taxes on CHF		Increase/Decrease in volatility assumption		Effect on result before taxes on CHF
Change in volatility		+5	%		—		—		—
		-5	%		—		—		—

Changes in liabilities arising from financing activities

						Non-cash changes
			Financing			Fair
			Cash			value			Other
	01.01.2022		Flows ¹⁾			revaluation			changes ²⁾			31.12.2022
Derivative financial instrument		1,233		—			(1,233	)		—			—
Loans		—		6,038,627			—			(168,830	)		5,869,797
Lease liabilities		575,736		(130,200	)		—			15,949			461,485
Total		576,969		5,908,427			(1,233	)		(152,881	)		6,331,282

						Non-cash changes
			Financing			Fair
			Cash			value			Other
	01.01.2021		Flows ¹⁾			revaluation			changes ²⁾			31.12.2021
Derivative financial instrument		316,757		—			410,918			(726,442	)		1,233
Loans		523,920		(50,000	)		—			(473,920	)		—
Lease liabilities		—		(21,700	)		—			597,436			575,736
Total		840,677		(71,700	)		410,918	)		(602,926	)		576,969

¹⁾

The financing cash flows are from loan borrowings or loan and lease repayments.

²⁾

Other non-cash changes include conversion of convertible loan including de-recognition of embedded derivative and initial recognition of lease liability.

Credit risk

Credit risk is managed on a Group basis. Credit risk arises from cash and cash equivalents and deposits with banks, as well as from trade and other receivables. The Company’s policy is to invest funds in low risk investments including interest bearing deposits. Trade and other receivables were current as of December 31, 2022 and December 31, 2021, not impaired and included only well-known counterparties.

The Group has been holding cash and cash equivalents in the Group’s principal operating currencies (CHF, USD, EUR and AUD) with international banks of high credit rating.

The Group’s maximum exposure to credit risk is represented by the carrying amount of each financial asset in the consolidated statement of financial position:

	December 31,		December 31,
	2022		2021
Financial assets
Cash and cash equivalents		15,395		984,191
Other non-current financial assets		194,263		199,105
Trade receivables		6,525		21,746
Other receivables		—		255,187
Total		216,183		1,460,229

As of December 31, 2021 other receivables consisted of cash receivable from a capital increase implemented over the year end.

Market risk

Currency risk

The Group operates internationally and is exposed to foreign exchange risk arising from various exposures, primarily with respect to US Dollar, Euro and Australian Dollar. Foreign exchange risk arises from future commercial transactions, recognized assets and liabilities and net investments in foreign operations. The summary of quantitative data about the exposure of the Group’s financial assets and liabilities to currency risk was as follows:

	2022								2021
in CHF	USD			EUR			AUD		USD			EUR			AUD
Cash and cash equivalents		1,791			3,462			—		388,950			539,474			—
Trade and other receivables		1,523,292			91,864			879,531		1,436,086			26,843			1,274,271
Trade and other payables		(1,086,206	)		(1,452,883	)		—		(104,676	)		(2,615,791	)		—
Accrued expenses		(220,616	)		(299,435	)		—		(163,823	)		(295,467	)		—
Net statement of financial position exposure -asset/(liability)		218,261			(1,656,992	)		879,531		1,556,537			(2,344,941	)		1,274,271

As of December 31, 2022, a 5% increase or decrease in the USD/CHF exchange rate with all other variables held constant would have resulted in a CHF 10,913 (2021: CHF 77,827) increase or decrease in the net result. A 5% increase or decrease in the EUR/CHF exchange rate with all other variables held constant would have resulted in a CHF 82,850 (2021: CHF 117,247) increase or decrease in the net result. Also, a 5% increase or decrease in the AUD/CHF exchange rate with all other variables held constant would have resulted in a CHF 43,977 (2021: CHF 63,714) increase or decrease in the net result. The Company has subsidiaries in the United States, Australia and Ireland, whose net assets are exposed to foreign currency translation risk. Due to the small size of the subsidiaries the translation risk is not significant.

Capital risk management

The Company and its subsidiaries are subject to capital maintenance requirements under local law in the country in which it operates. To ensure that statutory capital requirements are met, the Company monitors capital, at the entity level, on an interim basis as well as annually. From time to time the Company may take appropriate measures or propose capital increases to ensure the necessary capital remains intact.

Employee Benefits (Details) - Schedule of sensitivity analysis for actuarial assumptions - CHF (SFr)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Employee Benefits (Details) - Schedule of sensitivity analysis for actuarial assumptions [Line Items]
Percentage of reasonably possible increase in actuarial assumption	0.25% increase	0.25% increase
Discount rate [Member]
Employee Benefits (Details) - Schedule of sensitivity analysis for actuarial assumptions [Line Items]
Discount rate	SFr (117,546)	SFr (200,601)
Salary increase [Member]
Employee Benefits (Details) - Schedule of sensitivity analysis for actuarial assumptions [Line Items]
Discount rate	23,058	22,961
Pension indexation [Member]
Employee Benefits (Details) - Schedule of sensitivity analysis for actuarial assumptions [Line Items]
Discount rate	SFr 63,916	SFr 110,958
Change in assumption [Member]
Employee Benefits (Details) - Schedule of sensitivity analysis for actuarial assumptions [Line Items]
Life expectancy reasonably possible increase in actuarial assumption	+1 year	+ 1 year
Life expectancy {Member]
Employee Benefits (Details) - Schedule of sensitivity analysis for actuarial assumptions [Line Items]
Discount rate	SFr 48,531	SFr 98,983

Cost of Sales (Details) - Schedule of cost of sales - CHF (SFr)

12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Schedule Of Cost Of Sales Abstract

Product purchases, packaging and logistics

SFr 362,584

SFr 173,758

Employee benefit and expenses

150,438

89,238

Inventory write-down

930,833

1,977,558

Total cost of sales

SFr 1,443,855

SFr 2,240,554

^[1]

[1]	Revised, see note 33.

Warrants from Public Offering (Details) SFr / shares in Units, $ / shares in Units, $ in Millions	1 Months Ended						12 Months Ended
	Jul. 17, 2018 CHF (SFr) SFr / shares shares	Jan. 30, 2018 CHF (SFr) shares	Feb. 28, 2017 CHF (SFr)	Feb. 21, 2017 CHF (SFr) SFr / shares shares	Feb. 21, 2017 USD ($) shares	Feb. 15, 2017 shares	Dec. 31, 2022 CHF (SFr) shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 CHF (SFr) shares	Dec. 31, 2020 CHF (SFr)	Dec. 31, 2019 CHF (SFr) shares	Dec. 31, 2021 $ / shares shares	Jan. 30, 2018 $ / shares
Warrants from Public Offering (Details) [Line Items]
Number of shares issued (in Shares) \| shares							1,180,053	1,180,053				748,213
Share issue related cost \| $								$ 5.1
Exercise price (in Dollars per share) \| $ / shares								$ 24
Gross proceed offering cost			SFr 9,998,305
Warrants issued (in Shares) \| shares									1,986
Exercise price \| $ / shares												$ 4,800
Fair value of warrants									SFr 0
Derivative amount							SFr 1,233		SFr 5,085
Corresponding amount amount	SFr 572,249	SFr 2,483,747
Increased fair value	SFr 2,433,099
Warrants [Member]
Warrants from Public Offering (Details) [Line Items]
Common share price (in Francs per share) \| SFr / shares				SFr 8
Conversion ratio		0.6		0.7	0.7
Purchased shares (in Shares) \| shares						67,500
Common shares issued (in Shares) \| shares							397,250	397,250
Gross proceed offering cost			5,091,817
Warrants issued (in Shares) \| shares		3,125							1,875
Exercise price \| $ / shares												$ 2,000	$ 2,000
Fair value of warrants										SFr 0
Decreased fair value		SFr 2,483,747
Issued capital [member]
Warrants from Public Offering (Details) [Line Items]
Assigned warrants			SFr 4,906,488
Series B Warrants [member]
Warrants from Public Offering (Details) [Line Items]
Number of shares issued (in Shares) \| shares	0.25
Conversion ratio	44,872
Common shares issued (in Shares) \| shares											7,161
Exercise price \| SFr / shares	SFr 156
Fair value of warrants							SFr 0		SFr 1,233
Warrants exercised for aggregate amount											SFr 1,117,125
Number of warrants exercised (in Shares) \| shares											7,161
Fair value of warrant exercised											SFr 3,005,348
Series A Warrants [member]
Warrants from Public Offering (Details) [Line Items]
Number of shares issued (in Shares) \| shares	15,705
Conversion ratio	0.35
Common shares issued (in Shares) \| shares	11,218										7,261
Warrants exercised for aggregate amount											SFr 1,132,762
Public offering [Member]
Warrants from Public Offering (Details) [Line Items]
Number of shares issued (in Shares) \| shares				500,000	500,000
Conversion ratio				500,000	500,000
Net proceeds after underwriting discounts				SFr 9.1	$ 9.1
Share issue related cost				903,919
Transaction costs recognized in equity				397,685
Finance expense				SFr 506,234
Underwriters [Member]
Warrants from Public Offering (Details) [Line Items]
Purchased shares (in Shares) \| shares							75,000	75,000
Additional common shares (in Shares) \| shares							75,000	75,000

General and Administrative Expense (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure of general and administrative expense [Abstract]

Schedule of general and administrative expense

	December 31,		December 31,		December 31,
	2022		2021		2020
Employee benefits and expenses		735,139		1,554,778		811,373
Business development		15,727		967,046		95,663
Travel expenses		95,503		75,829		28,898
Administration expenses		2,669,460		2,245,862		1,645,530
Lease expenses from short-term lease		6,001		52,280		13,871
Depreciation of Right-of-use assets		118,887		29,722		—
Depreciation of tangible assets		—		—		3,555
Capital tax expenses		3,832		21,059		(4,228	)
Total general and administrative expenses		3,644,549		4,946,576		2,594,662

Taxation (Details) - Schedule of tax effect of major unrecognized temporary differences and loss - CHF (SFr)	Dec. 31, 2022	Dec. 31, 2021
Deductible temporary differences
Deferred income	SFr 111,025
Employee benefit plan	43,841	87,149
Other accounts payable		344,822
Total potential tax assets	154,866	431,971
Potential tax assets from loss carry-forwards not recognized	13,297,723	14,271,306
Total potential tax assets from loss carry-forwards and temporary differences not recognized	SFr 13,452,589	SFr 14,703,277

Loss Per Share (Details) - shares	12 Months Ended
Loss Per Share (Details) - shares	Dec. 31, 2022	Dec. 31, 2021
Loss per share [Abstract]
Antidilutive securities excluded from computation of earnings per share, Amount	157,320
Average number of options outstanding	910,723	662,314
Warrants to purchase	99,171
Warrant to purchase of common stock		12,305

Financial instruments and risk management (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Financial instruments and risk management (Details) [Line Items]
Increase or decrease in rate (as a percent)	5.00%
USD [Member]
Financial instruments and risk management (Details) [Line Items]
Increase or decrease in rate (as a percent)	5.00%
Impact of increase or decrease in rate on net result	SFr 10,913	SFr 77,827
EUR [member]
Financial instruments and risk management (Details) [Line Items]
Impact of increase or decrease in rate on net result	SFr 82,850	117,247
Australian dollar [Member]
Financial instruments and risk management (Details) [Line Items]
Increase or decrease in rate (as a percent)	5.00%
Impact of increase or decrease in rate on net result	SFr 43,977	SFr 63,714

Capital and Reserves

12 Months Ended

Dec. 31, 2022

Capital and reserves [Abstract]

Capital and reserves

14. Capital and reserves

Share capital

The issued share capital of the Company at December 31 consisted of:

	December 31,				December 31,
	2022				2021
	Number		CHF		Number		CHF
Common shares with a par value of CHF 0.20 each		1,180,053		236,011		748,213		149,643
Total		1,180,053		236,011		748,213		149,643

	Common Shares
	(Number)
	2022			2021
As of January 1		748,213			570,858
Exercise of warrants		—			44,872
LPC equity line		315,000			—
ATM program		116,843			59,235
Share-based payments (bonus)		—			8,731
Conversion convertible loan		—			25,841
Shares issued for Trasir acquisition		—			38,676
Fractional shares		(3	)		—
Total, as of December 31		1,180,053			748,213

On December 5, 2022, the Company entered into a purchase agreement and a Registration Rights Agreement with Lincoln Park Capital Fund, LLC (the “2022 Commitment Purchase Agreement”). Pursuant to the purchase agreement, LPC agreed to subscribe for up to $10,000,000 of our common shares over the 24-month term of the purchase agreement. As consideration for LPC’s irrevocable commitment to purchase common shares upon the terms of and subject to satisfaction of the conditions set forth in the 2022 Commitment Purchase Agreement, the Company agreed to issue 50,000 common shares immediately to LPC as commitment shares. In 2022, no common shares were issued to LPC under the 2022 Commitment Purchase Agreement. The 2022 Commitment Purchase Agreement replaced the 2020 Commitment Purchase Agreement. Under the 2020 Commitment Purchase Agreement, LPC agreed to subscribe for up to $10,000,000 of our common shares over the 30-month term of the purchase agreement. Prior to its termination we had issued 325,000 common shares for aggregate proceeds of $4.0 million to LPC under the 2020 Commitment Purchase Agreement. The 2020 Commitment Purchase Agreement replaced the 2018 Commitment Purchase Agreement. Under the 2018 Commitment Purchase Agreement agreed to purchase common shares for up to $10,000,000 over the 30-month term of the Purchase Agreement. Prior to its termination we had issued 29,375 common shares for aggregate proceeds of $1.8 million to LPC under the LPC Purchase Agreement.

On June 1, 2021, the Company completed the acquisition of Trasir. The upfront acquisition price of $2.5 million was paid with 38,219 non-registered common shares at $65.40 each to the selling shareholders. In addition, 459 non-registered common shares were issued to reimburse $30,000 in expenses incurred by certain selling Trasir shareholders.

On December 3, 2020, the Company entered into securities purchase agreements with several institutional investors for the purchase and sale of 100,000 common shares at an offering price of $80.00 per share, pursuant to a registered direct offering. The net proceeds of the offering were approximately $7.3 million.

On December 1, 2020, a tranche of the convertible loan provided by FiveT in the amount of CHF 895,455 was converted into 36,850 common shares at a conversion price of $27.00. On March 4, 2021 the remaining amount of CHF 604,545 plus interest of CHF 40,628 were converted into 25,841 common shares at a conversion price of $27.00.

On May 15, 2019, the Company completed a public offering of (i) 22,000 common shares with a par value of CHF 16.00 each, together with warrants to purchase 22,000 common shares, and (ii) 86,064 pre-funded warrants, with each pre-funded warrant exercisable for one common share, together with warrants to purchase 86,064 common shares, including 5,500 common shares and warrants to purchase 5,500 common shares sold pursuant to a partial exercise by the underwriters of the underwriters’ over-allotment option (the “May 2019 Registered Offering”). The exercise price for the pre-funded warrants was CHF 0.20 per common share and for the warrants CHF 86.80. The net proceeds to us from the May 2019 Registered Offering were approximately $7.7 million, after deducting underwriting discounts and other offering expenses payable by us. All pre-funded warrants were exercised in 2019. In December 2020, 63,192 warrants were exercised. The remaining 44,872 warrants were exercised in March 2021.

On November 30, 2018, we entered into the A.G.P. Sales Agreement with A.G.P. Pursuant to the terms of the A.G.P. Sales Agreement, as amended on April 5, 2019, we may offer and sell our common shares, from time to time through A.G.P. by any method deemed to be an “at-the-market” offering as defined in Rule 415(a)(4) promulgated under the Securities Act. Pursuant to the A.G.P. Sales Agreement, we may sell common shares up to a maximum aggregate offering price of $25.0 million. In 2022, we sold 116,843 shares under the ATM. As of the date of this Annual Report, we have sold 1,505,244 of our common shares for an aggregate offering price of $12.1 million pursuant to the A.G.P. Sales Agreement. The related transaction costs were charged to equity.

Authorized share capital

Our authorized share capital as of December 31, 2022 and December 31, 2021 consisted of 5,000,000 common shares, par value CHF 0.20 per share, and 20,000,000 preference shares, par value CHF 0.02 per share.

Research and Development Expense (Tables)

12 Months Ended

Dec. 31, 2022

Research and development expense [Abstract]

Schedule of research and development expense

	December 31,		December 31,		December 31,
	2022		2021		2020
Pre-clinical projects		509,224		587,019		242,617
Clinical projects		3,237,649		2,379,536		476,972
Product and process development		473,246		1,100,453		614,744
Employee benefits and expenses		2,585,242		1,897,155		1,120,814
Lease expenses from short-term lease		—		—		34,147
Patents and trademarks		240,380		465,587		246,592
Regulatory projects		153,863		354,507		110,612
Impairment intangible assets		12,397,148		1,529,929		—
Depreciation tangible assets		81,004		46,635		16,481
Total research and development expense		19,677,756		8,360,821		2,862,979

Significant accounting policies (Details) - Schedule of estimated useful lives	12 Months Ended
	Dec. 31, 2022
Production equipment [Member]
Significant accounting policies (Details) - Schedule of estimated useful lives [Line Items]
Useful life	5 years
Office furniture and electronic data processing equipment (“EDP”) [member]
Significant accounting policies (Details) - Schedule of estimated useful lives [Line Items]
Useful life	3 years

Property and Equipment

12 Months Ended

Dec. 31, 2022

Property and Equipment [Abstract]

Property and equipment

7. Property and Equipment

				Office
	Production			furniture
	equipment			and EDP			Total
At cost
As of January 1, 2021		353,488			233,706			587,194
Additions		—			—			—
Disposals		—			—			—
As of December 31, 2021		353,488			233,706			587,194
Additions		—			—			—
Disposals		—			—			—
As of December 31, 2022		353,488			233,706			587,194

Accumulated depreciation
As of January 1, 2021		(306,972	)		(233,586	)		(540,558	)
Charge for the year		(46,516	)		(119	)		(46,635	)
Disposals		—			—			—
As of December 31, 2021		(353,488	)		(233,705	)		(587,193	)
Charge for the year		—			—			—
Disposals		—			—			—
As of December 31, 2022		(353,488	)		(233,705	)		(587,193	)

Net book value
As of December 31, 2021		—			1			1
As of December 31, 2022		—			1			1

As of December 31, 2022, and 2021 no items of property and equipment were pledged.

Employee Benefits (Details) - Schedule of defined benefit plan expense recognized in profit or loss - CHF (SFr)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Defined Benefit Plan Expense Recognized In Profit or Loss Abstract
Salaries	SFr 2,815,411	SFr 1,865,633	SFr 1,260,359
Pension costs	266,256	165,801	156,843
Other social benefits	294,017	275,258	116,290
Share based payments costs	342,799	1,223,696	351,401
Other personnel expenditures	2,024	214,940	47,295
Total employee benefits	SFr 3,720,507	SFr 3,745,328	SFr 1,932,188

Reporting entity (Details) - 12 months ended Dec. 31, 2022	CHF (SFr)	USD ($)	EUR (€)	AUD ($)
Auris Medical AG [Member]
Reporting entity (Details) [Line Items]
Ownership percentage in subsidiary	100.00%
Share capital of subsidiary	SFr 2,500,000
Otolanum AG [Member]
Reporting entity (Details) [Line Items]
Ownership percentage in subsidiary	100.00%
Share capital of subsidiary	SFr 100,000
Zilentin AG [Member]
Reporting entity (Details) [Line Items]
Ownership percentage in subsidiary	100.00%
Share capital of subsidiary	SFr 100,000
Altamira Medica AG [Member]
Reporting entity (Details) [Line Items]
Ownership percentage in subsidiary	100.00%
Share capital of subsidiary	SFr 3,000,000
Auris Medical Inc [Member]
Reporting entity (Details) [Line Items]
Ownership percentage in subsidiary	100.00%
Share capital of subsidiary \| $		$ 100
Auris Medical Ltd [Member]
Reporting entity (Details) [Line Items]
Ownership percentage in subsidiary	100.00%
Share capital of subsidiary \| €			€ 100
Principal place of business	Dublin
Country of incorporation	Ireland
Auris Medial Pty Ltd [Member]
Reporting entity (Details) [Line Items]
Ownership percentage in subsidiary	100.00%
Share capital of subsidiary \| $				$ 100

Loans (Tables)

12 Months Ended

Dec. 31, 2022

Loans [Abstract]

Schedule of loans

	December 31,		December 31,
	2022		2021
Convertible loan February 2022		4,898,377		—
Loans with warrants		871,420		—
Short-term loan from related party		100,000		—
Total		5,869,797		—

Schedule of convertible loan agreement

	December 31,			December 31,
	2022			2021
As of January 1		—			473,920
Gross proceeds at disbursement date		5,000,000			—
Embedded derivative, separated		(449,898	)		—
Transaction costs allocated to host		(10,236	)		—
Carrying amount at initial recognition		4,539,866			—

Converted principal amount		—			(644,813	)
Accrued interest		447,945			8,348
Amortization		358,511			162,545
Total		5,346,322			—
Accrued interest balance of December 31		447,945			—
Convertible loan balance of December 31		4,898,377			—

Taxation

12 Months Ended

Dec. 31, 2022

Taxation [Abstract]

Taxation

27. Taxation

The Group’s income tax expense recognized in the consolidated statement of profit or loss and other comprehensive loss was as follows:

	2022			2021			2020
Deferred income tax expense		(52,004	)		(570,730	)		(389,384	)
Deferred income tax gain		62,332			549,110			410,668
Income tax gain/(loss)		10,329			(21,620	)		21,284

The Group’s effective income tax expense differed from the expected theoretical amount computed by applying the Group’s applicable weighted average tax rate of 13.7% in 2022 (2021: 13.5%, 2020: 12.1%) as summarized in the following table:

Reconciliation	2022			2021			2020
Loss before income tax		(26,538,740	)		(17,036,823	)		(8,221,449	)
Income tax at statutory tax rates applicable to results in the respective countries		3,641,775			2,348,057			991,120
Effect of unrecognized temporary differences		(125,260	)		(632,031	)		(302,557	)
Effect of unrecognized taxable losses		(3,015,088	)		(1,885,486	)		(184,881	)
Effect of impairment of assets		—			(75,375	)		—
Effect of previously unrecognized deferred tax asset		—			—			97,458
Effect of expenses not considerable for tax purposes		—			—			(47,894	)
Effect of impact from application of different tax rates		(491,098	)		223,215			(531,962	)
Income tax gain/(loss)		10,329			(21,620	)		21,284

The tax effect of taxable temporary differences that give rise to deferred income tax liabilities or to deferred income tax assets as of December 31 is presented below:

	December 31,			December 31,
Deferred Tax Liabilities	2022			2021
Intangible assets		—			(51,914	)
Deferred unrealized foreign exchange gains		—			—
Other receivables		(167,299	)		(122,449	)
Total		(167,299	)		(174,363	)

	December 31,			December 31,
Deferred Tax Asset	2022			2021
Net operating loss (NOL)		41,429			31,879
Total		41,429			31,879
Deferred Tax, net		(125,870	)		(142,484	)

	Opening			Recognized in			Recognized in		Exchange			Closing
Deferred Tax 2022	Balance			Profit or Loss			Equity		Differences			Balance
Intangible assets		(51,914	)		51,958			—		(44	)		—
Other receivables		(122,449	)		(52,004	)		—		7,154			(167,299	)
Net operating loss (NOL)		31,879			10,374			—		(825	)		41,429
Total		(142,484	)		10,329			—		6,285			(125,870	)

	Opening			Recognized in			Recognized in		Exchange			Closing
Deferred Tax 2021	Balance			Profit or Loss			Equity		Differences			Balance
Intangible assets		(252,174	)		199,056			—		1,204			(51,914	)
Deferred unrealized foreign exchange gains		(350,054	)		350,054			—		—			—
Derivative financial asset		—			(127,000	)		—		4,551			(122,449	)
Net operating loss (NOL)		476,363			(443,730	)		—		(754	)		31,879
Total		(125,865	)		(21,620	)		—		5,001			(142,484	)

As of December 31, 2022, the Group had unrecognized tax loss carryforwards amounting to CHF 103.1 million (2021: CHF 109.9 million), of which CHF 101.4 million related to Auris Medical AG, Otolanum AG, Zilentin AG and Altamira Medica AG in Switzerland, CHF 1.7 million to Altamira Therapeutics Inc. in the United States (2021: CHF 108.6 million for Auris Medical AG, Otolanum AG, Zilentin AG and Altamira Medica AG and CHF 1.3 million for Auris Medical Inc.).

The Group’s unrecognized tax loss carryforwards with their expiry dates are as follows:

	December 31,		December 31,
	2022		2021
Within 1 year		27,956,899		28,909,896
Between 1 and 3 years		31,668,498		50,673,943
Between 3 and 7 years		41,797,708		29,007,049
More than 7 years		1,691,572		1,264,262
Total		103,114,677		109,855,150

Due to the uncertainty surrounding the future results of operations and the uncertainty as to whether the Group can use the loss carryforwards for tax purposes, deferred tax assets on tax loss carryforwards were only considered to the extent that they offset taxable temporary differences within the same taxable entity. No deferred tax assets are calculated on temporary differences related to pension obligations from IAS 19.

The tax effect of the major unrecognized temporary differences and loss carryforwards is presented in the table below:

	December 31,		December 31,
	2022		2021
Deductible temporary differences
Deferred income		111,025		—
Employee benefit plan		43,841		87,149
Other accounts payable		—		344,822
Total potential tax assets		154,866		431,971
Potential tax assets from loss carry-forwards not recognized		13,297,723		14,271,306
Total potential tax assets from loss carry-forwards and temporary differences not recognized		13,452,589		14,703,277

Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated balance sheet	Dec. 31, 2021 USD ($)
As reported [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated balance sheet [Line Items]
Other receivables	$ 917,833
Prepayments	996,910
Total current assets	3,759,901
Total assets	18,838,598
Accumulated deficit	(176,018,660)
Total shareholders’ equity attributable to owners of the company	12,704,528
Total equity and liabilities	18,838,598
Adjustment [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated balance sheet [Line Items]
Other receivables	(246,493)
Prepayments	578,216
Total current assets	331,723
Total assets	331,723
Accumulated deficit	331,723
Total shareholders’ equity attributable to owners of the company	331,723
Total equity and liabilities	331,723
As revised [Member]
Revision of Prior Period Financial Statements (Details) - Schedule of revised consolidated balance sheet [Line Items]
Other receivables	671,340
Prepayments	1,575,126
Total current assets	4,091,624
Total assets	19,170,321
Accumulated deficit	(175,686,937)
Total shareholders’ equity attributable to owners of the company	13,036,251
Total equity and liabilities	$ 19,170,321

Employee Benefits (Details) - Schedule of defined benefit obligation - CHF (SFr)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Defined Benefit Obligation Abstract
Defined benefit obligation at beginning	SFr 4,677,632	SFr 3,529,602
Service costs	256,336	162,200
Plan participants’ contribution	154,116	101,066
Interest cost	13,762	10,464
Actuarial losses	(931,636)	159,845
Plan amendments		(3,115)
Benefits paid through pension assets	(626,049)	717,570
Defined benefit obligation at ending	3,544,161	4,677,632
Fair value of plan assets at beginning	4,009,313	2,662,226
Interest income	12,187	8,586
Return on plan assets excluding interest income	(490,359)	424,829
Employer contributions	154,116	101,066
Plan participants’ contributions	154,116	101,066
Benefits paid through pension assets	(626,049)	717,570
Administration expense	(5,369)	(6,030)
Fair value of plan assets at ending	3,207,955	4,009,313
Present value of funded defined benefit obligation	3,544,161	4,677,632
Fair value of plan assets	(3,207,955)	(4,009,313)
Net defined benefit liability	SFr 336,206	SFr 668,319

Basis of preparation

12 Months Ended

Dec. 31, 2022

Basis of preparation [Abstract]

Basis of preparation

2. Basis of preparation

Statement of compliance

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”).

These consolidated financial statements were approved by the Board of Directors and the Audit Committee of the Company on May 16, 2023.

Basis of measurement

The consolidated financial statements are prepared on the historical cost basis, except for the revaluation to fair value of certain financial liabilities. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services. The principal accounting policies adopted are set out below.

In addition, for financial reporting purposes, fair value measurements are categorized into Level 1, 2 or 3 based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows:

●

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date

●

Level 2 inputs are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly; and

●

Level 3 inputs are unobservable inputs for the asset or liability.

Functional and reporting currency

These consolidated financial statements are presented in Swiss Francs (“CHF”), which is the Company’s functional (“functional currency”) and the Group’s reporting currency.

Going Concern

We have incurred recurring losses and negative cash flows from operations since inception and we expect to generate losses from operations for the foreseeable future primarily due to incurring research and development costs for our potential product candidates. We expect our research and development expenses to remain significant as we advance or initiate the pre-clinical and clinical development of AM-401, AM-411 or any other product candidate. We expect our total additional cash need in 2023 to be in the range of CHF 15 to 17 million. As of December 31, 2022, our cash and cash equivalents were CHF 15 thousand. In 2023, through the issuance date of the financial statements, we have raised $5.1 million from the issuance of common shares under the A.G.P. Sales Agreement and the 2022 LPC Purchase Agreement, and CHF 2.5 million through a convertible loan provide under the 2023 FiveT Loan Agreement. In addition, we expect to receive another milestone payment of $1.0 million from Nuance upon market approval of Bentrio in China (during the 2^nd quarter of 2024) as well as CHF 0.7 million in grant funding (during the 2^nd and 3^rd quarter of 2023). Further, the 2022 convertible loan from FiveT IM got converted into equity in April 2023.

The Board of Directors have considered the cash flow forecasts and the funding requirements of the business and continue to explore grant funding, licensing opportunities and equity investment opportunities in the Company. Apart from the inner ear therapeutic assets, the Company intends to partner or divest also its OTC consumer health products business, in order to focus on the development of its OligoPhore™/SemaPhore™ RNA delivery platform. In addition, the Company intends to raise further capital. The Board of Directors considers it feasible to generate CHF 15 to 17 million in funding within 12 months from the reporting date. At the date of issuing these financial statements, such plans have not yet been realized.

Our assumptions may prove to be wrong, and we may have to use our capital resources sooner than we currently expect. As is often the case with drug development companies, the ability of the consolidated entity to continue its development activities as a going concern is dependent upon it deriving sufficient cash from investors, from licensing and partnering activities, in particular the intended divestiture or partnering of the Company’s legacy assets in the fields of inner ear therapeutics and OTC consumer health products, and from other sources of revenue such as grant funding.

To the extent that we will be unable to generate sufficient cash proceeds from the planned divestiture or partnering of our legacy assets or other partnering activities, we will need substantial additional financing to meet our funding requirements. While Management and the Board of Directors continue to apply best efforts to evaluate available options, there is no guarantee that any transaction can be realized or that such transaction would generate sufficient funds to finance operations for twelve months from the issuance of these financial statements. These factors raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements have been prepared on a going concern basis, which contemplates the continuity of normal activities and realization of assets and settlement of liabilities in the normal course of business. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The lack of a going concern assessment may negatively affect the valuation of the Company’s investments in its subsidiaries and result in a revaluation of these holdings. The Board of Directors will need to consider the interests of our creditors and take appropriate action to restructure the business if it appears that we are insolvent or likely to become insolvent.

We expect that we will require additional funding to continue our development activities for the OligoPhore™ and SemaPhore™ platforms and AM-401 and AM-411 product candidates. Should the Company be unable to raise sufficient funding through equity or debt financings, partnerships, collaborations, or other sources, it may elect to raise additional funding under the A.G.P. Sales Agreement or the 2022 LPC Purchase Agreement. The funding capacity under this financing instruments is $12.9 million and $9.1 million, respectively. Although these agreements are binding, the ability to raise capital under these programs is subject to market and contractual conditions and the availability of registration statements filed with the SEC.

If additional capital is not available when required, the Company may need to delay or curtail its operations until such funding is received. Various internal and external factors will affect whether and when the Company’s product candidates become approved for marketing and successful commercialization. The regulatory approval and market acceptance of the Company’s product candidates, length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the approval process will materially affect the Company’s financial condition and future operations. Such matters are not within the control of the Company and thus all associated outcomes are uncertain.

If we receive regulatory approval or clearance for any of our product candidates, and if we choose to not grant any licenses to partners, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize. We also expect to continue to incur additional costs associated with operating as a public company. Additional funds may not be available on a timely basis, on favorable terms, or at all, and such funds, if raised, may not be sufficient to enable us to continue to implement our long-term business strategy. If we are not able to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts, which could materially harm our business, prospects, financial condition and operating results. This could then result in bankruptcy, or the liquidation of the Company.

2022 Reverse Share Split

The Company effected the 2022 Reverse Share Split of its common shares at a ratio of 1-for-20. No fractional common shares were issued as fractional common shares were settled in cash. Impacted amounts and share information included in the consolidated financial statements and notes thereto have been adjusted for the reverse share split as if such reverse share split occurred on the first day of the periods presented. Certain amounts in the notes to the consolidated financial statements may be slightly different than previously reported due to rounding of fractional shares as a result of the reverse share split.

Use of estimates and judgments

The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions of accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

Information about judgments made in applying accounting policies that have the most significant effects on the amounts recognized in the consolidated financial statements are described below.

Income taxes

As disclosed in Note 27 the Group has significant tax losses in Switzerland. These tax losses represent potential value to the Group to the extent that the Group is able to create taxable profits in Switzerland prior to expiry of such losses. Tax losses may be used within 7 years from the year the losses arose.

The Group also has tax losses in the United States which may be used within 20 years of the end of the year in which losses arose, or for a shorter time period in accordance with prevailing state law.

Other than a tax asset in the amount of CHF 41,430 (2021: CHF 31,879), the Group has not recorded any deferred tax assets in relation to these tax losses. Deferred tax assets on tax losses were only considered to the extent that they offset taxable temporary differences within the same entity. The key factors which have influenced management in arriving at this evaluation are the fact that the business is still in a development phase and the Group has not yet a history of making profits. Should management’s assessment of the likelihood of future taxable profits change, a deferred tax asset will be recorded. Income tax gain reflects the reassessment of deferred tax assets and liabilities booked in the 2022 fiscal year.

Development expenditures

The project stage forms the basis for the decision as to whether costs incurred for the Group’s development projects can be capitalized. We do not capitalize clinical development expenditures until the Group obtains regulatory approval (i.e. approval to commercially use the product), as this is considered to be essentially the first point in time where it becomes probable that future revenues can be generated. Up to 2022, direct development expenditures for the Group’s intranasal betahistine program for the treatment of vertigo (AM-125) were capitalized as the development is primarily focused on the delivery route and formulation and not the drug itself (already an approved generic) and aims to demonstrate higher bioavailability through intranasal delivery. All capitalized direct development expenditures were impaired as of December 31, 2022 based on the impairment test performed under IFRS.

As of each reporting date, the Group estimates the level of service performed by the vendors and the associated costs incurred for the services performed. As part of the process of preparing the Group’s financial statements, the Group is required to estimate its accrued expenses. This process involves reviewing contracts, identifying services that have been performed on the Group’s behalf and estimating the level of service performed and the associated cost incurred for the service when it has not yet been invoiced or otherwise notified of the actual cost.

Employee benefits

The Group’s net obligation in respect of defined benefit plans is calculated by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods, discounting that amount and deducting the fair value of any plan assets. The Company makes relevant actuarial assumptions with regard to the discount rate, future salary increases and life expectancy.

Research and Development and Accrued Expenses

The Company records the costs associated with research, nonclinical and clinical trials, and manufacturing process development as incurred. These costs are a significant component of the Company’s research and development expenses, with a substantial portion of the Company’s on-going research and development activities being conducted by third party service providers, including contract research and manufacturing organizations.

The Company accrues for expenses resulting from obligations under agreements with contract research organizations (“CROs”), contract manufacturing organizations (“CMOs”), and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accrued expenses are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrued expense balance in each reporting period. In the event advance payments are made to a CRO, CMO, or outside service provider, the payments will be recorded as prepayments which will be expensed as the contracted services are performed. Inputs, such as the services performed, the number of patients enrolled, or the trial duration, may vary from the Company’s estimates. As actual costs become known, the Company adjusts its prepayments and accrued expenses.

Finance Income and Finance Expense

12 Months Ended

Dec. 31, 2022

Finance income and finance expense [Abstract]

Finance income and finance expense

26. Finance income and finance expense
	2022			2021			2020
Interest income		969			3,219			258
Net foreign currency exchange gain		745,260			1,458,429			3,207,649
Revaluation gain from derivative financial instruments		451,131			5,085			—
Total finance income		1,197,360			1,466,733			3,207,907
Interest expense (incl. Bank charges)		911,869			189,695			135,151
Net foreign currency exchange loss		690,615			1,129,788			3,541,202
Revaluation loss from derivative financial instruments		—			416,003			2,250,222
Transaction costs		1,137			—			219,615
Total finance expense		1,603,621			1,735,486			6,146,190
Finance expense, net		(406,261	)		(268,753	)		(2,938,283	)

In 2022, the revaluation gain from derivative financial instruments of CHF 451,131 includes CHF 449,898 related to the revaluation of the financial derivatives embedded in the 2022 FiveT convertible loan (note 31) and CHF 1,233 related to the revaluation of outstanding warrants from public offerings (note 32). In 2021, the revaluation loss from derivative financial instruments of CHF 416,003 was related to the revaluation of the financial derivatives embedded in the 2020 FiveT convertible loan at conversion. The revaluation gain of CHF 5,085 was related to the revaluation of outstanding warrants from public offerings. In 2022, finance expenses included interest paid of CHF 19,503 (2021: CHF 3,699; 2020: CHF 0).

Finance Income and Finance Expense (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure of finance income and finance expense [Abstract]

Schedule of finance income and finance expense

26. Finance income and finance expense
	2022			2021			2020
Interest income		969			3,219			258
Net foreign currency exchange gain		745,260			1,458,429			3,207,649
Revaluation gain from derivative financial instruments		451,131			5,085			—
Total finance income		1,197,360			1,466,733			3,207,907
Interest expense (incl. Bank charges)		911,869			189,695			135,151
Net foreign currency exchange loss		690,615			1,129,788			3,541,202
Revaluation loss from derivative financial instruments		—			416,003			2,250,222
Transaction costs		1,137			—			219,615
Total finance expense		1,603,621			1,735,486			6,146,190
Finance expense, net		(406,261	)		(268,753	)		(2,938,283	)

Share-Based Compensation

12 Months Ended

Dec. 31, 2022

Share-Based Compensation [Abstract]

Share-based compensation

15. Share-based compensation

Description

In 2014, the Group introduced an equity incentive plan (the (“EIP”), which was amended in 2017 and 2019. In 2022, the Company granted 97,742 options (2021: 17,113 options) under the EIP.

Holders of vested options are entitled to purchase common shares of the Company. Under the Equity Incentive Plan, the Board of Directors defined the exercise price as the average daily closing price of the Company’s shares during the 30 days preceding the date of grant. All options are to be settled by the physical delivery of shares. The key terms and conditions related to the grants under these programs at December 31, 2022 are as follows:

	Number of			Contractual
	options			life of
Plan	outstanding		Vesting conditions	options
Equity Incentive Plan Board		22,268	1 year service from grant date	6 years
Equity Incentive Plan Management & Staff		67,682	2 years’ service from grant date (50%)	8 years
Equity Incentive Plan Management & Staff		67,682	3 years’ service from grant date (50%)	8 years

Measurement of fair values

The fair value of the options was measured based on the Black-Scholes formula.

			Stock Option Plan
	Equity Incentive		Equity Incentive		Equity Incentive		Equity Incentive
	Plan 2022		Plan 2022		Plan 2021		Plan 2021
Fair value at grant date	USD 4.347 (2 year vesting) ¹⁾ USD 5.011 (3 year vesting) ¹⁾		USD 6.644 (1 year vesting) ²⁾ USD 8.760 (2 year vesting) ²⁾ USD 10.604 (3 year vesting) ²⁾		USD 18.64 (2 year vesting) ¹⁾ USD 22.14 (3 year vesting) ¹⁾		USD 24.82 (1 year vesting) ²⁾ USD 37.00 (2 year vesting) ²⁾ USD 43.66 (3 year vesting) ²⁾

Share price at grant date	USD 7.48		USD 17.8		USD 32.80		USD 70.80
Exercise price	USD 6.353		USD 20.78		USD 37.78		USD 70.220
Expected volatility	100.2%	99.1%		93.4%		101.3%
Expected life	2 and 3 years		1, 2 and 3 years		2 and 3 years		1, 2 and 3 years
Expected dividends	—		—		—		—
Risk-free interest rate	4.45%	2.87%		0.47%		0.06%

¹⁾

October grants for the respective year

²⁾

April grants for the respective year

The Company uses its own historic volatility to calculate expected volatility. The expected life of all options is assumed to correspond to the vesting period.

The total expense recognized for equity-settled share-based payment transactions were CHF 346,035 in 2022 (2021: CHF 1,206,303, 2020: CHF 368,793).

Share based compensation loss related to employee stock options amounted to CHF 346,035 in 2022 (2021: CHF 1,223,696, 2020: CHF 351,401).

The number and weighted average exercise prices (in CHF) of options under the share option programs are as follows:

	2022							2021
				Weighted		Weighted					Weighted		Weighted
	Number of			average exercise		average remaining		Number of			average exercise		average remaining
	options			price		term		options			price		term
Outstanding at January 1		66,476			33.00		6.56		51,927			31.60		7.01
Expired during the year		—			—		—		—			—		—
Forfeited during the year		(6,488	)		—		—		(2,565	)		—		—
Exercised during the year		—			—		—		—			—		—
Granted during the year		97,742			9.40		—		17,113			45.40		—
Outstanding at December 31		157,730			19.28		6.22		66,476			33.00		6.56
Exercisable at December 31		28,796			—		—		14,419			—		—

The range of exercise prices for outstanding options was CHF 5.88 to CHF 584.66 as of December 31, 2022 and CHF 15.03 to CHF 575.80 as of December 31, 2021.

Significant accounting policies

12 Months Ended

Dec. 31, 2022

Significant accounting policies [Abstract]

Significant accounting policies

3. Significant accounting policies

The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements, unless otherwise indicated.

Basis of consolidation

Subsidiaries

Transactions eliminated on consolidation

Segment reporting

Foreign currency

Foreign currency transactions

Foreign operations

Closing rates for the most significant foreign currencies relative to CHF:

		Geographical	Reporting	December 31,		December 31,		December 31,
Currency		area	entities	2022		2021		2020
CHF	Swiss Franc	Switzerland	5		1.0000		1.0000		1.0000
USD	Dollar	United States	1		0.9251		0.9110		0.8840
EUR	Euro	Europe	1		0.9901		1.0361		1.0817
AUD	Dollar	Australia	1		0.6305		0.6620		0.6822

Average exchange rates for the year for the most significant foreign currencies relative to CHF:

		Geographical	Reporting
Currency		area	entities	2022		2021		2020
CHF	Swiss Franc	Switzerland	5		1.0000		1.0000		1.0000
USD	Dollar	United States	1		0.9550		0.9142		0.9581
EUR	Euro	Europe	1		1.0050		1.0810		1.0825
AUD	Dollar	Australia	1		0.6629		0.6866		0.6546

Property and equipment

Production equipment		5 years
Office furniture and electronic data processing equipment (“EDP”)		3 years

Intangible assets

Research and development

Expenditures on the Group’s research programs are not capitalized, they are expensed when incurred.

Licenses, intellectual property and data rights

Measurement

Intangible assets acquired that have finite useful lives are measured at cost less accumulated amortization and any accumulated impairment losses.

Subsequent expenditure

Amortization

Impairment of non-financial assets

Asset purchase

Leases

Right-of-use assets

Lease liabilities

Short-term leases and leases of low-value assets

Inventories

Financial instruments

Recognition and derecognition of non-derivative financial assets and liabilities

The Group derecognizes a financial liability when its contractual obligations are discharged, cancelled, or expired.

Non-derivative financial assets and liabilities—measurement

Loans and receivable

Cash and cash equivalents

Non-derivative financial liabilities—measurement

Convertible loans

Share capital

The Company has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future.

Repurchase and reissue of ordinary shares (treasury shares)

Impairment of non-derivative financial assets

Financial assets are assessed at each reporting date to determine whether there is objective evidence of impairment.

Objective evidence that financial assets are impaired includes:

●

default or delinquency by a debtor;

●

indications that a debtor or issuer will enter bankruptcy;

●

adverse changes in the payment status of borrowers or issuers;

●

the disappearance of an active market for a security; or

●

observable data indicating that there is measurable decrease in expected cash flows from a group of financial assets.

Financial assets measured at amortized cost

Derivative Financial Instruments

Embedded Derivatives

Derivatives may be embedded in another contractual arrangement. The Group accounts for an embedded derivative separately from the host contract when:

The host contract is not an asset in the scope of IFRS 9

The host contract is not itself carried at fair value through profit and loss (FVPL)

The terms of the Embedded Derivative would meet the definition of a derivative if they were contained in a separate contract

The economic characteristics and risks of the embedded derivative are not closely related to the economic characteristics and risks of the host

Income tax

Current tax

Deferred tax

●

temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss;

●

taxable temporary differences arising on the initial recognition of goodwill.

Employee benefits

Share-based compensation

Valuation of share options

Option pricing and values are determined based on the Black Scholes option pricing model and assumptions are made for inputs such as volatility of the Company’s stock and the risk-free rate.

Provisions

Revenue recognition

License of intellectual property

Sale of products

Government grants

Earnings/(loss) per share

Share-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2022

Share-Based Compensation [Abstract]

Schedule of key terms and conditions related to the grants

	Number of			Contractual
	options			life of
Plan	outstanding		Vesting conditions	options
Equity Incentive Plan Board		22,268	1 year service from grant date	6 years
Equity Incentive Plan Management & Staff		67,682	2 years’ service from grant date (50%)	8 years
Equity Incentive Plan Management & Staff		67,682	3 years’ service from grant date (50%)	8 years

Schedule of fair value of the options measured

			Stock Option Plan
	Equity Incentive		Equity Incentive		Equity Incentive		Equity Incentive
	Plan 2022		Plan 2022		Plan 2021		Plan 2021
Fair value at grant date	USD 4.347 (2 year vesting) ¹⁾ USD 5.011 (3 year vesting) ¹⁾		USD 6.644 (1 year vesting) ²⁾ USD 8.760 (2 year vesting) ²⁾ USD 10.604 (3 year vesting) ²⁾		USD 18.64 (2 year vesting) ¹⁾ USD 22.14 (3 year vesting) ¹⁾		USD 24.82 (1 year vesting) ²⁾ USD 37.00 (2 year vesting) ²⁾ USD 43.66 (3 year vesting) ²⁾

Share price at grant date	USD 7.48		USD 17.8		USD 32.80		USD 70.80
Exercise price	USD 6.353		USD 20.78		USD 37.78		USD 70.220
Expected volatility	100.2%	99.1%		93.4%		101.3%
Expected life	2 and 3 years		1, 2 and 3 years		2 and 3 years		1, 2 and 3 years
Expected dividends	—		—		—		—
Risk-free interest rate	4.45%	2.87%		0.47%		0.06%

Schedule of number and weighted average exercise prices

	2022							2021
				Weighted		Weighted					Weighted		Weighted
	Number of			average exercise		average remaining		Number of			average exercise		average remaining
	options			price		term		options			price		term
Outstanding at January 1		66,476			33.00		6.56		51,927			31.60		7.01
Expired during the year		—			—		—		—			—		—
Forfeited during the year		(6,488	)		—		—		(2,565	)		—		—
Exercised during the year		—			—		—		—			—		—
Granted during the year		97,742			9.40		—		17,113			45.40		—
Outstanding at December 31		157,730			19.28		6.22		66,476			33.00		6.56
Exercisable at December 31		28,796			—		—		14,419			—		—

Revenue (Details) - Schedule of disaggregation of the group’s revenue from contracts with customers - CHF (SFr)	3 Months Ended	12 Months Ended
	Mar. 08, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Disaggregation of The Group SRevenue From Contracts With Customers Abstract
Product sales	SFr 100,000	SFr 305,616	SFr 63,882
Total revenue		SFr 305,616	SFr 63,882

Intangible assets (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure of intangible assets [Abstract]

Schedule of intangible assets

				IP & Data						Internally
	Licenses			rights			Patents			generated			Total
At cost
As of January 1, 2021		1,482,520			193,989			417,216			7,021,685			9,115,410
Exchange differences		—			—			—			(3,654	)		(3,654	)
Additions		3,893,681			—			55,938			2,783,431			6,733,050
As of December 31, 2021		5,376,201			193,989			473,154			9,801,462			15,844,806
Exchange differences		—			—			—			168			168
Additions		—			—			275,281			1,700,503			1,975,784
As of December 31, 2022		5,376,201			193,989			748,435			11,502,133			17,820,758

Accumulated amortization and impairment losses
As of January 1, 2021		—			—			—			—			—
Impairment		(1,482,520	)		(47,409	)		—			—			(1,529,929	)
As of December 31, 2021		(1,482,520	)		(47,409	)		—			—			(1,529,929	)
Impairment		—			(146,580	)		(748,435	)		(11,502,133	)		(12,397,148	)
As of December 31, 2022		(1,482,520	)		(193,989	)		(748,435	)		(11,502,133	)		(13,927,077	)

Net book value
As of December 31, 2021		3,893,681			146,580			473,154			9,801,462			14,314,877
As of December 31, 2022		3,893,681			—			—			—			3,893,681

Prepayments

12 Months Ended

Dec. 31, 2022

Prepayments [Abstract]

Prepayments

12. Prepayments

	December 31,		December 31,
	2022		2021
Advance payments to suppliers		659,861		1,437,708
Insurance		49,405		137,418
Total prepayments		709,266		1,575,126

Related Party Transactions

12 Months Ended

Dec. 31, 2022

Related party transactions

30. Related party transactions

For purposes of these consolidated financial statements, parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial or operational decisions. Also, parties under common control of the Group are considered to be related. Key management personnel are also related parties. In considering each possible related party relationship, attention is directed to the substance of the relationship, and not merely the legal form.

Ante Treuhand AG (“Ante Treuhand”) provided the Chief Financial Officer to the Company until November 18, 2021. The Chief Financial Officer is an employee of Ante Treuhand and is not paid directly by the Company. Fees paid to Ante Treuhand for CFO services in 2021 were CHF 231,770. Fees paid to Ante Treuhand for other services provided during the year ended December 31, 2021 were CHF 3,025.

Gremaud GmbH provides the Chief Financial Officer to the Company since November 19, 2021. The Chief Financial Officer is an employee of Gremaud GmbH and is not paid directly by the Company. Fees paid to Gremaud GmbH for CFO services in 2022 were CHF 195,988 (2021: CHF 14,720). Fees paid to Gremaud GmbH for other services provided during the year ended December 31, 2022 were CHF 0 (2021: CHF 161,596).

Thomas Meyer, the Company’s CEO lent CHF 200,000 to the Company under the “September 9, 2022 Loan Agreement” with FiveT Investment Management Ltd., Dominik Lysek and Thomas Meyer for a total amount of CHF 600,000, please refer to note 30.

From December 8, 2022 to March 8, 2023, Mr. Meyer’s spouse provided one of the Company’s subsidiaries with a short-term loan of CHF 100,000.00, bearing interest at the rate of 5% per annum.

Compensation of the members of the Board of Directors and Management

In 2022, the compensation paid to management, excluding share bonuses and share-based payment charge, amounted to CHF 1,038,810 (2021: CHF 810,671; 2020: CHF 434,017). The fees paid to members of the Board of Directors in 2022 for their activities as board members totaled CHF 183,058 (2021: CHF 165,245; 2020: CHF 163,476).

	Executive Management						Board of Directors						Total
	2022		2021		2020		2022		2021		2020		2022		2021		2020
Short term benefits		989,760		781,204		407,147		183,058		165,245		163,476		1,172,818		946,449		570,623
Post-employee benefits years		49,050		29,467		26,870		—		—		—		49,050		29,467		26,870
Share Bonuses		—		902,817		—		—		—		—		—		902,817		—
Share-based payment charge		172,115		192,362		204,840		51,171		48,046		57,148		223,286		240,408		261,988
Total		1,210,925		1,905,850		638,857		234,229		213,291		220,624		1,445,154		2,119,141		859,481

In 2022, CHF 223,286 (2021: CHF 240,408; 2020: CHF 261,988) was expensed for grants of stock options to members of the Board of Directors and management. Contributions to pension schemes amounted to CHF 49,050, CHF 29,467 and CHF 26,870 during the years 2022, 2021 and 2020, respectively. No termination benefits or other long-term benefits were paid.

Members of the Board of Directors and management held 107,110, 49,480 and 38,455 stock options as of December 31, 2022, 2021, and 2020, respectively.

Taxation (Details) - Schedule of deferred taxes assets and liabilities	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2022 CHF (SFr)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 CHF (SFr)	Dec. 31, 2021 USD ($)
Taxation (Details) - Schedule of deferred taxes assets and liabilities [Line Items]
Deferred Tax Liabilities	$ (167,299)	$ (174,363)
Deferred Tax Asset				$ 41,429		$ 31,879
Deferred Tax, net			SFr (125,870)	(125,870)	SFr (142,484)	(142,484)
Intangible assets [Member]
Taxation (Details) - Schedule of deferred taxes assets and liabilities [Line Items]
Deferred Tax Liabilities		(51,914)
Deferred unrealized foreign exchange gains [Member]
Taxation (Details) - Schedule of deferred taxes assets and liabilities [Line Items]
Deferred Tax Liabilities
Other receivables [Member]
Taxation (Details) - Schedule of deferred taxes assets and liabilities [Line Items]
Deferred Tax Liabilities	$ (167,299)	$ (122,449)
Net operating loss (NOL) [Member]
Taxation (Details) - Schedule of deferred taxes assets and liabilities [Line Items]
Deferred Tax Asset				$ 41,429		$ 31,879

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure of commitments and contingencies [Abstract]

Schedule of future minimum lease payments under non-cancellable operating leases

	December 31,		December 31,
	2022		2021
Within one year		3,450		3,450
Between one and five years		—		—
Total		3,450		3,450

Other Operating Income

12 Months Ended

Dec. 31, 2022

Other operating income [Abstract]

Other operating income

19. Other operating income

	December 31,		December 31,		December 31,
	2022		2021		2020
Income from R&D tax incentive (Government grants)		700,122		211,664		—
Refund of share issuance stamp duty		—		—		100,002
Other income		9,327		2,553		74,473
Total other operating income		709,449		214,217		174,475

Loans (Details) - Schedule of convertible loan agreement - CHF (SFr)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Convertible Loan Agreement Abstract
As of January 1		SFr 473,920
Gross proceeds at disbursement date	5,000,000
Embedded derivative, separated	(449,898)
Transaction costs allocated to host	(10,236)
Carrying amount at initial recognition	4,539,866
Converted principal amount		(644,813)
Accrued interest	447,945	8,348
Amortization	358,511	162,545
Total	5,346,322
Accrued interest balance of December 31	447,945
Convertible loan balance of December 31	SFr 4,898,377

Sales and Marketing Expense (Details) - Schedule of Sales and marketing expense - CHF (SFr)

12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Sales and Marketing Expense (Details) - Schedule of Sales and marketing expense [Line Items]

Marketing and sales expenses [Member]

SFr 2,381,384

SFr 1,498,218

^[1]

Sales and Marketing Expense (Details) - Schedule of Sales and marketing expense [Line Items]

Employee benefits and expenses [Member]

2,131,696

1,132,864

Sales and Marketing Expense (Details) - Schedule of Sales and marketing expense [Line Items]

Sales and Marketing Expense (Details) - Schedule of Sales and marketing expense [Line Items]

249,688

204,157

Product samples [Member]